Teva Pharmaceutical Industries Limited (TEVA) 10-K 9 Feb 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Annual Report	true
Entity Registrant Name	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Entity Central Index Key	0000818686
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding	1,103,329,696
Title of 12(b) Security	American Depositary Shares, each representing one Ordinary Share
Trading Symbol	TEVA
Security Exchange Name	NYSE
Entity File Number	001-16174
Entity Incorporation, State or Country Code	L3
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	124 Dvora HaNevi’a St.
Entity Address, City or Town	Tel Aviv
Entity Address, Postal Zip Code	6944020
Entity Address, Country	IL
City Area Code	+972 (3)
Local Phone Number	914-8213
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Public Float		$ 9,550
ICFR Auditor Attestation Flag	true
Auditor Name	Kesselman & Kesselman
Auditor Firm ID	1309
Auditor Location	Israel

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 2,165	$ 2,177
Accounts receivables, net of allowance for credit losses of $90 million and $126 million as of December 31, 2021 and December 31, 2020, respectively	4,529	4,581
Inventories	3,818	4,403
Prepaid expenses	1,075	945
Other current assets	965	710
Assets held for sale	19	189
Total current assets	12,573	13,005
Deferred income taxes	596	695
Other non-current assets	515	538
Property, plant and equipment, net	5,982	6,296
Operating lease right-of-use assets	495	559
Identifiable intangible assets, net	7,466	8,923
Goodwill	20,040	20,624
Total assets	47,666	50,640
Current liabilities:
Short-term debt	1,426	3,188
Sales reserves and allowances	4,241	4,824
Accounts payables	1,686	1,756
Employee-related obligations	563	685
Accrued expenses	2,208	1,780
Other current liabilities	903	933
Total current liabilities	11,027	13,164
Long-term liabilities:
Deferred income taxes	784	964
Other taxes and long-term liabilities	2,578	2,240
Senior notes and loans	21,617	22,731
Operating lease liabilities	416	479
Total long-term liabilities	25,395	26,414
Commitments and contingencies, see note 12
Total liabilities	36,422	39,579
Teva shareholders' equity:
Ordinary shares of NIS 0.10 par value per share; December 31, 2021 and December 31, 2020: authorized 2,495 million shares; issued 1,209 million shares and 1,202 million shares, respectively	57	57
Additional paid-in capital	27,561	27,443
Accumulated deficit	(10,529)	(10,946)
Accumulated other comprehensive loss	(2,683)	(2,399)
Treasury shares as of December 31, 2021 and December 31, 2020: 106 million ordinary shares	(4,128)	(4,128)
Stockholders' equity attributable to Teva shareholders	10,278	10,026
Non-controlling interests	966	1,035
Total equity	11,244	11,061
Total liabilities and equity	$ 47,666	$ 50,640

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) $ in Millions	Dec. 31, 2021USD ($)shares	Dec. 31, 2021SFr / shares	Dec. 31, 2020USD ($)shares	Dec. 31, 2020SFr / shares
Allowance for credit losses | $	$ 90		$ 126
Common stock, par or stated value per share | SFr / shares		SFr 0.10		SFr 0.10
Ordinary shares, authorized	2,495,000,000		2,495,000,000
Ordinary shares, issued	1,209,000,000		1,202,000,000
Treasury shares	106,000,000		106,000,000

Consolidated Statements of Inco

Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net revenues	$ 15,878	$ 16,659	$ 16,887
Cost of sales	8,284	8,933	9,351
Gross profit	7,594	7,726	7,537
Research and development expenses, net	967	997	1,010
Selling and marketing expenses	2,429	2,498	2,614
General and administrative expenses	1,099	1,173	1,192
Intangible assets impairments	424	1,502	1,639
Goodwill impairment	0	4,628	0
Other asset impairments, restructuring and other items	341	479	423
Legal settlements and loss contingencies	717	60	1,178
Other income	(98)	(40)	(76)
Operating (loss) income	1,716	(3,572)	(443)
Financial expenses—net	1,058	834	822
Income (loss) before income taxes	658	(4,406)	(1,265)
Income taxes (benefit)	211	(168)	(278)
Share in (profits) losses of associated companies—net	(9)	(138)	13
Net income (loss)	456	(4,099)	(1,000)
Net income (loss) attributable to non-controlling interests	39	(109)	(2)
Net income (loss) attributable to Teva	$ 417	$ (3,990)	$ (999)
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ 0.38	$ (3.64)	$ (0.91)
Diluted	$ 0.38	$ (3.64)	$ (0.91)
Weighted average number of shares (in millions):
Basic	1,102	1,095	1,091
Diluted	1,107	1,095	1,091

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net income (loss)	$ 456	$ (4,099)	$ (1,000)
Other comprehensive income (loss), net of tax:
Currency translation adjustment	(462)	(69)	97
Unrealized gain (loss) on derivative financial instruments, net	39	57	84
Unrealized gain (loss) on available-for-sale securities, net	0	0	(1)
Unrealized gain (loss) on defined benefit plans, net	32	(18)	(20)
Total other comprehensive income (loss)	(391)	(30)	160
Total comprehensive income (loss)	65	(4,129)	(840)
Comprehensive income (loss) attributable to non-controlling interests	(68)	(53)	12
Comprehensive income (loss) attributable to Teva	$ 133	$ (4,076)	$ (852)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions	Total	Ordinary Shares [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Shares [Member]	Total Teva Shareholders' Equity [Member]	Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2018	$ 15,794	$ 56	$ 27,210	$ (5,958)	$ (2,459)	$ (4,142)	$ 14,707	$ 1,087
Beginning balance, shares at Dec. 31, 2018		1,196
Net income (loss)	(1,000)			(999)			(999)	(2)
Other comprehensive income (loss)	160				147		147	14
Issuance of Treasury Shares	6		(8)			14	6
Issuance of Shares, shares		2
Stock-based compensation expense	119		119				119
Transactions with non-controlling interests	(8)							(8)
Other	(8)		(8)				(8)
Ending balance at Dec. 31, 2019	15,063	$ 56	27,312	(6,956)	(2,312)	(4,128)	13,972	1,091
Ending balance, shares at Dec. 31, 2019		1,198
Net income (loss)	(4,099)			(3,990)			(3,990)	(109)
Other comprehensive income (loss)	(30)				(86)		(86)	56
Issuance of Shares, value	1						1
Issuance of Shares, shares		4
Stock-based compensation expense	129		129				129
Transactions with non-controlling interests	(2)							(2)
Ending balance at Dec. 31, 2020	11,061	$ 57	27,443	(10,946)	(2,399)	(4,128)	10,026	1,035
Ending balance, shares at Dec. 31, 2020		1,202
Net income (loss)	456			417			417	39
Other comprehensive income (loss)	(391)				(283)		(283)	(107)
Issuance of Shares, shares		7
Stock-based compensation expense	119		119				119
Transactions with non-controlling interests	(2)							(2)
Ending balance at Dec. 31, 2021	$ 11,244	$ 57	$ 27,561	$ (10,529)	$ (2,683)	$ (4,128)	$ 10,278	$ 966
Ending balance, shares at Dec. 31, 2021		1,209

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Maximum [Member] | Ordinary Shares [Member]
Exercise of options by employees and vested RSUs	$ 0.5	$ 0.5	$ 0.5

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities:
Net income (loss)	$ 456	$ (4,099)	$ (1,000)
Adjustments to reconcile net loss to net cash provided by operations:
Impairment of goodwill, long-lived assets and assets held for sale	584	6,546	1,778
Depreciation and amortization	1,330	1,557	1,722
Net change in operating assets and liabilities	(1,701)	(2,188)	(896)
Deferred income taxes—net and uncertain tax positions	(120)	(696)	(985)
Stock-based compensation	119	129	119
Other items	16	100	28
Research and development in process	10	80	0
Net loss (gain) from investments and from sale of business and long lived assets	104	(213)	(18)
Net cash provided by operating activities	798	1,216	748
Investing activities:
Beneficial interest collected in exchange for securitized trade receivables	1,648	1,405	1,487
Proceeds from sale of business and long lived assets	311	67	343
Purchases of property, plant and equipment	(562)	(578)	(525)
Purchases of investments and other assets	(47)	(55)	(8)
Proceeds from sale of investments	172	12	2
Other investing activities	1	12	56
Net cash provided by investing activities	1,523	863	1,355
Financing activities:
Repayment of senior notes and loans and other long-term liabilities	(6,649)	(1,871)	(3,944)
Proceeds from senior notes, net of issuance costs	4,974	0	2,083
Proceeds from short term debt	700	550	500
Repayment of short term debt	(700)	(559)	(502)
Redemption of convertible debentures	(491)	0	0
Other financing activities	(6)	(5)	(11)
Tax withholding payments made on shares and dividends	0	0	(52)
Net cash used in financing activities	(2,172)	(1,885)	(1,926)
Translation adjustment on cash and cash equivalents	(128)	8	16
Net change in cash, cash equivalents and restricted cash	21	202	193
Balance of cash, cash equivalents and restricted cash at beginning of year	2,177	1,975	1,782
Balance of cash, cash equivalents and restricted cash at end of year	2,198	2,177	1,975
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:
Cash and cash equivalents	2,165	2,177	1,975
Restricted cash included in other current assets	33	0	0
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	2,198	2,177	1,975
Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized trade receivables	1,635	1,397	1,511
Cash paid during the year for:
Interest	913	846	840
Income taxes, net of refunds	495	709	552
Net change in operating assets and liabilities:
Other current assets	(2,271)	(1,473)	(1,416)
Trade payables, accrued expenses, employee-related obligations and other liabilities	764	(463)	643
Trade receivables net of sales reserves and allowances	(574)	(293)	(394)
Inventories	380	41	271
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information	$ (1,701)	$ (2,188)	$ (896)

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Significant Accounting Policies	NOTE 1—Significant accounting policies: a. General: Operations Teva Pharmaceutical Industries Limited (the “Parent Company”), headquartered in Israel, together with its subsidiaries and associated companies (the “Company,” “Teva” or the “Group”), is engaged in the development, manufacturing, marketing and distribution of generics, specialty medicines and biopharmaceuticals. The majority of the Group’s revenues are in the United States and Europe. Basis of presentation and use of estimates The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). In preparing the Company’s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of intangible assets and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. The inputs into Teva’s judgments and estimates also consider the economic implications of the COVID-19 pandemic on its critical accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva’s employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the COVID-19 pandemic within its financial statements may change in future periods. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. Functional currency A major part of the Group’s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (“dollar” or “$”). The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year. Differences resulting from translation are presented as other comprehensive income (loss) in the consolidated statements of comprehensive income (loss). In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). Principles of consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and variable interest entities (“VIEs”) for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders’ interests are shown as non-controlling interests in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, are carried on the equity basis. For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated. b. New accounting pronouncements Recently adopted accounting pronouncements In March 2020, the FASB issued ASU 2020-04 “Reference Rate Reform (Topic 848)—Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March 12, 2020 through December 31, 2022. There was no material impact to the Company’s consolidated financial statements for the period ended December 31, 2021 as a result of adopting this standard update. The Company has completed negotiations to transform the facility base rate of its securitization program and is continuing to evaluate the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities. However, it is not expected to have a material impact on the consolidated financial results of operations, financial position or cash flows. In December 2019, the FASB issued ASU 2019-12 “Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes” (the “update”). The amendments in this update simplify the accounting for income taxes by removing the following exceptions in ASC 740: (1) exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items; (2) exception to accounting for basis differences for equity method investments when a foreign subsidiary becomes an equity method investment; (3) exception to accounting for basis differences for a foreign subsidiary when a foreign equity method investment becomes a subsidiary; and (4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the update also simplifies the accounting for income taxes in certain topics as follows: (1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax; (2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; (3) specifying that an entity can elect (rather than be required to) allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; and (4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. Teva adopted the provisions of this update as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial results of operations, financial position or cash flows. Recently issued accounting pronouncements, not yet adopted In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832)”, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2021. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. In October 2021, the FASB issued ASU 2021-08 “Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments to this guidance are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company expects to apply modified retrospective basis adoption of this guidance, which will not have a significant impact on the Company’s consolidated financial statements. c. Acquisitions: Teva’s consolidated financial statements include the operations of acquired businesses from the date of the acquisition’s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed unless it has an alternative future use. Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period, with any adjustments in fair value recognized in earnings under other assets impairments, restructuring and other items. d. Collaborative arrangements: Collaborative arrangements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. The Company recognizes revenue generated and costs incurred on sales to third parties as it relates to collaborative agreements as gross or net. If the Company is the principal participant in a transaction, revenues and costs are recorded on a gross basis; otherwise, revenues are recorded on a net basis. e. Equity investments: The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative prescribed within ASU 2016-01 “Financial Instruments—Recognition and Measurement of Financial Assets and Financial Liabilities” to the extent such investments are not subject to consolidation or the equity method. Under the measurement alternative, these financial instruments are carried at cost, less any impairment (assessed quarterly), adjusted for changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. In addition, income is recognized when dividends are received only to the extent they are distributed from net accumulated earnings of the investee. Otherwise, such distributions are considered returns of investment and are recorded as a reduction of the cost of the investment. The Company accounts for equity investments as current when the Company has the intent and ability to sell such assets within the next twelve months. f. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. g. Investment in debt securities: Investment in securities consists of debt securities classified as available-for-sale and recorded at fair value. The fair value of quoted securities is based on current market value. When debt securities do not have an active market, fair value is determined using a valuation model. This model is based on reference to other instruments with similar characteristics, or a discounted cash flow analysis, or other pricing models making use of market inputs and relying as little as possible on entity-specific inputs. The Company’s investment in debt securities accounting policy until December 31, 2019, prior to the adoption of the new Current Expected Credit Losses (“CECL”) standard Unrealized gains of available for sale debt securities, net of taxes, are reflected in other comprehensive income. Unrealized losses considered to be temporary are reflected in other comprehensive income; unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for debt securities are included in financial expenses, net. The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. For debt securities, an other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income. The Company’s investment in debt securities accounting policy from January 1, 2020, following the adoption of the new CECL standard Unrealized gains and losses for available-for-sale securities are excluded from earnings and reported net of the related tax effect in the accumulated other comprehensive income component of shareholders’ equity. The CECL methodology, which became effective January 1, 2020, requires the Company to estimate lifetime expected credit losses for all available-for-sale debt securities in an unrealized loss position. Comparative information continues to be reported in accordance with the methodology in effect for prior periods. When estimating a security’s probability of default and the recovery rate, the Company assesses the security’s credit indicators, including credit ratings. If the assessment indicates that an expected credit loss exists, the Company determines the portion of the unrealized loss attributable to credit deterioration and records an allowance for the expected credit loss through the Consolidated Statements of Income. Unrealized gains and any portion of a security’s unrealized loss attributable to non-credit losses are recorded in the Consolidated Statements of Comprehensive Income, net of tax. h. Cash and cash equivalents: All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents. i. Restricted cash: Restricted cash represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet under other current assets. j. Accounts Receivable: The Company’s accounts receivables accounting policy until December 31, 2019, prior to the adoption of the new CECL standard Accounts receivable are stated at their net realizable value. The allowance against gross accounts receivable reflects the best estimate of losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. An allowance for doubtful debts is reflected in net accounts receivable. Accounts receivable are written off after all reasonable means to collect the full amount have been exhausted. The Company’s accounts receivables accounting policy from January 1, 2020, following the adoption of the new CECL standard Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. Write-off activity and recoveries for the periods presented were not material. k. Concentration of credit risks: Most of Teva’s cash and cash equivalents (which, along with investment in securities, totaled $2,191 million at December 31, 2021) were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. The pharmaceutical industry, particularly in the United States, has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately 46% of Teva’s consolidated revenues in 2021. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance. l. Inventories: Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. Inventories acquired in a business combination are stepped-up to their estimated fair value and amortized to cost of sales as that inventory is sold. m. Long-lived assets: Teva’s long-lived, non-current assets are comprised mainly of goodwill, identifiable intangible assets, property, plant and equipment, and operating lease right-of-use (“ROU”) assets. All long-lived assets are monitored for impairment indicators throughout the year. Impairment testing for goodwill and all indefinite-lived intangible assets is performed at least annually. When necessary, charges for impairments of long-lived assets, other than goodwill, are recorded for the amount by which the fair value is less than the carrying value of these assets. Goodwill Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any non-controlling interest in the acquiree, over the assigned fair values of the identifiable net assets acquired. Goodwill is not amortized, and is assigned to reporting units and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. The goodwill impairment test is performed according to the following principles: 1. An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. 2. If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value is recognized. An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company’s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company’s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. Identifiable intangible assets Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (“FDA”) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (“S&M”) expenses when separable. Indefinite life intangible assets are mainly comprised of IPR&D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. IPR&D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset’s estimated life, calculates the undiscounted value of the asset’s or asset group’s cash flows and compares such value against the asset’s or asset group’s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. For indefinite life intangible assets, Teva performs an impairment test annually in the second quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Teva determines the fair value of the asset based on discounted cash flows and records an impairment loss if its book value exceeds fair value. In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company’s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i) for IPR&D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii) for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. Property, plant and equipment Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly 20 years; and other assets, between 5 to 10 years. For property, plant and equipment and lease right-of-use assets, whenever impairment indicators are identified, Teva reconsiders the asset’s estimated life, calculates the undiscounted value of the asset’s cash flows and compares such value against the asset’s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value. Lease right-of-use (ROU) assets See note 8 and note 1dd for further discussion. n. Contingencies: The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. Legal costs are expensed as incurred. The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved. o. Treasury shares: Treasury shares are presented as a reduction of Teva shareholders’ equity and carried at their cost to Teva, under treasury shares. p. Stock-based compensation: Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (“RSUs”) and performance share units (“PSUs”). The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option’s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards to expense over the vesting period on a straight-line basis. Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting. q. Deferred income taxes: Deferred income taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as non-current. Tax has not been provided on the following items: 1. Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company’s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. 2. Amounts of tax-exempt income generated from the Company’s current Approved Enterprises and unremitted earnings from foreign subsidiaries retained for reinvestment in the Group. See note 13f. r. Uncertain tax positions: Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly re-evaluates its tax positions based on developments in its tax audits, statute of limitations expirations, changes in tax laws and new information that can affect the technical merits and change the assessment of Teva’s ability to sustain the tax benefit. In addition, the Company classifies interest and penalties recognized in the financial statements relating to uncertain tax position under the income taxes line item. Provisions for uncertain tax positions, whereas Teva has net operating losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss. s. Derivatives and hedging: The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to

Certain transactions

Certain transactions	12 Months Ended
	Dec. 31, 2021
Certain transactions	NOTE 2—Certain transactions: The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company’s most significant agreements of this nature are summarized below. MODAG In October 2021, Teva announced a license agreement with MODAG GmbH (“Modag”), that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag’s lead compound (anle138b) and a related compound (sery433). Anle138b was initially developed for the treatment of Multiple System Atrophy (MSA) and Parkinson’s disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer’s disease. A phase 1b clinical trial is currently being completed. In the fourth quarter of 2021, after obtaining required approval, Teva made an upfront payment of $10 million that was recorded as R&D expense. Modag may be eligible for future development milestone payments, totaling an aggregate amount of up to $70 million, as well as future commercial milestones and royalties . Alvotech In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including a proposed biosimilar to Humira ® ® ® ® Eli Lilly and Alder BioPharmaceuticals In December 2018, Teva entered into an agreement with Eli Lilly (“Lilly”) resolving the European Patent Office opposition they had filed against Teva’s AJOVY patents. The settlement agreement with Lilly also resolved Lilly’s action to revoke the patent protecting AJOVY in the United Kingdom. On January 8, 2018, Teva signed a global license agreement with Alder BioPharmaceuticals (“Alder”). The agreement validates Teva’s intellectual property and resolves Alder’s opposition to Teva’s European patent with respect to anti-calcitonin gene-related peptide (CGRP) antibodies, including the withdrawal of Alder’s appeal before the European Patent Office. Under the terms of the agreement, Alder received a non-exclusive license to Teva’s anti-CGRP antibodies patent portfolio to develop, manufacture and commercialize eptinezumab in the United States and worldwide, excluding Japan. Teva received a $25 million upfront payment that was recognized as revenue during the first quarter of 2018, and a $25 million milestone payment in March 2020 that was recognized as revenue in the first quarter of 2020. The agreement stipulates additional development and commercial milestone payments to Teva of up to $150 million, as well as future royalties. AUSTEDO On September 19, 2017, Teva entered into a partnership agreement with Nuvelution Pharma, Inc. (“Nuvelution”) for development of AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the United States. There are no further plans in this indication following clinical trial results received in February 2020, which failed to meet their primary endpoints. The partnership agreement was terminated on February 5, 2021. Otsuka On May 12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (“Otsuka”) providing Otsuka with an exclusive license to develop and commercialize AJOVY in Japan. Otsuka paid Teva an upfront payment of $50 million in consideration for the transaction. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $15 million, which was recognized as revenue in the third quarter of 2020. AJOVY was approved in Japan in June 2021 and launched on August 30, 2021. As a result of the launch, Otsuka paid Teva a milestone payment of $35 million, which was recognized as revenue in the third quarter of 2021. Teva may receive additional milestone payments upon achievement of certain revenue targets. Otsuka also pays Teva royalties on AJOVY sales in Japan. Celltrion In October 2016, Teva and Celltrion entered into a collaborative agreement to commercialize Truxima ® ® Regeneron In September 2016, Teva and Regeneron Pharmaceuticals, Inc. (“Regeneron”) entered into a collaborative agreement to develop and commercialize Regeneron’s pain medication product, fasinumab. Teva and Regeneron share in the global commercial rights to this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&D costs of approximately $1 billion. Teva made an upfront payment of $250 million to Regeneron in the third quarter of 2016 and additional payments for achievement of development milestones in an aggregate amount of $120 million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to $2,230 million, as well as future royalties. Currently, all non-essential activities and related expenditures for fasinumab have been put on hold. Next steps will be assessed together with Regeneron, with the intention of discussing data with the FDA. MedinCell In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable products. The lead product candidate selected was risperidone LAI (TV-46000) suspension for subcutaneous use for the treatment of schizophrenia. In August 2021, the FDA accepted the new drug application (“NDA”) for risperidone LAI, based on phase 3 data from two pivotal studies. Teva leads the clinical development and regulatory process and is responsible for commercialization of this product candidate. MedinCell may be eligible for development milestones, and future commercial milestones of up to $112 million in respect of risperidone LAI. Teva will also pay MedinCell royalties based on net sales. Assets and Liabilities Held For Sale: Certain assets of Teva’s business venture in Japan Teva operates its business in Japan, which was part of Teva’s International Markets segment, through a business venture with The Takeda Pharmaceutical Company Limited (“Takeda”), in which Teva owns a 51% stake and Takeda owns the remaining 49%. In July 2020, Teva and Takeda entered into a purchase agreement with Nichi-Iko to sell the majority of the business venture’s generic and operational assets. This transaction was completed on February 1, 2021. The business venture retains its specialty portfolio and other selected generic molecules, pipeline assets authorized generics and long listed products (LLPs). Until the closing date, Teva accounted for the business venture assets and liabilities that were sold as held for sale and determined that the fair value less cost of sale did not exceed the carrying value, resulting in an impairment charge of $247 million in other assets impairments, restructuring and other items recognized in 2020. General Assets and liabilities held for sale as of December 31, 2021 include certain manufacturing assets that are expected to be sold within the next year. Assets held for sale as of December 31, 2020 included the Teva-Takeda business venture assets sold during the first quarter of 2021, certain OTC assets sold during the second quarter of 2021 and other manufacturing assets. The table below summarizes all Teva assets and liabilities included as held for sale as of December 31, 2021 and December 31, 2020: December 31, December 31, (U.S. $ in millions) Inventories 2 146 Property, plant and equipment, net and others 86 312 Goodwill 7 27 Adjustments of assets held for sale to fair value (76 ) (296 ) Total assets of the disposal group classified as held for sale in the consolidated balance sheets $ 19 $ 189 Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets under accrued expenses ($23 million) and other long-term liabilities ($20 million) $ (43 ) $ —

Revenue from contracts with cus

Revenue from contracts with customers	12 Months Ended
	Dec. 31, 2021
Revenue from contracts with customers	NOTE 3—Revenue from contracts with customers: Disaggregation of revenue The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. Year ended December 31, 2021 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,394 4,807 1,889 739 13,829 Licensing arrangements 92 50 13 4 160 Distribution 1,323 1 65 — 1,390 Other (1 ) 27 65 408 500 $ 7,809 $ 4,886 $ 2,032 $ 1,151 $ 15,878 Year ended December 31, 2020 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,902 4,736 1,946 772 14,354 Licensing arrangements 84 32 9 4 129 Distribution 1,462 3 30 — 1,495 Other § (14 ) 169 527 680 $ 8,447 $ 4,757 $ 2,154 $ 1,302 $ 16,659 Year ended December 31, 2019 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,941 4,770 2,045 754 14,510 Licensing arrangements 109 29 4 5 147 Distribution 1,492 2 20 — 1,514 Other § (6 ) 177 545 716 $ 8,542 $ 4,795 $ 2,246 $ 1,304 $ 16,887 § Represents an amount less than $1 million. Variable consideration Variable consideration mainly includes SR&A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. For description of the nature of each deduction and how provisions are estimated see note 1. SR&A to U.S. customers comprised approximately 76% of the Company’s total SR&A as of December 31, 2021, with the remaining balance primarily in Canada and Germany. The changes in SR&A for third-party sales for the period ended December 31, 2021 and 2020 were as follows: Sales Reserves and Allowances Reserves Rebates Medicaid and Chargebacks Returns Other Total Total (U.S.$ in millions) Balance at January 1, 2020 $ 87 2,895 $ 1,109 $ 1,342 $ 637 $ 176 $ 6,159 $ 6,246 Provisions related to sales made in current year period 391 4,703 744 8,438 459 71 14,415 $ 14,806 Provisions related to sales made in prior periods — (219 ) (184 ) (65 ) (28 ) (1 ) (497 ) $ (497 ) Credits and payments (398 ) (5,360 ) (849 ) (8,614 ) (386 ) (100 ) (15,309 ) $ (15,707 ) Translation differences — 35 8 7 4 2 56 $ 56 Balance at December 31, 2020 $ 80 2,054 $ 828 $ 1,108 $ 686 $ 148 $ 4,824 $ 4,904 Provisions related to sales made in current year period 382 4,030 852 7,967 263 314 13,426 $ 13,808 Provisions related to sales made in prior periods (9 ) (125 ) (51 ) (47 ) (60 ) (26 ) (309 ) $ (318 ) Credits and payments (385 ) (4,275 ) (768 ) (7,937 ) (350 ) (321 ) (13,651 ) $ (14,036 ) Translation differences — (29 ) (7 ) (6 ) (4 ) (3 ) (49 ) $ (49 ) Balance at December 31, 2021 $ 68 1,655 854 1,085 535 112 4,241 $ 4,309 Allowance for credit losses Accounts receivable are recognized net of allowance for credit losses. Allowances for credit losses were $90 million and $126 million as of December 31, 2021 and December 31, 2020, respectively. The decrease is mainly due to write offs of the allowance balances against the corresponding accounts receivable.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventories	NOTE 4—Inventories: December 31, 2021 2020 (U.S. $ in millions) Finished products $ 1,932 $ 2,378 Raw and packaging materials 1,136 1,231 Products in process 587 605 Materials in transit and payments on account 163 189 $ 3,818 $ 4,403

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment	NOTE 5—Property, plant and equipment: Property, plant and equipment, net, consisted of the following: December 31, 2021 2020 (U.S. $ in millions) Machinery and equipment $ 5,098 $ 5,245 Buildings 2,568 2,720 Computer equipment and other assets 2,261 2,197 Assets under construction and payments on account 1,034 933 Land 262 292 11,223 11,388 Less—accumulated depreciation (5,241 ) (5,092 ) $5,982 $6,296 Depreciation expenses were $528 million, $537 million and $609 million in the years ended December 31, 2021, 2020 and 2019, respectively. During the years ended December 31, 2021, 2020 and 2019, Teva recorded impairments of property, plant and equipment in the amount of $160 million, $416 million and $139 million, respectively. See note 15.

Identifiable Intangible Assets

Identifiable Intangible Assets	12 Months Ended
	Dec. 31, 2021
Identifiable Intangible Assets	NOTE 6—Identifiable intangible assets: Identifiable intangible assets consisted of the following: Gross carrying amount Accumulated Net carrying amount December 31, 2021 2020 2021 2020 2021 2020 (U.S. $ in millions) Product rights $ 18,815 $ 19,650 $ 12,318 $ 12,094 $ 6,497 $ 7,556 Trade names 590 621 198 165 392 456 In-process research and development (IPR&D) 577 911 — — 577 911 Total $ 19,982 $ 21,182 $ 12,516 $ 12,259 $ 7,466 $ 8,923 Product rights and trade names Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various categories with a weighted average life of approximately 10 years. Amortization of intangible assets amounted to $802 million, $1,020 million and $1,113 million in the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, the estimated aggregate amortization of intangible assets for the years 2022 to 2026 is as follows: 2022—$689 million; 2023—$711 million; 2024—$651 million; 2025—$630 million and 2026—$652 million. These estimates do not include the impact of IPR&D that is expected to be successfully completed and reclassified to product rights. IPR&D Teva’s IPR&D are assets that have not yet been approved in major markets. IPR&D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. During 2021, Teva reclassified $192 million of products from IPR&D to product rights, of which $153 million were reclassified in connection with lenalidomide (generic equivalent of Revlimid ® Intangible assets impairment Impairments of identifiable intangible assets were $424 million, $1,502 million and $1,639 million in the years ended December 31, 2021, 2020 and 2019, respectively. These amounts are recorded in the statement of income (loss) under intangible assets impairments. Impairments in 2021 consisted of: (a) Identifiable product rights and trade names of $297 million due to: (i) $267 million, mainly related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States, and, (ii) $30 million related to lenalidomide (generic equivalent of Revlimid ® (b) IPR&D assets of $127 million, mainly due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States. Impairments in 2020 consisted of: (a) IPR&D assets of $797 million, mainly due to: (i) $300 million related to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States; (ii) $262 million related to lenalidomide (generic equivalent of Revlimid ® (b) Identifiable product rights of $705 million, mainly due to: (i) $398 million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States; (ii) $165 million in Japan in connection with ongoing regulatory pricing reductions and generic competition; and (iii) $110 million related to a change in the assumptions regarding competition for the expected relaunch of metformin tablets. Impairments in 2019 consisted of: (a) Identifiable product rights of $958 million, mainly due to: (i) $647 million due to updated market assumptions regarding price and volume of certain products acquired from Actavis Generics and primarily marketed in the United States, (ii) $128 million related to a decrease in future expected sales in Japan as a result of generic competition, and (iii) $123 million related to the discontinuation of certain products from Actavis Generics’ portfolio in several international markets; and (b) IPR&D assets of $681 million, due to: (i) $497 million related to various generic pipeline products acquired from Actavis Generics due to development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date or discount rate) in the United States (ii) $125 million related to lenalidomide (generic equivalent of Revlimid ® The fair value measurement of the impaired intangible assets in 2021 is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The discount rate applied ranged from 7.25% to 10%. A probability of success factor ranging from 20% to 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&D.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2021
Goodwill	NOTE 7—Goodwill: The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 were as follows: North Europe International Other Total (U.S. $ in millions) Balance as of December 31, 2019 (1) $ 11,091 $ 8,536 $ 2,532 $ 2,687 $ 24,846 Changes during the period: Goodwill reclassified as assets held for sale — (8 ) (19 ) — (27 ) Goodwill impairment (4,628 ) — — — (4,628 ) Translation differences 10 574 (151 ) — 433 Balance as of December 31, 2020 (1) $ 6,473 $ 9,102 $ 2,362 $ 2,687 $ 20,624 Changes during the period: Goodwill reclassified as assets held for sale — (7 ) — (11 ) (18 ) Translation differences 1 (551 ) (34 ) 18 (566 ) Balance as of December 31, 2021 (1) $ 6,474 $ 8,544 $ 2,328 $ 2,694 $ 20,040 (1) Accumulated goodwill impairment as of December 31, 2021, December 31, 2020 and December 31, 2019 was approximately $25.6 billion, $25.6 billion and $21.0 billion, respectively. Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva’s production and sale of APIs to third parties (“Teva API”) and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. The Teva API and Medis reporting units are included under “Other” in the above table. See note 19 for additional segment information. Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva’s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (“WACC”), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva’s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future. The current projections related to AUSTEDO and the resolution of the opioid and price fixing litigation in North America are significant assumptions in Teva’s future projections. Additionally, certain parts of its business volumes, particularly in Europe, were impacted by the COVID-19 pandemic. Management continues to analyze the expected pace of recovery of volumes and the related impact of the COVID-19 pandemic on Teva’s business. First Quarter Developments During the first quarter of 2021, management assessed developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount. Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of March 31, 2021 and, therefore, no quantitative assessment was performed. Second Quarter Developments During the second quarter of 2021, Teva completed its long-range planning (“LRP”) process. The LRP is part of Teva’s internal financial planning and budgeting processes and is discussed and reviewed by Teva’s management and its board of directors. Additionally, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test with the assistance of an independent valuation expert. Based on this analysis, no goodwill impairment charge was recorded during the second quarter of 2021. Third Quarter Developments During the third quarter of 2021, management assessed developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount. Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of September 30, 2021 and, therefore, no quantitative assessment was performed. Fourth Quarter Developments During the fourth quarter of 2021, management assessed developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount. Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of December 31, 2021 and, therefore, no quantitative assessment was performed. Changes to Teva’s current assessment regarding the impact of the COVID-19 pandemic on its projections and its long-term forecast related to AUSTEDO could result in future impairments. Teva noted its market capitalization has been below management’s assessment of the aggregated fair value of the Company’s reporting units. However, as of December 31, 2021, the Company’s market capitalization plus a reasonable control premium exceeded its book value.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases	NOTE 8—Leases: The components of operating lease cost for the years ended December 31, 2021, 2020 and 2019 were as follows: Year ended Year ended Year ended 2021 2020 2019 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Operating lease cost: Fixed payments and variable payments that depend on an index or rate $ 135 $ 148 $ 166 Variable lease payments not included in the lease liability 4 4 6 Short-term lease cost 2 3 6 $ 141 $ 155 $ 178 Supplemental cash flow information related to operating leases was as follows: Year ended Year ended Year ended 2021 2020 2019 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 143 $ 151 $ 169 Right-of-use assets obtained in exchange for lease obligations (non-cash): Operating leases $ 81 $ 211 $ 142 Supplemental balance sheet information related to operating leases was as follows: December 31, December 31, 2021 2020 (U.S. $ in millions) (U.S. $ in millions) Operating leases: Operating lease ROU assets $ 495 $ 559 Other current liabilities 109 116 Operating lease liabilit 416 479 Total operating lease liabilities $ 525 $ 595 December 31, December 31, 2021 2020 Weighted average remaining lease term Operating leases 7.3 years 7.5 years Weighted average discount rate Operating leases 5.4 % 5.2 % Maturities of operating lease liabilities were as follows: December 31, 2021 (U.S. $ in millions) 2022 $ 133 2023 106 2024 81 2025 71 2026 and thereafter 255 Total operating lease payments $ 646 Less: imputed interest 121 Present value of lease liabilities $ 525 At the end of the third quarter of 2020, after obtaining the right to use the building, Teva began transitioning its corporate headquarters to a consolidated site in Tel-Aviv, Israel. Teva has an operating lease for the office space in Tel Aviv for an initial term of twelve and a half years, with an option for three extensions. Teva estimates that the reasonably certain holding period of the lease for accounting purposes is twelve and a half years. As of September 30, 2020, upon initial recognition, Teva booked $74 million as operating lease ROU assets and $66 million as operating lease liability. As of December 31, 2021, Teva’s total finance lease assets finance lease liabilities

Debt obligations

Debt obligations	12 Months Ended
	Dec. 31, 2021
Debt obligations	NOTE 9—Debt obligations: a. Short-term debt: December 31, Weighted average Maturity 2021 2020 (U.S. $ in millions) Convertible debentures 0.25 % 2026 23 514 Current maturities of long-term liabilities 1,403 2,674 Total short term debt $ 1,426 $ 3,188 Convertible senior debentures The principal amount of Teva’s 0.25% convertible senior debentures due 2026 was $23 million as of December 31, 2021 and $514 million as of December 31, 2020. These convertible senior debentures include a “net share settlement” feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the “net share settlement” feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt. Holders of the convertible senior debentures exercised their optional repurchase right and redeemed $491 million of the convertible senior debentures on February 1, 2021, which was the date to exercise this right. b. Long-term debt: Weighted average Maturity December 31, December 31, % (U.S. $ in millions) Senior notes EUR 1,500 million (6) 1.13 % 2024 708 1,839 Sustainability-linked senior notes EUR 1,500 million (2)(*) 4.38 % 2030 1,699 — Senior notes EUR 1,300 million (6) 1.25 % 2023 670 1,595 Sustainability-linked senior notes EUR 1,100 million (3)(*) 3.75 % 2027 1,246 — Senior notes EUR 1,000 million 6.00 % 2025 1,134 1,230 Senior notes EUR 900 million 4.50 % 2025 1,020 1,107 Senior notes EUR 750 million 1.63 % 2028 844 916 Senior notes EUR 700 million (6) 3.25 % 2022 307 861 Senior notes EUR 700 million 1.88 % 2027 792 860 Senior notes USD 3,500 million 3.15 % 2026 3,496 3,495 Senior notes USD 3,000 million (6) 2.80 % 2023 1,453 2,996 Senior notes USD 2,000 million 4.10 % 2046 1,986 1,986 Senior notes USD 1,475 million (1) 2.20 % 2021 — 1,472 Senior notes USD 1,250 million 6.00 % 2024 1,250 1,250 Senior notes USD 1,250 million 6.75 % 2028 1,250 1,250 Senior notes USD 1,000 million 7.13 % 2025 1,000 1,000 Sustainability-linked senior notes USD 1,000 million (4)(*) 4.75 % 2027 1,000 — Sustainability-linked senior notes USD 1,000 million (5)(*) 5.13 % 2029 1,000 — Senior notes USD 844 million (6) 2.95 % 2022 715 853 Senior notes USD 789 million 6.15 % 2036 783 783 Weighted average Maturity December 31, December 31, % (U.S. $ in millions) Senior notes USD 613 million (7) 3.65 % 2021 — 616 Senior notes USD 588 million (7) 3.65 % 2021 — 586 Senior notes CHF 350 million 0.50 % 2022 382 397 Senior notes CHF 350 million 1.00 % 2025 383 398 Total senior notes 23,118 25,490 Other long-term debt 2 1 Less current maturities (1,403 ) (2,674 ) Less debt issuance costs (100 ) (86 ) Total senior notes and loans $ 21,617 $ 22,731 (1) In July 2021, Teva repaid $1,475 million of its 2.2% senior notes at maturity. (2) In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of 1,500 million euro bearing 4.38% annual interest and due May 2030. (3) In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of 1,100 million euro bearing 3.75% annual interest and due May 2027. (4) In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of $1,000 million bearing 4.75% annual interest and due May 2027. (5) In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of $1,000 million bearing 5.13% annual interest and due May 2029 (6) In November 2021, Teva consummated a cash tender offer and extinguished 873 million euro aggregate principal amount of its 1,500 million euro 1.13% senior notes due in October 2024 March 2023 April 2022 July 2023 December 2022 (7) In November 2021, Teva repaid $613 million and $588 million of its 3.65% senior notes at maturity. (8) Debt issuance costs as of December 31, 2021 include $40 million * Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 10c. Long term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts (as defined), if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. Long term debt as of December 31, 2021 is effectively denominated in the following currencies: U.S. dollar 61%, euro 37% and Swiss franc 2%. Teva’s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $2.3 billion unsecured syndicated revolving credit facility entered into in April 2019, which will be reduced to $2.2 billion in April 2022 (“RCF”). The RCF agreement provides for two separate tranches, a $1.15 billion tranche A and a $1.15 billion tranche B. Tranche A had a maturity date of April 8, 2022, of which an amount of $1.065 billion was extended twice, initially to April 8, 2023 and then to April 8, 2024. Tranche B has a maturity date of April 8, 2024. Loans and letters of credit will be available from time to time under each tranche for Teva’s general corporate purposes. The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including the requirement to maintain compliance with a net debt to EBITDA ratio, which becomes more restrictive over time. The net debt to EBITDA ratio limit was 5.00x through the fourth quarter of 2021, gradually declines to 4.50x in the first and second quarters of 2022, 4.00x in the third and fourth quarters of 2022, and will decline to 3.50x in the first quarter of 2023. The RCF can be used for general corporate purposes, including repaying existing debt. As of December 31, 2021 and as of the date of this Annual Report on Form 10-K, no amounts were outstanding under the RCF. Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes and sustainability-linked senior notes is outstanding, could lead to an event of default under the Company’s senior notes and sustainability-linked senior notes , Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date these financial statements are issued. Due to the fact that Teva’s cash flow generation and EBITDA vary between quarters, there is a possibility that Teva will not be compliant with its financial covenants during a specific period and could temporarily be unable to draw upon the RCF. If this were to occur, Teva expects to continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that these financial statements are issued without drawing upon the RCF. Teva continually evaluates its expected compliance with the covenants described above, and intends, if needed, to proactively renegotiate and amend such covenants. As of December 31, 2021, the required annual principal payments of long-term debt (excluding debt discount and issuance costs and fair value hedge adjustments), including convertible senior debentures, starting from the year 2023, are as follows: December 31, (U.S. $ in millions) 2023 $ 2,124 2024 1,960 2025 3,535 2026 * 3,523 2027 and thereafter 10,626 $ 21,768 * including $23 million convertible notes. See note 9a.

Derivative instruments and hedg

Derivative instruments and hedging activities	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities	NOTE 10—Derivative instruments and hedging activities: a. Foreign exchange risk management: In 2021, approximately 48% of Teva’s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. The Company enters into forward exchange contracts, purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: the euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar, the Polish zloty, the Indian rupee and other European and Latin American currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (“net investment hedge”) and entered into cross currency swaps and forward contracts in the past in order to hedge such an exposure. Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. b. Interest risk management: The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans, convertible debentures and syndicated revolving credit facility that bear a fixed or variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (“fair value hedge”) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (“cash flow hedge”), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. c. Bifurcated embedded derivatives: Upon issuance of sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential one-time premium payment upon failure to achieve certain sustainability performance targets, such as access to medicines in low-to-middle-income countries and absolute greenhouse gas emissions reduction, which were bifurcated and are accounted for separately as derivative financial instruments. As of December 31, 2021 the fair value of these derivative instruments is negligible. d. Derivative instrument outstanding: The following table summarizes the classification and fair values of derivative instruments: Fair value Not designated as hedging instruments December 31, 2021 December 31, 2020 Reported under (U.S. $ in millions) Asset derivatives: Other current assets: Option and forward contracts $ 30 $ 24 Liability derivatives: Other current liabilities: Option and forward contracts (23 ) (79 ) The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives designated in fair value or cash flow hedging relationships: Financial expenses, net Other comprehensive Year ended December 31, Year ended December 31, 2021 2020 2019 2021 2020 2019 Reported under (U.S. $ in millions) Line items in which effects of hedges are recorded $ 1,058 $ 834 $ 822 $ (391 ) $ (30 ) $ 160 Cross-currency swaps—cash flow hedge (1) — — (2 ) — — (33 ) Cross-currency swaps—net investment hedge (2) — (2 ) (29 ) — (21 ) (22 ) Interest rate swaps—fair value hedge (3) . — — 2 — — — The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives not designated as hedging instruments: Financial expenses, net Net revenues Year ended December 31, Year ended December 31, 2021 2020 2019 2021 2020 2019 Reported under (U.S. $ in millions) Line items in which effects of hedges are recorded $ 1,058 $ 834 $ 822 $ 15,878 $ 16,659 $ 16,887 Option and forward contracts (4) (45 ) 130 (51 ) — — — Option and forward contracts (5) — — — 31 * 14 * Represents an amount less than $0.5 million. (1) With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $588 million in cross-currency swap agreements against its outstanding 3.65% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $95 million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. (2) In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500 million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva’s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the float-for-float interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3 million. (3) In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its 2.8% senior notes due 2023 with respect to $500 million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $10 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. (4) Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. (5) Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2021 and 2022. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In 2021, the positive impact from these derivatives recognized under revenues was $31 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. e. Amortizations due to terminated derivative instruments: Forward starting interest rate swaps and treasury lock agreements In 2015, Teva entered into forward starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. The termination of these transactions resulted in a loss position of $493 million, which was recorded in other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. With respect to these forward starting interest rate swaps and treasury lock agreements, losses of $37 million, $31 million and $29 million were recognized under financial expenses, net for the years ended December 31, 2021, 2020 and 2019, respectively. Fair value hedge In the third quarter of 2016, Teva terminated interest rate swap agreements designated as a fair value hedge relating to its 2.95% senior notes due 2022 with respect to $844 million notional amount and its 3.65% senior notes due 2021 with respect to $450 million notional amount. Settlement of these transactions resulted in a gain position of $41 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. In the third quarter of 2019, Teva terminated $500 million interest rate swap agreements designated as a fair value hedge relating to its 2.8% senior notes due 2023 with respect to $3,000 million notional amount. Settlement of these transactions resulted in cash proceeds of $10 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt. Cash flow hedge In the fourth quarter of 2019, Teva terminated $588 million cross-currency swap agreements against its outstanding 3.65% senior notes which were repaid in November 2021. Settlement of these transactions resulted in cash proceeds of $95 million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, were amortized under financial expenses, net over the life of the debt. With respect to the interest rate swap and cross-currency swap agreements, gains of $5 million, $3 million and $6 million were recognized under financial expenses, net for the years ended December 31, 2021, 2020 and 2019, respectively. f. Securitization: In April 2011, Teva established a trade receivables securitization program to sell trade receivables to BNP Paribas Bank (“BNP”). Under the program Teva (on a consolidated basis) receives an initial cash purchase price and the right to receive a deferred purchase price (“DPP”), according to the purchase price for the receivables sold by it. On an individual seller basis, each Teva subsidiary sells receivables to BNP for an amount equal to their nominal amount. BNP then immediately on-sells such receivables to a bankruptcy-remote special-purpose entity (“SPE”), for an amount equal to the nominal amount of such trade receivables. The SPE then on-sells such receivables to a conduit sponsored by BNP (“the conduit”) for an initial cash purchase price (equal to the nominal amount of such receivables less a discount) and the right to receive a DPP. The SPE is a VIE for which Teva is considered to be the primary beneficiary. The SPE’s sole business consists of the purchase of receivables from Teva subsidiaries and the subsequent transfer of such receivables to the conduit. Although the SPE is included in Teva’s consolidated financial statements, it is a separate legal entity with separate creditors. The conduit and other designated creditors of the SPE are entitled, both before and upon the SPE’s liquidation, to be paid out of the SPE’s assets prior to the DPP payable to Teva. The assets of the SPE are not available to pay creditors of Teva or its subsidiaries. In August 2021, Teva has reached an agreement with BNP Paribas to extend the asset backed securitization agreement by additional five years, to August 2026. The amended agreement includes several improvements related to the commercial terms. No changes were applied with the program volume, scope or associated processes. Once sold to BNP, the relevant Teva subsidiary as seller has no retained interests in the receivables sold and they are unavailable to the relevant seller should the relevant seller become insolvent. The conduit has all the rights in the securitized trade receivables, including the right to pledge or dispose of such receivables. Consequently, receivables sold under this agreement are de-recognized from Teva’s consolidated balance sheet. The portion of the purchase price for the receivables which is not paid in cash by the conduit is a DPP asset. The conduit pays the SPE the DPP from collections received by the conduit from the securitized trade receivables (after paying senior costs and expenses, including the conduit’s debt service obligations), which the SPE then pays to Teva. The DPP asset represents a beneficial interest in the transferred financial assets and is recognized at fair value as part of the sale transaction. The DPP asset is included in other current assets on Teva’s consolidated balance sheet. Teva has collection and administrative responsibilities for the sold receivables. The fair value of these servicing arrangements as well as the fees earned was immaterial. The DPP asset as of December 31, 2021 and 2020 was $235 million and $266 million, respectively. As of December 31, 2021 and 2020, the balance of Teva’s securitized assets sold were $685 million and $734 million, respectively. The following table summarizes the sold receivables outstanding balance net of the DPP asset under the outstanding securitization program: As of and for the year ended 2021 2020 (U.S. $ in millions) Sold receivables at the beginning of the year $ 734 $ 690 Proceeds from sale of receivables 5,139 4,606 Cash collections (remitted to the owner of the receivables) (5,152 ) (4,607 ) Effect of currency exchange rate changes (36 ) 45 Sold receivables at the end of the year $ 685 $ 734

Legal Settlements and Loss Cont

Legal Settlements and Loss Contingencies	12 Months Ended
	Dec. 31, 2021
Legal Settlements and Loss Contingencies	NOTE 11—Legal settlements and loss contingencies: Legal settlements and loss contingencies in 2021 were expenses of $717 million, compared to expenses of $60 million in 2020 and an expense of $1,178 million in 2019. The expenses in 2021 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, the provision for the carvedilol patent litigation as well as a liability which was substantially offset by insurance receivable related to the Ontario Teachers Securities Litigation discussed in note 12. The expenses in 2020 were mainly related to a fine imposed by the European Commission in relation to a 2005 patent settlement agreement and an increase of a reserve for certain product liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics). The expenses in 2019 were mainly related to an estimated provision recorded in connection with settlement of the remaining opioid cases. As of December 31, 2021 and 2020, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $2,710 million and $1,625 million, respectively. In connection with Teva’s provision for legal settlements and loss contingencies as of December 31, 2021 related to the Ontario Teachers Securities Litigation, Teva also recognized an insurance receivable as mentioned above.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and contingencies	NOTE 12—Commitments and contingencies: a. Commitments: Royalty commitments: The Company is committed to pay royalties to owners of know-how, partners in alliances and other certain arrangements and to parties that financed research and development, at a wide range of rates as a percentage of sales or of the gross margin of certain products, as defined in the underlying agreements. Royalty expenses in each of the years ended December 31, 2021, 2020 and 2019 were $522 million, $505 million and $403 million, respectively. Milestone commitments: Teva has committed to make potential future milestone payments to third parties under various agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, Teva may be required to pay such amounts. As of December 31, 2021, if all development milestones and targets, for compounds in phase 2 and more advanced stages of development, are achieved, the total contingent payments could reach an aggregate amount of up to $121 million. Additional contingent payments are owed upon achievement of product approval or launch milestones. b. Contingencies: General From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. Based upon the status of the cases described below, management’s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management’s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva’s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA data. Intellectual Property Litigation From time to time, Teva seeks to develop generic versions of patent-protected pharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator’s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator’s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic version even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act. For example, Teva could be sued for patent infringement after commencing sales of a product. In addition, for biosimilar products, Teva could be sued according to the “patent dance” procedures of the Biologics Price Competition and Innovation Act (BPCIA). The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva’s product. The amount of lost profits would generally be based on the lost sales of the patentee’s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. In July 2014, GlaxoSmithKline (“GSK”) sued Teva in Delaware federal court for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK’s Coreg ® jury verdict, finding no induced infringement by Teva and that Teva did not owe any damages. On August 5, 2021, the Court of Appeals for the Federal Circuit issued a two-to-one decision reinstating the $235.5 million verdict and finding Teva liable for patent infringement. On October 7, 2021, Teva filed a petition for en banc , which petition is pending. If further appeals are decided against Teva, the case would be remanded to the district court for it to consider Teva’s other legal and equitable defenses that have not yet been considered by the district court. In the first quarter of 2021, Teva recognized a provision based on its offer to settle such matter. In October 2016, Adapt and Emergent Biosciences Inc. (“EBSI”) sued Teva in the District Court of New Jersey, asserting infringement of its patents expiring in 2035, as a result of Teva’s filing of its ANDA seeking to market a generic version of Narcan ® ® ® $420 million at the time Teva launched its generic version in December 2021, based on EBSI’s financial forecast for 2021. Product Liability Litigation Teva’s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both approaches, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in all of its markets. Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (API) supplied by multiple API manufacturers. Teva’s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (“MDL”) pending in the United States District Courts against Teva and numerous other manufacturers. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. Teva is not named in complaints with respect to irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring class claims. Defendants’ motions to dismiss in the valsartan, losartan and irbesartan MDL were denied in part and granted in part. Plaintiffs have moved to file amended complaints, which defendants have opposed. In the ranitidine MDL, the generics manufacturers’ motions to dismiss have been granted, although certain plaintiffs have appeals pending. Teva, as well as other generic manufacturers, is also named in several state court actions asserting allegations similar to those in the ranitidine MDL and the valsartan and losartan MDL. The state court valsartan and losartan actions are pending in New Jersey and Delaware and are currently stayed. In addition to these MDLs, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva’s, as well as other generic manufacturers’ metformin products. The defendants’ motion to dismiss the metformin complaint was granted, and on June 21, 2021, plaintiffs filed an amended complaint. Defendants’ motion to dismiss the amended metformin complaint is pending. Teva has also been named in one personal injury metformin case filed in Florida state court, which has been removed to federal court. Teva has filed a motion to dismiss in the Florida metformin action, which is currently pending. Similar lawsuits are pending in Canada and Germany. Competition Matters As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva’s patent challenges have resulted in litigation relating to Teva’s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. Teva and its subsidiaries have increasingly been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases, which are usually direct and indirect purchasers of pharmaceutical products, and often assert claims on behalf of classes of all direct and indirect purchasers, typically allege that (1) Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (2) significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These class action cases seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are automatically tripled under the relevant statutes, plus attorneys’ fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial—potentially measured in multiples of the annual brand sales—particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva’s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (“FTC”) v. Actavis, Inc. (the “AndroGel case”), that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This new test has resulted in increased scrutiny of Teva’s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva’s currently pending antitrust litigations. In May 2015, Cephalon Inc., a Teva subsidiary (“Cephalon”), entered into a consent decree with the FTC (the “Modafinil Consent Decree”) under which the FTC dismissed antitrust claims against Cephalon related to certain finished modafinil products (marketed as PROVIGIL ® In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling €60.5 million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. Teva and its affiliates have been named as defendants in lawsuits alleging that multiple patent litigation settlement agreements relating to AndroGel ® ® ® In December 2011, three groups of plaintiffs sued Wyeth and Teva for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving extended release venlafaxine (generic Effexor XR ® ® ® In February 2012, two purported classes of direct-purchaser plaintiffs sued GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal ® ® ® In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan ® ® ® Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of end-payers for, and direct-purchasers of, Actos ® ® ® ® In January 2019, generic manufacturer Cipla Limited filed a lawsuit against Amgen, which was later amended to include Teva as a defendant, in Delaware federal court, alleging, among other things, that a January 2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar ® ® ® On July 15, 2021, the U.K. Competition and Markets Authority (“CMA”) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK and Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA’s three prior investigations into the supply of hydrocortisone tablets in the U.K. and encompasses those allegations which were subject to prior statements of objections (a provisional finding of breach of the Competition Act), in particular those under case 50277-1 (unfair pricing, originally subject to a statement of objections on December 16, 2016), case 50277-2 (anti-competitive agreement with AMCo, originally subject to a statement of objections on March 3, 2017) as well as the CMA’s subsequent investigation relating to an anti-competitive agreement with Waymade. On January 9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to the December 16, 2016 and March 3, 2017 statements of objections, and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On October 6, 2021, Accord UK and Auden Mckenzie appealed the CMA’s decision. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. In March 2021, following the 2019 European Commission’s inspection of Teva and subsequent request for information, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. Annual sales of COPAXONE in the European Economic Area for 2021 were approximately $373 million. Between September 1, 2020 and December 20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and opt-out retailer purchasers of Bystolic ® ® ® In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV. Between September and December 2021, several retailers and health insurance providers filed similar claims in federal court in the Northern District of California and in the District of Minnesota. As they relate to Teva, the lawsuits challenge settlement agreements Teva entered into with Gilead in 2013 and 2014 to resolve patent litigation relating to Teva’s generic versions of Viread ® ® ® ® ® ® ® ® ® In August 2021, a plaintiff filed a putative class action suit in the United States District Court for the Eastern District of Pennsylvania against Takeda and several generic manufacturers, including Watson and Teva, alleging violations of the antitrust laws in connection with their settlement of patent litigation involving colchicine tablets (generic Colcrys ® ® Government Investigations and Litigation Relating to Pricing and Marketing Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (“DOJ”) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August 25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three count indictment charging Teva USA with criminal felony Sherman Act violations. See No. 20-cr-200 (E.D. Pa.). The indictment alleges Teva USA participated in a conspiracy with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream E-Cream, Gel, and Ointment), Warfarin, Nadolol, Temozolomide, and Tobramycin. On September 8, 2020, Teva USA pled not guilty to all counts. A tentative trial date is yet to be scheduled. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company’s business, including monetary penalties and debarment from federally funded health care programs. In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January 1, 2009 relevant to the Civil Division’s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December 15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June 18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May 10, 2019, most (though not all) of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November 1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June 10, 2020, most, but not all, of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA, in a similar complaint relating to dermatological generics products. On September 9, 2021, the states’ attorneys general amended their third complaint to, among other things, add California as a plaintiff. In the various complaints described above, the states seek a finding that the defendants’ actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (“Pennsylvania MDL”). On July 13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys’ general November 1, 2019 amended complaint, referenced above, along with certain complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. Teva moved the court to reconsider that ruling. On February 9, 2021, Teva’s motion to reconsider that ruling was granted, and on May 7, 2021, the Court chose the attorneys’ general third complaint filed on June 10, 2020 and subsequently amended to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. In June 2021, Teva settled with the State of Mississippi for $925,000, and the State dismissed its claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to that settlement. On December 9, 2021, the Court entered an order setting the schedule for the proceedings in the bellwether cases. The order did not include trial dates, but provides for the parties to complete briefing on motions for summary judgement in early 2024. Beginning on March 2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser opt-out plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October 16, 2018, the court denied certain of the defendants’ motions to dismiss as to certain federal claims, pending as of that date, and on February 15, 2019, the court granted in part and denied in part defendants’ motions to dismiss as to certain state law claims. On July 18, 2019, May 6, 2020 and October 8, 2021, certain individual plaintiffs commenced civil actions in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaints have been filed in the actions and three of the cases have been placed in deferred status. Certain counties in New York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been, or are in the process of being transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages. In March 2017, Teva received a subpoena from the U.S. Attorney’s office in Boston, Massachusetts requesting documents related to Teva’s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney’s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. It is alleged that Teva caused the submission of false claims to Medicare through Teva’s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On October 19, 2020, Teva filed a motion to dismiss the complaint on the grounds that it fails to state a claim. On September 10, 2021, the Court granted Teva’s motion to dismiss the unjust enrichment claim and denied the remainder of the motion. On October 15, 2021, Teva filed an answer to the complaint. The proceeding is in early stages. Additionally, on January 8, 2021, Humana, Inc. filed an action against Teva in the United States District Court for the Middle District of Florida based on the allegations raised in the August 2020 complaint filed by the U.S. Attorney’s Office in Boston. On April 2, 2021, Teva filed a motion to dismiss the claims on the grounds that the claims are time-barred and/or insufficiently pled, and that motion remains pending. In April 2021, a city and county in Washington sued Teva in the United States District Court for the Western District of Washington for alleged violations of the Racketeer Influenced and Corrupt Organizations Act, Washington’s Consumer Protection Act, and unjust enrichment concerning Teva’s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On September 28, 2021, plaintiffs filed an amended complaint. On November 17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffs’ claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. That motion remains pending. On June 29, 2021, Mylan Pharmaceuticals sued Teva in District Court for the District of New Jersey for alleged violations of the Lanham Act, unfair competition, monopolization, tortious interference, and trade libel. Plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, treble damages, attorneys’ fees and costs, and injunctive relief. On November 19, 2021, Teva filed a motion to dismiss the complaint on the grounds, among others, that none of its challenged conduct violates the law. Briefing on Teva’s motion remains ongoing. Opioids Litigation Since May 2014, more than 3,500 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio (“MDL Opioid Proceeding”) and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were transferred back to federal district court for additional discovery, pre-trial proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., No. 14-cv-04361 ® ® measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek non-economic damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. On April 19, 2021, a bench trial in California (The People of the State of California, acting by and through Santa Clara County Counsel James R. Williams, et. al. v. Purdue Pharma L.P., et. al.) commenced against Teva and other defendants focused on the marketing of branded opioids. On December 14, 2021, the court issued its final judgment in favor of the defendants on all claims. Teva expects that the plaintiffs will appeal this judgment. On June 29, 2021, a jury trial in New York ( In re Opioid Litigation In May 2019, Teva settled the Oklahoma litigation brought by the Oklahoma Attorney General (State of Oklahoma, ex. rel. Mike Hunter, Attorney General of Oklahoma vs. Purdue Pharma L.P., et. al.) for $85 million. The settlement did not include any admission of violation of law for any of the claims or allegations made. As the Company demonstrated a willingness to settle part of the litigation, for accounting purposes, management considered a portion of opioid-related cases as probable and, as such, recorded an estimated provision in the second quarter of 2019. Given the relatively early stage of the cases, manag

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2021
Income taxes	NOTE 13—Income taxes: a. Income (loss) before income taxes: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Parent Company and its Israeli subsidiaries $ 126 $ 947 $ 542 Non-Israeli subsidiaries 532 (5,353 ) (1,807 ) $ 658 $ (4,406 ) $ (1,265 ) b. Income taxes: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) In Israel $ 124 $ 60 $ 107 Outside Israel 87 (228 ) (385 ) $ 211 $ (168 ) $ (278 ) Current $ 270 $ 182 $ 885 Deferred (59 ) (350 ) (1,163 ) $ 211 $ (168 ) $ (278 ) 2021 2020 2019 (U.S. $ in millions) Income (loss) before income taxes $ 658 $ (4,406 ) $ (1,265 ) Statutory tax rate in Israel 23 % 23 % 23 % Theoretical provision for income taxes $ 151 $ (1,013 ) $ (291 ) Increase (decrease) in the provision for income taxes due to: The Parent Company and its Israeli subsidiaries - Tax benefits arising from reduced tax rates under benefit programs (12 ) (153 ) (77 ) Mainly nondeductible items and prior year tax 20 (30 ) 33 Non-Israeli subsidiaries, including impairments (*) 117 1,369 (115 ) Increase (decrease) in other uncertain tax positions—net (65 ) (341 ) 172 Effective consolidated income taxes $ 211 $ (168 ) $ (278 ) (*) In 2020, income before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect. The effective tax rate is the result of a variety of factors, including the geographic mix and type of products sold during the year, interest expense disallowance, amortization, legal settlement charges, impairments, the impact of adjustments to uncertain tax positions, adjustments to valuation allowances on deferred tax assets and the different effective tax rates applicable to non-Israeli subsidiaries that have tax rates different than Teva’s average tax rate. In 2020, Teva released a valuation allowance on its deferred tax assets in one jurisdiction and recorded a valuation allowance in another jurisdiction, with both adjustments reflecting changes in the business forecasts of profitability in these jurisdictions. The net effect of these changes did not materially impact Teva’s effective tax rate for 2020. c. Deferred income taxes: December 31, 2021 2020 (U.S. $ in millions) Deferred tax assets (liabilities), net: Inventory related $ 104 $ 212 Sales reserves and allowances 136 173 Provision for legal settlements 360 235 Intangible assets (*) (814 ) (1,064 ) Carryforward losses and deductions and credits (**) 2,093 2,176 Property, plant and equipment (215 ) (142 ) Deferred interest 617 527 Provisions for employee related obligations 95 107 Other 159 54 2,535 2,278 Valuation allowance—in respect of carryforward losses and deductions that may not be (2,723 ) (2,547 ) $ (188 ) $ (269 ) (*) The decrease in deferred tax liability is mainly due to impairment and amortization. (**) The amounts are shown following a reduction for unrecognized tax benefits of $10 million and $63 million as of December 31, 2021 and 2020, respectively. The amount as of December 31, 2021 represents the tax effect of gross carryforward losses and deductions with the following expirations: 2022 2023 2024 2031 2032 The deferred income taxes are reflected in the balance sheets among: December 31, 2021 2020 (U.S. $ in millions) Long-term assets—deferred income taxes 596 695 Long-term liabilities—deferred income taxes (784 ) (964 ) $ (188 ) $ (269 ) d. Uncertain tax positions: The following table summarizes the activity of Teva’s gross unrecognized tax benefits: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Balance at the beginning of the year $ 888 $ 1,223 $ 1,072 Increase (decrease) related to prior year tax positions, net (106 ) (238 ) 23 Increase related to current year tax positions 7 10 246 Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations (115 ) (105 ) (118 ) Other (2 ) (2 ) — Balance at the end of the year $ 672 $ 888 $ 1,223 Uncertain tax positions, mainly of a long-term nature, include accrued potential penalties and interest of $210 million, $173 million and $164 million as of December 31, 2021, 2020 and 2019, respectively. The total amount of interest and penalties reflected in the consolidated statements of income was a net increase of $37 million, $9 million and $33 million for the years ended December 31, 2021, 2020 and 2019, respectively. Substantially all the above uncertain tax benefits, if recognized, would reduce Teva’s annual effective tax rate. Teva does not expect uncertain tax positions to change significantly over the next 12 months, except in the case of settlements with tax authorities or court decisions, the likelihood and timing of which is difficult to estimate. e. Tax assessments: Teva files income tax returns in various jurisdictions with varying statutes of limitations. Teva and its subsidiaries in Israel have received final tax assessments through tax year 2007. In 2013, Teva settled the 2005-2007 income tax assessment with the Israeli tax authorities, paying $213 million. No further taxes are due in relation to these years. Certain guidelines which were set pursuant to the agreement reached in relation to the 2005-2007 assessment have been implemented in the audit of tax years 2008-2011 The Israeli tax authorities issued tax assessment decrees for 2008-2012 and 2013-2016, challenging the Company’s positions on several issues. Teva has protested the 2008-2012 and 2013-2016 decrees before the Central District Court in Israel. In October 2021, the Central District Court in Israel held in favor of the Israeli tax authorities with respect to 2008-2011 decrees. The case with respect to 2012-2016 remains pending with similar legal claims. The October 2021 Central District Court ruling found that Teva has a tax liability to the Israeli government for 2008-2011 of approximately $ million, of which a portion will be paid in cash during 2022 and 2023, and the remaining portion will be offset by carried forward losses that Teva would otherwise be entitled to. Teva intends to appeal the holding to the Supreme Court during the first quarter of 2022. The Company believes it has adequately provided for all of its uncertain tax positions, including those items currently under dispute, however, adverse results could be material. In the United States, Teva has one tax issue in dispute for the 2009-2011 audit cycle, which is currently in litigation. The 2012-2014 audit cycle is ongoing, with an assessment report expected to be received in 2022. Additionally, Teva’s U.S. subsidiaries have multiple audit cycles open. The Company believes it has adequately provided for these items and that any adverse results would have an immaterial impact on Teva’s financial statements. Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is ongoing. A final and binding decision against Teva in this case may lead to an impairment in the amount of $141 million. The Company’s subsidiaries in Europe have received final tax assessments mainly through tax year 2015. f. Basis of taxation: The Company and its subsidiaries are subject to tax in many jurisdictions, and estimation is required in recording the assets and liabilities related to income taxes. The Company believes that its accruals for tax liabilities are adequate for all open years. The Company considers various factors in making these assessments, including past history, recent interpretations of tax law, and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these assessments can involve a series of complex judgments regarding future events. An assessment of the tax that would have been payable had the Company’s foreign subsidiaries distributed their income to the Company is not practicable because of the multiple levels of corporate ownership and multiple tax jurisdictions involved in each hypothetical dividend distribution. Incentives Applicable until 2013 Under the incentives regime applicable to the Company until 2013, industrial projects of Teva and certain of its Israeli subsidiaries were eligible for “Approved Enterprise” status. Most of the projects in Israel have been granted Approved Enterprise status under the “alternative” tax benefit track which offered tax exemption on undistributed income for a period of two to ten years, depending on the location of the enterprise. Upon distribution of such exempt income, the distributing company is subject to corporate tax at the rate ordinarily applicable to the Approved Enterprise’s income. Amendment 69 to the Investment Law Pursuant to Amendment 69 to the Investment Law (“Amendment 69”), a company that elected by November 11, 2013 to pay a corporate tax rate as set forth in that amendment (rather than the tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company up The New Technological Enterprise Incentives Regime – Amendment 73 to the Investment Law Since 2017, a portion of the Company’s taxable income in Israel is entitled to a preferred 6% tax rate under Amendment 73 to the Investment Law as it pertains to Special Preferred Technological Enterprises. The new incentives regime applies to “Preferred Technological Enterprises” or “Special Preferred Technological Enterprises.” A “Preferred Technological Enterprise” is an enterprise that meet certain conditions, including, inter alia: • Investment of at least 7% of income, or at least NIS 75 million (approximately $22 million) in R&D activities; and • One of the following: a. At least 20% of the workforce (or at least 200 employees) are employed in R&D; b. A venture capital investment approximately equivalent to at least $2 million was previously made in the company; or c. Growth in sales or workforce by an average of 25% over the three years preceding the tax year. A “Special Preferred Technological Enterprise” is an enterprise that meets, inter alia conditions 1 and 2 above, and in addition has total annual consolidated revenues above NIS 10 billion (approximately $2.9 billion). until December 31, 2011 is entitled to distribute a dividend from such income without being required to pay additional corporate tax with respect to such dividend. A company that has so elected must make certain qualified investments in Israel over the five-year period commencing in 2013. Teva invested the entire required amount in 2013. During 2013, Teva applied the provisions of Amendment 69 to certain exempt profits Teva accrued prior to 2012. Consequently, Teva paid $577 million in corporate tax on exempt income of $9.4 billion. Part of this income was distributed as dividends during 2013-2018, while the remainder is available to be distributed as dividends in future years with no additional corporate tax liability. Incentives Applicable starting 2014 : The Incentives Regime – Amendment 68 to the Investment Law Under Amendment 68 to the Investment Law, which Teva started applying in 2014, upon an irrevocable election made by a company, a uniform corporate tax rate will apply to all qualifying industrial income of such company (“Preferred Enterprise”), as opposed to the previous law’s incentives, which were limited to income from Approved Enterprises during the benefits period. Under the law, when the election is made, the uniform tax rate for 2014 until 2016 was 9% in areas in Israel designated as Development Zone A and 16% elsewhere in Israel. The uniform tax rate for Development Zone A, as of January 1, 2017, is 7.5% (as part of changes enacted in Amendment 73, as described below). The profits of these “Preferred Enterprise” will be freely distributable as dividends, subject to a 20% or lower withholding tax, under an applicable tax treaty. Certain “Special Preferred Enterprises” that meet more stringent criteria (significant investment, R&D or employment thresholds) will enjoy further reduced tax rates of 5% in Zone A and 8% elsewhere. In order to be classified as a “Special Preferred Enterprises,” the approval of three governmental authorities in Israel is required. Preferred Technological Enterprises are subject to a corporate tax rate of 7.5% on their income derived from intellectual property in areas in Israel designated as Zone A and 12% elsewhere, while Special Preferred Technological Enterprises are subject to 6% on such income. The withholding tax on dividends from these enterprises is 4% to foreign companies (or a lower rate under a tax treaty, if applicable). Income not eligible for Preferred Technological Enterprise benefits is taxed at the regular corporate tax rate, which is %, or the preferred tax rate, as the case may be. The Parent Company and its Israeli subsidiaries elected to compute their taxable income in accordance with Income Tax Regulations (Rules for Accounting for Foreign Investors Companies and Certain Partnerships and Setting their Taxable Income), 1986. Accordingly, the taxable income or loss is calculated in U.S. dollars. Applying these regulations reduces the effect of U.S. dollar – NIS exchange rate on the Company’s Israeli taxable income. Non-Israeli subsidiaries are taxed according to the tax laws in their respective country of residence. Certain manufacturing subsidiaries operate in several jurisdictions outside Israel, some of which benefit from tax incentives such as reduced tax rates, investment tax credits and accelerated deductions. The 2021 Budget Law On November 15, 2021, the Israeli Parliament released its 2021-2022 Budget Law (“2021 Budget Law”). The 2021 Budget Law introduces a new dividend ordering rule that apportions every dividend between previously tax-exempt and previously taxed income. Consequently, distributions (including deemed distributions as per Section 51(h)/51B of the Investment Law) may entail additional corporate tax liability to the distributing company. The new dividend ordering rule may have an adverse effect on Teva’s financial condition and results of operation in future years, as the Company still has tax-exempt profits in its retained earnings. Income taxes have not been recognized for amounts of tax-exempt income generated from the Company’s current Approved Enterprises retained for reinvestment.

Equity

Equity	12 Months Ended
	Dec. 31, 2021
Equity	NOTE 14—Equity: a. Ordinary shares and ADSs As of December 31, 2021 and 2020, Teva had approximately 1.2 billion ordinary shares issued. Teva ordinary shares are traded on the Tel-Aviv Stock Exchange and on the New York Stock Exchange, in the form of American Depositary Shares (“ADSs”), each of which represents one ordinary share. b. Stock-based compensation plans Stock-based compensation plans are comprised of stock options, RSUs, PSUs, and other equity-based awards to employees, officers, directors and consultants of the Company and its affiliates. The purpose of the plans is to (a) attract, retain, motivate, and reward such individuals, and (b) promote the creation of long-term value for shareholders of the Company by closely aligning the interests of such individuals with those of the shareholders. On June 29, 2010, the Teva 2010 Long-Term Equity-Based Incentive Plan (“2010 Plan”) was approved by Teva’s shareholders, under which 70 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. The 2010 Plan expired on June 28, 2015 (except with respect to awards outstanding on that date), and no additional awards under the 2010 Plan may be made. On September 3, 2015, the Teva 2015 Long-Term Equity-Based Incentive Plan (“2015 Plan”) was approved by Teva’s shareholders, under which 43.7 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. On April 18, 2016, Teva’s shareholders approved an increase of an additional million equivalent share units to the share reserve of the 2015 Plan, so that million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, are approved for grant. On July 13, 2017, Teva’s shareholders approved an increase of an additional 65 million equivalent share units to the share reserve of the 2015 Plan, so that 142 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, are approved for grant. The 2015 Plan expired on June 30, 2020 (except with respect to awards outstanding on that date), and no additional awards under the 2015 Plan may be made. On June 11, 2020, the Teva 2020 Long-Term Equity-Based Incentive Plan (“2020 Plan”) was approved by Teva’s shareholders and became effective on July 1, 2020. Under the 2020 Plan , 68 million shares, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. As of December 31, 2021, 78.8 million shares remain available for future awards under the 2020 Plan. In the past, Teva had various employee stock and incentive plans under which stock options and other share-based awards were granted. Stock options and other share-based awards granted under such prior plans continue in accordance with the terms of the respective plans. The vesting period of the outstanding options and RSUs is generally between 1 to 4 years from the date of grant. The vesting period of PSUs is generally 3 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for ten years. Status of options A summary of the status of the options granted by Teva as of December 31, 2021, 2020 and 2019, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). Year ended December 31, 2021 2020 2019 Number (in thousands) Weighted average Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 35,234 $ 37.27 40,064 $ 37.90 48,393 $ 38.62 Changes during the year: Exercised — — — — (11 ) 16.99 Forfeited (3,644 ) 36.09 (3,610 ) 40.24 (8,318 ) 42.12 Expired (2,575 ) 42.40 (1,220 ) 49.35 — — Balance outstanding at end of year 29,015 36.96 35,234 37.27 40,064 37.90 Balance exercisable at end of year 26,989 38.30 28,556 40.56 26,601 43.41 No options were granted during 2019, 2020 and 2021. The following tables summarize information as of December 31, 2021 regarding the number of ordinary shares issuable upon (1) outstanding options and (2) vested options: (1) Number of ordinary shares issuable upon exercise of outstanding options Range of exercise prices Balance at end of Weighted average Weighted average Number of shares $ Years Lower than $15.01 592 11.40 5.84 $15.01 - $25.00 8,762 18.95 6.12 $25.01 - $35.00 6,364 34.61 5.16 $35.01 - $45.00 2,679 39.83 0.96 $45.01 - $55.00 6,801 51.01 3.18 $55.01 - $65.00 3,817 59.15 3.33 Total 29,015 36.96 4.37 (2) Number of ordinary shares issuable upon exercise of vested options Range of exercise prices Balance at end of Weighted average Weighted average Number of shares $ Years Lower than $15.01 592 11.40 5.84 $15.01 - $25.00 6,736 18.90 6.11 $25.01 - $35.00 6,364 34.61 5.16 $35.01 - $45.00 2,679 39.83 0.96 $45.01 - $55.00 6,801 51.01 3.18 $55.01 - $65.00 3,817 59.15 3.33 Total 26,989 38.30 4.24 The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $8.01 on December 31, 2021, less the weighted average exercise price in each range. This represents the potential amount receivable by the option holders had all option holders exercised their options as of such date. As of December 31, 2021, there were no exercisable options that were in-the-money. The total intrinsic value of options exercised during the year ended December 31, 2019 was immaterial, based on the Company’s average stock price of $11.50. No options were exercised during 2020 and 2021. Status of non-vested RSUs and PSUs The following table summarizes information about the number of RSUs and PSUs granted and outstanding: Year ended December 31, 2021 2020 2019 Number (in thousands) Weighted Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 20,720 $ 13.81 15,977 $ 16.49 10,403 $ 20.93 Granted 12,748 10.42 10,848 11.42 9,303 15.36 Vested (6,818 ) 15.60 (4,324 ) 19.49 (2,435 ) 30.24 Forfeited (2,238 ) 12.18 (1,781 ) 18.18 (1,294 ) 18.74 Balance outstanding at end of year 24,412 11.58 20,720 13.81 15,977 16.49 The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2021, 2020 and 2019, the Company recorded stock-based compensation costs as follows: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Employee stock options $ 16 $ 30 $ 46 RSUs and PSUs 103 99 73 Total stock-based compensation expense 119 129 119 Tax effect on stock-based compensation expense 12 14 14 Net effect $ 107 $ 115 $ 105 As of December 31, 2021, the total unrecognized compensation cost before tax on employee stock options and RSUs/PSUs amounted to $ million and $ million, respectively. This cost is expected to be recognized over a weighted average period of approximately years and years, respectively. d. Dividends Teva has not paid dividends on Teva ordinary shares or ADSs since December 2017. e. Accumulated other comprehensive loss The components of accumulated other comprehensive loss attributable to Teva are presented in the table below: Net Unrealized Gains/(Losses) Benefit Plans Foreign Available- Derivative Actuarial Total (U.S. $ in millions) Balance as of January 1, 2019 $ (1,878 ) $ 1 $ (504 ) $ (78 ) $ (2,459 ) Other comprehensive income/(loss) before reclassifications 100 (1 ) 54 (11 ) 142 Amounts reclassified to the statements of income — — 30 (10 ) 20 Net other comprehensive income/(loss) before tax 100 (1 ) 84 (21 ) 162 Corresponding income tax (16 ) — — 1 (15 ) Net other comprehensive income/(loss) after tax* 84 (1 ) 84 (20 ) 147 Balance as of December 31, 2019 (1,794 ) — (420 ) (98 ) (2,312 ) Other comprehensive income/(loss) before reclassifications (190 ) — 22 (7 ) (175 ) Amounts reclassified to the statements of income — — 35 (12 ) 23 Net other comprehensive income/(loss) before tax (190 ) — 57 (19 ) (152 ) Corresponding income tax 65 — — 1 66 Net other comprehensive income/(loss) after tax* (125 ) — 57 (18 ) (86 ) Balance as of December 31, 2020 (1,919 ) — (363 ) (117 ) (2,399 ) Other comprehensive income/(loss) before reclassifications (386 ) — — 18 (368 ) Amounts reclassified to the statements of income — — 39 18 57 Net other comprehensive income/(loss) before tax (386 ) — 39 36 (311 ) Corresponding income tax 31 — — (4 ) 27 Net other comprehensive income/(loss) after tax* (355 ) — 39 32 (283 ) Balance as of December 31, 202 1 $ (2,274 ) — $ (324 ) $ (85 ) $ (2,683 ) * Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $107 million loss in 2021, $56 million gain in 2020 and $14 million gain in 2019.

Other assets impairments, restr

Other assets impairments, restructuring and other items	12 Months Ended
	Dec. 31, 2021
Other assets impairments, restructuring and other items	NOTE 15—Other assets impairments, restructuring and other items: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Impairment of long-lived tangible assets (1) $ 160 $ 416 $ 139 Contingent consideration (see note 20) 7 (81 ) 59 Restructuring 133 120 199 Other 41 24 26 Total $ 341 $ 479 $ 423 (1) Including impairments related to exit and disposal activities. Impairments Impairments of tangible assets for the years ended December 31, 2021, 2020 and 2019 were $160 million, $416 million and $139 million, respectively. The impairment for the year ended December 31, 2021 was mainly related to certain assets in the Europe and North America segments. The impairment for the year ended December 31, 2020 was mainly related to the sale of certain assets from Teva’s business venture in Japan, which was completed on February 1, 2021, as well as plant rationalization. See note 2. Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities. Contingent consideration In 2021, Teva recorded an expense of $7 million for contingent consideration, compared to income of $81 million in 2020 and an expense of $59 million in 2019, respectively. The income in 2020 was mainly related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid ® Restructuring In 2021, Teva recorded $133 million of restructuring expenses, compared to $120 million in 2020 and $199 million in 2019. The expenses in 2021 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017. The following tables provide the components of restructuring costs: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Restructuring Employee termination $ 117 $ 71 $ 159 Other 16 49 40 Total $ 133 $ 120 $ 199 The following table provides the components of and changes in the Company’s restructuring accruals: Employee Other Total (U.S. $ in millions ) Balance as of January 1, 2019 $ (204 ) $ (29 ) $ (233 ) Provision (159 ) (40 ) (199 ) Utilization and other* 155 62 217 Balance as of January 1, 2020 $ (208 ) $ (7 ) $ (215 ) Provision (71 ) (49 ) (120 ) Utilization and other* 164 49 213 Balance as of December 31, 2020 $ (115 ) $ (7 ) $ (122 ) Provision (117 ) (16 ) (133 ) Utilization and other* 101 16 117 Balance as of December 31, 2021 $ (131 ) $ (7 ) $ (138 ) * Includes adjustments for foreign currency translation. Significant regulatory and other events In July 2018, the FDA completed an inspection of Teva’s manufacturing plant in Davie, Florida in the United States, and issued a Form FDA-483 to the site. In October 2018, the FDA notified Teva that the inspection of the site had been classified as “official action indicated” (“OAI”), and on February 5, 2019, Teva received a warning letter from the FDA that contained four additional enumerated concerns related to production, quality control and investigations at this site. Since the inspection, Teva has been working diligently to address the FDA’s concerns in a manner consistent with current good manufacturing practice (cGMP) requirements as quickly and as thoroughly as possible. FDA follow up inspections occurred in January 2020 and in May 2021. In an official “Warning Letter Closeout Letter” dated September 1, 2021, FDA notified Teva that FDA had completed its evaluation of Teva’s corrective actions, and it appeared that Teva had adequately addressed the warning letter. In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown nitrosamine impurity called NDMA found in valsartan API supplied by Zhejiang Huahai Pharmaceuticals Co. Ltd. (“Huahai”). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva’s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue. In addition, multiple lawsuits have been filed in connection with this matter, which may lead to additional customer penalties, impairments and litigation costs. In the second quarter of 2020, Teva’s operations in its manufacturing facilities in Goa, India were temporarily suspended due to a water supply issue. During the second half of 2020, Teva completed partial remediation of this issue and restarted limited supply from its Goa facilities. The site experienced some additional delays in the first quarter of 2021 due to labor related issues, but the situation stabilized during the second quarter of 2021. The water supply remediation is expected to be completed during the second quarter of 2022, and in the meantime the site is operating under an interim water solution without any material impact expected on compliance and supply capacity. The impact to Teva’s financial results for the twelve months ended December 31, 2021 was immaterial. In June 2021, the Company temporarily paused manufacturing at its Irvine, California facility in the United States, and suspended release of product from the facility pending completion of an open manufacturing investigation. In July 2021, the FDA initiated an establishment inspection at the facility. On August 18, 2021, the Company issued field alert reports to the FDA for products manufactured at the Irvine facility and put Irvine-manufactured products in Teva’s distribution center on hold. On August 20, 2021, the FDA completed its inspection and issued a Form FDA-483 to the Irvine facility with ten observations and, on December 17, 2021, the FDA notified the Company that the inspection classification of this site is OAI. Teva is working diligently to address the FDA’s concerns in a manner consistent with current good manufacturing practice (CGMP) requirements. In addition, Teva has been in discussions with the FDA Drug Shortage Staff (DSS) and FDA Office of Manufacturing Quality (OMQ) to recommence the distribution, release and manufacture of certain medically necessary products from the site under defined controls and protocols to minimize the impact on public health. If Teva is unable to address such inspection issues satisfactorily, it could be subject to additional regulatory actions. Teva has considered these developments and has recorded immaterial costs in its financial statements related to this matter. Teva will continue to assess potential financial implications, including loss of revenues, impairments, inventory write offs, customer penalties, idle capacity charges, costs of additional remediation and/or FDA enforcement actions.

Other income

Other income	12 Months Ended
	Dec. 31, 2021
Other income	NOTE 16—Other income: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Gain on divestitures, net of divestitures related costs (1) 51 8 50 Section 8 and similar payments (2) 19 — 5 Gain (loss) on sale of assets 7 11 (1 ) Other, net 22 20 22 Total other income $ 98 $ 40 $ 76 (1) In 2021, mainly In 2020 and 2019, mainly related to the divestment of several activities in the International Markets segment. (2) Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada.

Financial expenses, net

Financial expenses, net	12 Months Ended
	Dec. 31, 2021
Financial expenses, net	NOTE 17—Financial expenses, net: Year ended December, 31 2021 2020 2019 (U.S. $ in millions) Interest expenses and other bank charges 891 901 822 (Income) loss from investments (1) 90 (104 ) (41 ) Foreign exchange (gains) losses, net 7 (26 ) (15 ) Other, net (2) 71 62 55 Total finance expense, net $ 1,058 $ 834 $ 822 (1) (Income) loss from investments in 2021 and 2020 comprised mainly of revaluation gains and loss of Teva’s investment in American Well Corporation (“American Well”). See note 20. (2) Amortization of issuance costs and terminated derivative instruments.

Earnings (Loss) per Share

Earnings (Loss) per Share	12 Months Ended
	Dec. 31, 2021
Earnings (Loss) per Share	NOTE 18—Earnings (loss) per share: Net income (loss) attributable to Teva and weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2021, 2020 and 2019 are as follows: Year ended December, 31 2021 2020 2019 (U.S. $ in millions, except share data) Net income (loss) used for the computation of basic and diluted earnings (loss) per share 417 $ (3,990 ) $ (999 ) Weighted average number of shares used in the computation of basic earnings (loss) per share 1,102 1,095 1,091 Weighted average number of shares used in the computation of diluted earnings (loss) per share 1,107 1,095 1,091 Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested restricted share units (“RSUs”) and performance share units (“PSUs”) during the period, net of treasury shares. In computing diluted earnings per share for the year ended December 31, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans, amounting to 5 million weighted average shares, using the treasury stock method. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share. In computing diluted loss per share for the years ended December 31, 2020 and 2019, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans, amounting to 104 million and 113 million weighted average shares, respectively, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. Basic and diluted earnings per share was $0.38 for the year ended December 31, 2021, compared to basic and diluted loss per share of $3.64 and $0.91 for the years ended December 31, 2020 and December 31, 2019, respectively.

Segments

Segments	12 Months Ended
	Dec. 31, 2021
Segments	NOTE 19—Segments: Teva operates its business and reports its financial results in three segments: (a) North America segment, which includes the United States and Canada. (b) Europe segment, which includes the European Union, the United Kingdom and certain other European countries. (c) International Markets segment, which includes all countries other than those in the North America and Europe segments. In addition to these three segments, Teva has other sources of revenues included in other activities, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. Teva’s Chief Executive Officer (“CEO”), who is the chief operating decision maker (“CODM”), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance. Segment profit is comprised of gross profit for the segment less R&D expenses, S&M expenses, G&A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva’s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. Teva’s CEO may review its strategy and organizational structure. Any changes in strategy may lead to a reevaluation of the Company’s segments and goodwill allocation to reporting units, as well as fair value a. Segment information: Year ended December 31, 2021 North America Europe International Markets (U.S. $ in millions) Revenues $ 7,809 $ 4,886 $ 2,032 Gross profit 4,226 2,823 1,118 R&D expenses 618 244 68 S&M expenses 988 846 417 G&A expenses 427 244 109 Other income (31 ) (5 ) (5 ) Segment profit $ 2,224 $ 1,494 $ 529 Year ended December 31, 2020 North America Europe International Markets (U.S. $ in millions) Revenues $ 8,447 $ 4,757 $ 2,154 Gross profit 4,489 2,666 1,096 R&D expenses 622 247 70 S&M expenses 1,013 830 427 G&A expenses 443 261 136 Other income (10 ) (3 ) (11 ) Segment profit $ 2,421 $ 1,331 $ 474 Year ended December 31, 2019 North America Europe International Markets (U.S. $ in millions) Revenues $ 8,542 $ 4,795 $ 2,246 Gross profit 4,350 2,704 1,167 R&D expenses 652 262 88 S&M expenses 1,021 890 481 G&A expenses 439 239 138 Other income (14 ) (5 ) (3 ) Segment profit $ 2,252 $ 1,318 $ 464 Year ended December 31, 2021 2020 2019 (U.S. $ in millions) North America profit $ 2,224 $ 2,421 $ 2,252 Europe profit 1,494 1,331 1,318 International Markets profit 529 474 464 Total reportable segments profit 4,246 4,225 4,034 Profit of other activities 154 163 108 Total segments profit 4,401 4,388 4,142 Amounts not allocated to segments: Amortization 802 1,020 1,113 Other assets impairments, restructuring and other items 341 479 423 Goodwill impairment — 4,628 — Intangible asset impairments 424 1,502 1,639 Legal settlements and loss contingencies 717 60 1,178 Other unallocated amounts 402 271 232 Consolidated operating income (loss) 1,716 (3,572 ) (443 ) Financial expenses, net 1,058 834 822 Consolidated income (loss) before income taxes $ 658 $ (4,406 ) $ (1,265 ) b. Segment revenues by major products and activities: The following tables present revenues by major products and activities for each segment for the year ended December 31, 2021, 2020 and 2019: North America segment: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Generic products $ 3,769 $ 4,010 $ 3,963 AJOVY 176 134 93 AUSTEDO 802 637 412 BENDEKA/TREANDA 385 415 496 COPAXONE 577 884 1,017 ProAir* 180 241 274 Anda 1,323 1,462 1,492 Other 597 664 796 Total $ 7,809 $ 8,447 $ 8,542 * Does not include revenues from the ProAir authorized generic, which are included under generic products. Europe segment: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Generic products $ 3,569 $ 3,513 $ 3,470 AJOVY 87 31 3 COPAXONE 391 400 432 Respiratory products 356 353 354 Other 483 459 536 Total $ 4,886 $ 4,757 $ 4,795 International Markets segment: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Generic products $ 1,649 $ 1,792 $ 1,893 AJOVY 50 18 § COPAXONE 37 53 63 Other 295 291 291 Total $ 2,032 $ 2,154 $ 2,246 § Represents an amount less than $1 million Revenues are attributable to countries based on sales to third parties in such countries. Revenues within the United States constituted 46%, 48% and 47% of Teva’s consolidated revenues for the years ended December 31, 2021, 2020 and 2019, respectively. Revenues within the Company’s country of domicile (Israel) constituted 2%, 2% and 2% of Teva’s consolidated revenues for the years ended December 31, 2021, 2020 and 2019, respectively. c. Supplemental data—major customers: The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2021, 2020 and 2019. Percentage of Third Party Net Sales 2021 2020 2019 McKesson Corporation 11 % 12 % 13 % AmerisourceBergen Corporation 11 % 12 % 12 % Most of Teva’s revenues from these customers were in the North America segment. d. Property, plant and equipment—by geographical location were as follows: December 31, 2021 2020 (U.S. $ in millions) Israel $ 1,543 $ 1,611 United States 692 790 Croatia 481 539 Germany 1,045 933 Czech republic 324 330 Hungary 321 325 Ireland 269 267 Other 1,307 1,501 Total property, plant and equipment $ 5,982 $ 6,296

Fair value measurement

Fair value measurement	12 Months Ended
	Dec. 31, 2021
Fair value measurement	NOTE 20—Fair value measurement: Financial items carried at fair value as of December 31, 2021 and 2020 are classified in the tables below in one of the three categories described in note 1f: December 31, 2021 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 220 $ — $ — $ 220 Cash, deposits and other 1,945 — — 1,945 Investment in securities: Equity securities* 18 — — 18 Other 6 — 1 7 Restricted cash 33 — — 33 Derivatives: Asset derivatives—options and forward contracts — 30 — 30 Liabilities derivatives: — Options and forward contracts — (23 ) — (23 ) Bifurcated embedded derivatives — — § — Contingent consideration** — — (176 ) (176 ) Total $ 2,222 $ 7 $ (175 ) $ 2,054 § Represents an amount less than 0.5 million. December 31, 2020 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 367 $ — $ — $ 367 Cash, deposits and other 1,810 — — 1,810 Investment in securities: Equity securities 25 259 — 284 Other, mainly debt securities 5 — 10 15 Derivatives: Asset derivatives—options and forward contracts — 24 — 24 Liability derivatives—options and forward contracts — (79 ) — (79 ) Contingent consideration** — — (268 ) (268 ) Total $ 2,207 $ 204 $ (258 ) $ 2,153 * During the first quarter of 2021, Teva’s shares in American Well Corporation (“American Well”) moved from a Level 2 measurement to a Level 1 measurement within the fair value hierarchy, since they were no longer subject to a sale restriction. By the end of September, 2021, Teva sold all of its holdings in American Well. ** Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor ranging from 90% to 100% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&D. The discount rate applied ranged from 7.5% to 8.0%. The weighted average discount rate, calculated based on the relative fair value of Teva’s contingent consideration liabilities, was 7.7%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs. December 31, December 31, (U.S. $ in millions) Fair value at the beginning of the period $ (258 ) $ (448 ) Transfer into Level 3- equity securities — 179 Revaluation of equity securities — 80 Redemption of debt securities (9 ) — Revaluation of debt securities — (2 ) Reclassification to Level 2- equity securities — (259 ) Bifurcated embedded derivatives § — Adjustments to provisions for contingent consideration: Actavis Generics transaction 15 156 Eagle transaction (23 ) (75 ) Settlement of contingent consideration: Eagle transaction 100 111 Fair value at the end of the period $ (175 ) $ (258 ) § Represents an amount less than $0.5 million. Teva’s financial instruments consist mainly of cash and cash equivalents, investments in securities, current and non-current receivables, short-term credit, accounts payable and accruals, loans, senior notes and sustainability-linked senior notes, convertible senior debentures and derivatives. The fair value of the financial instruments included in working capital and non-current receivables approximates their carrying value. The fair value of long-term bank loans mostly approximates their carrying value, since they bear interest at rates close to the prevailing market rates. Financial instruments not measured at fair value Financial instruments measured on a basis other than fair value consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value: Estimated fair value* December 31, 2021 2020 (U.S. $ in millions) Senior notes and sustainability-linked senior notes included under senior notes and loans $ 21,477 $ 22,684 Senior notes and convertible senior debentures included under short-term debt 1,426 3,207 Total $ 22,903 $ 25,891 * The fair value was estimated based on quoted market prices.

Long-term Employee-related Obli

Long-term Employee-related Obligations	12 Months Ended
	Dec. 31, 2021
Long-term Employee-related Obligations	NOTE 21—Long-term employee-related obligations: a. Long-term employee-related obligations consisted of the following: December 31, 2021 2020 (U.S. $ in millions) Accrued severance obligations $ 83 $ 82 Defined benefit plans 142 192 Total $ 225 $ 275 As of December 31, 2021 and 2020, Teva had $97 million and $86 million, respectively, deposited in funds managed by financial institutions and earmarked by management to cover severance pay liability. Such deposits are not considered to be “plan assets” and are therefore included in other non-current assets. Most of the change resulted from actuarial updates, as well as from exiting from several defined benefit plans in several countries. The Company expects to expense an approximate contribution of $114 million in 2022 to pension funds and insurance companies in connection with its severance and pension pay obligations. The main terms of the different arrangements with employees are described in below. b. Terms of arrangements: Israel Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Parent Company and its Israeli subsidiaries make ongoing deposits into employee pension plans to fund their severance liabilities. Generally, employees that joined the Company after 2005, have signed an arrangement, pursuant to which such deposits are made in lieu of the Company’s severance liability. Therefore, no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who were employed by the Parent Company and its Israeli subsidiaries prior to that date, as well as employees who have special contractual arrangements, are provided for in the financial statements based upon the number of years of service and the latest monthly salary of such employees. Europe Many of the employees in the Company’s European subsidiaries are entitled to a retirement grant when they leave the Company. In the consolidated financial statements, the liability of the European subsidiaries is accrued, based on the length of service and remuneration of each employee at the balance sheet date. Other employees in Europe are entitled to a pension according to a defined benefit scheme providing benefits based on final or average pensionable pay or according to a hybrid pension scheme that provides retirement benefits on a defined benefit and a defined contribution basis. Independent certified actuaries value these schemes and determine the rates of contribution payable. Pension costs for the defined benefit section of the scheme are accounted for on the basis of charging the expected cost of providing pensions over the period during which the subsidiaries benefit from the employees’ services. The Company uses December 31 as the measurement date for defined benefit plans. North America The Company’s North American subsidiaries mainly provide various defined contribution plans for the benefit of their employees. Under these plans, contributions are based on specified percentages of pay. Additionally, a multi-employer plan is maintained in accordance with various union agreements. Latin America The majority of the employees in Latin America are entitled to severance under local law. The severance payments are calculated based on service term and employee remuneration, and accruals are maintained to reflect these amounts. In some Latin American countries it is Teva’s practice to offer retirement health benefits to qualifying employees. Based on the specific plan requirements, benefits accruals are maintained to reflect the estimated amounts or adjusted if future plans are modified. The Company expects to pay the following future minimum benefits to its employees: $13 million in 2022; $12 million in 2023; $11 million in 2024; $11 million in 2025; $11 million in 2026 and $63 million in the aggregate between 2027 to 2031. These amounts do not include amounts that may be paid to employees who cease working with the Company before their normal retirement age.

Schedule of Valuation and Quali

Schedule of Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2021
Schedule of Valuation and Qualifying Accounts	Column A Column B Column C Column D Column E Balance at Charged to costs Charged to other Deductions Balance at end Allowance for doubtful accounts: Year ended December 31, 2021 $ 200 $ (8 ) $ — $ (28 ) $ 164 Year ended December 31, 2020 $ 209 $ (11 ) $ 2 $ — $ 200 Year ended December 31, 2019 $ 232 $ (16 ) $ — $ (7 ) $ 209 Allowance in respect of carryforward tax losses and deductions that may not be utilized: Year ended December 31, 2021 $ 2,547 $ 336 $ — $ (160 ) $ 2,723 Year ended December 31, 2020 $ 1,974 $ 670 $ — $ (97 ) $ 2,547 Year ended December 31, 2019 $ 1,633 $ 555 $ — $ (214 ) $ 1,974

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
General	a. General: Operations Teva Pharmaceutical Industries Limited (the “Parent Company”), headquartered in Israel, together with its subsidiaries and associated companies (the “Company,” “Teva” or the “Group”), is engaged in the development, manufacturing, marketing and distribution of generics, specialty medicines and biopharmaceuticals. The majority of the Group’s revenues are in the United States and Europe. Basis of presentation and use of estimates The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). In preparing the Company’s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of intangible assets and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. The inputs into Teva’s judgments and estimates also consider the economic implications of the COVID-19 pandemic on its critical accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva’s employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the COVID-19 pandemic within its financial statements may change in future periods. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. Functional currency A major part of the Group’s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (“dollar” or “$”). The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year. Differences resulting from translation are presented as other comprehensive income (loss) in the consolidated statements of comprehensive income (loss). In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). Principles of consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and variable interest entities (“VIEs”) for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders’ interests are shown as non-controlling interests in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, are carried on the equity basis. For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated.
New accounting pronouncements	b. New accounting pronouncements Recently adopted accounting pronouncements In March 2020, the FASB issued ASU 2020-04 “Reference Rate Reform (Topic 848)—Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March 12, 2020 through December 31, 2022. There was no material impact to the Company’s consolidated financial statements for the period ended December 31, 2021 as a result of adopting this standard update. The Company has completed negotiations to transform the facility base rate of its securitization program and is continuing to evaluate the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities. However, it is not expected to have a material impact on the consolidated financial results of operations, financial position or cash flows. In December 2019, the FASB issued ASU 2019-12 “Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes” (the “update”). The amendments in this update simplify the accounting for income taxes by removing the following exceptions in ASC 740: (1) exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items; (2) exception to accounting for basis differences for equity method investments when a foreign subsidiary becomes an equity method investment; (3) exception to accounting for basis differences for a foreign subsidiary when a foreign equity method investment becomes a subsidiary; and (4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the update also simplifies the accounting for income taxes in certain topics as follows: (1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax; (2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; (3) specifying that an entity can elect (rather than be required to) allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; and (4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. Teva adopted the provisions of this update as of January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s consolidated financial results of operations, financial position or cash flows. Recently issued accounting pronouncements, not yet adopted In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832)”, which requires annual disclosures that increase the transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2021. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. In October 2021, the FASB issued ASU 2021-08 “Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments to this guidance are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company expects to apply modified retrospective basis adoption of this guidance, which will not have a significant impact on the Company’s consolidated financial statements.
Acquisitions	c. Acquisitions: Teva’s consolidated financial statements include the operations of acquired businesses from the date of the acquisition’s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed unless it has an alternative future use. Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period, with any adjustments in fair value recognized in earnings under other assets impairments, restructuring and other items.
Collaborative arrangements	d. Collaborative arrangements: Collaborative arrangements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. The Company recognizes revenue generated and costs incurred on sales to third parties as it relates to collaborative agreements as gross or net. If the Company is the principal participant in a transaction, revenues and costs are recorded on a gross basis; otherwise, revenues are recorded on a net basis.
Equity investments	e. Equity investments: The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative prescribed within ASU 2016-01 “Financial Instruments—Recognition and Measurement of Financial Assets and Financial Liabilities” to the extent such investments are not subject to consolidation or the equity method. Under the measurement alternative, these financial instruments are carried at cost, less any impairment (assessed quarterly), adjusted for changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. In addition, income is recognized when dividends are received only to the extent they are distributed from net accumulated earnings of the investee. Otherwise, such distributions are considered returns of investment and are recorded as a reduction of the cost of the investment. The Company accounts for equity investments as current when the Company has the intent and ability to sell such assets within the next twelve months.
Fair value measurement	f. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
Investment in debt securities	g. Investment in debt securities: Investment in securities consists of debt securities classified as available-for-sale and recorded at fair value. The fair value of quoted securities is based on current market value. When debt securities do not have an active market, fair value is determined using a valuation model. This model is based on reference to other instruments with similar characteristics, or a discounted cash flow analysis, or other pricing models making use of market inputs and relying as little as possible on entity-specific inputs. The Company’s investment in debt securities accounting policy until December 31, 2019, prior to the adoption of the new Current Expected Credit Losses (“CECL”) standard Unrealized gains of available for sale debt securities, net of taxes, are reflected in other comprehensive income. Unrealized losses considered to be temporary are reflected in other comprehensive income; unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for debt securities are included in financial expenses, net. The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. For debt securities, an other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income. The Company’s investment in debt securities accounting policy from January 1, 2020, following the adoption of the new CECL standard Unrealized gains and losses for available-for-sale securities are excluded from earnings and reported net of the related tax effect in the accumulated other comprehensive income component of shareholders’ equity. The CECL methodology, which became effective January 1, 2020, requires the Company to estimate lifetime expected credit losses for all available-for-sale debt securities in an unrealized loss position. Comparative information continues to be reported in accordance with the methodology in effect for prior periods. When estimating a security’s probability of default and the recovery rate, the Company assesses the security’s credit indicators, including credit ratings. If the assessment indicates that an expected credit loss exists, the Company determines the portion of the unrealized loss attributable to credit deterioration and records an allowance for the expected credit loss through the Consolidated Statements of Income. Unrealized gains and any portion of a security’s unrealized loss attributable to non-credit losses are recorded in the Consolidated Statements of Comprehensive Income, net of tax.
Cash and cash equivalents	h. Cash and cash equivalents: All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents.
Restricted cash	i. Restricted cash: Restricted cash represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet under other current assets.
Accounts receivable	j. Accounts Receivable: The Company’s accounts receivables accounting policy until December 31, 2019, prior to the adoption of the new CECL standard Accounts receivable are stated at their net realizable value. The allowance against gross accounts receivable reflects the best estimate of losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. An allowance for doubtful debts is reflected in net accounts receivable. Accounts receivable are written off after all reasonable means to collect the full amount have been exhausted. The Company’s accounts receivables accounting policy from January 1, 2020, following the adoption of the new CECL standard Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. Write-off activity and recoveries for the periods presented were not material.
Concentration of credit risks	k. Concentration of credit risks: Most of Teva’s cash and cash equivalents (which, along with investment in securities, totaled $2,191 million at December 31, 2021) were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. The pharmaceutical industry, particularly in the United States, has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately 46% of Teva’s consolidated revenues in 2021. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance.
Inventories	l. Inventories: Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. Inventories acquired in a business combination are stepped-up to their estimated fair value and amortized to cost of sales as that inventory is sold.
Long-lived assets	m. Long-lived assets: Teva’s long-lived, non-current assets are comprised mainly of goodwill, identifiable intangible assets, property, plant and equipment, and operating lease right-of-use (“ROU”) assets. All long-lived assets are monitored for impairment indicators throughout the year. Impairment testing for goodwill and all indefinite-lived intangible assets is performed at least annually. When necessary, charges for impairments of long-lived assets, other than goodwill, are recorded for the amount by which the fair value is less than the carrying value of these assets. Goodwill Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any non-controlling interest in the acquiree, over the assigned fair values of the identifiable net assets acquired. Goodwill is not amortized, and is assigned to reporting units and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. The goodwill impairment test is performed according to the following principles: 1. An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. 2. If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value is recognized. An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company’s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company’s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. Identifiable intangible assets Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (“FDA”) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (“S&M”) expenses when separable. Indefinite life intangible assets are mainly comprised of IPR&D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. IPR&D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset’s estimated life, calculates the undiscounted value of the asset’s or asset group’s cash flows and compares such value against the asset’s or asset group’s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. For indefinite life intangible assets, Teva performs an impairment test annually in the second quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Teva determines the fair value of the asset based on discounted cash flows and records an impairment loss if its book value exceeds fair value. In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company’s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i) for IPR&D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii) for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. Property, plant and equipment Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly 20 years; and other assets, between 5 to 10 years. For property, plant and equipment and lease right-of-use assets, whenever impairment indicators are identified, Teva reconsiders the asset’s estimated life, calculates the undiscounted value of the asset’s cash flows and compares such value against the asset’s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value. Lease right-of-use (ROU) assets See note 8 and note 1dd for further discussion.
Contingencies	n. Contingencies: The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. Legal costs are expensed as incurred. The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved.
Treasury shares	o. Treasury shares: Treasury shares are presented as a reduction of Teva shareholders’ equity and carried at their cost to Teva, under treasury shares.
Stock-based compensation	p. Stock-based compensation: Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (“RSUs”) and performance share units (“PSUs”). The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option’s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards to expense over the vesting period on a straight-line basis. Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting.
Deferred income taxes	q. Deferred income taxes: Deferred income taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as non-current. Tax has not been provided on the following items: 1. Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company’s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. 2. Amounts of tax-exempt income generated from the Company’s current Approved Enterprises and unremitted earnings from foreign subsidiaries retained for reinvestment in the Group. See note 13f.
Uncertain tax positions	r. Uncertain tax positions: Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly re-evaluates its tax positions based on developments in its tax audits, statute of limitations expirations, changes in tax laws and new information that can affect the technical merits and change the assessment of Teva’s ability to sustain the tax benefit. In addition, the Company classifies interest and penalties recognized in the financial statements relating to uncertain tax position under the income taxes line item. Provisions for uncertain tax positions, whereas Teva has net operating losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss.
Derivatives and hedging	s. Derivatives and hedging: The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to hedge the Company’s currency and interest rate exposures. The Company does not enter into derivative transactions for trading purposes. Derivative instruments are recognized on the balance sheet at their fair value. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item attributable to the hedged risk is recognized in financial expenses, net in the statements of income in the period that the changes in fair value occur. For derivative instruments that are designated and qualify as a cash-flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the anticipated transaction in the same period or periods during which the hedged transaction affects earnings. For derivative instruments that are designated as net-investment hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income. The effective portion is determined by looking into changes in spot exchange rate. The change in fair value attributable to changes other than those due to fluctuations in the spot exchange rate are excluded from the assessment of hedge effectiveness and are recognized in the statement of income under financial expenses, net. For derivative instruments that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of the cash flows from the underlying hedged items that these derivatives are hedging. Derivative instruments that do not qualify for hedge accounting are recognized on the Balance Sheet at their fair value, with changes in the fair value recognized as a component of financial expenses, net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.
Revenue recognition	t. Revenue recognition: A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“performance obligations”), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer, excluding amounts collected on behalf of other third parties and sales taxes. The amount of consideration to which Teva expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances (“SR&A”) that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&A. If a minimum cannot be reasonably estimated, such revenue may be deferred to a future period when better information is available. For further description of SR&A components and how they are estimated, see “Variable Consideration” below. Shipping and handling costs, after control of the product has transferred to a customer, are accounted for as a fulfillment cost and are recorded under S&M expenses. Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one year or less, based on the practical expedient. The Company’s credit terms to customers are, on average, between thirty The Company generally recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under S&M expenses. Similarly, Teva does not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or less. Nature of revenue streams Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped once the Company has a present right to payment and legal title, and risk and rewards of ownership are obtained by the customer. Licensing arrangements performance obligations generally include intellectual property (“IP”) rights, certain R&D and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct—i.e. if they are separately identifiable from other items in the arrangement and if the customer can benefit from them on their own or with other resources that are readily available to the customer. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company’s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company’s IP. Revenue from sales based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. Revenues from licensing arrangements included royalty income of $160 million, $129 million and $147 million for the years ended December 31, 2021, 2020 and 2019, respectively. Distribution revenues are derived from sales of third-party products for which the Company acts as distributor, mostly in the United States via Anda and in Israel via Salomon Levin and Elstein Ltd. (SLE). In the United States, the Company is the principal in these arrangements and therefore records revenue on a gross basis as it controls the promised goods before transferring these goods to the customer. In Israel, the Company is the agent in these arrangements and therefore records revenue on a net basis as it has no discretion in establishing prices for any specified goods or services, limited inventory risk and is not primarily responsible for contract fulfillment. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. Other revenues are primarily comprised of contract manufacturing services, sales of medical devices and other miscellaneous items. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. Trade receivables and contract liabilities Trade receivables are presented net of allowance for credit losses, which includes amounts billed and currently due from customers. Contract liabilities are mainly comprised of deferred revenues (defined as obligations to provide products or services to customers when payment has been made in advance and delivery or performance has not yet occurred), which were immaterial as of December 31, 2021 and 2020. Variable consideration Variable consideration mainly includes SR&A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. The following describes the nature of each deduction and how provisions are estimated: Rebates Rebates are primarily related to volume incentives and are offered to key customers to promote loyalty. These rebate programs provide that, upon the attainment of pre-established volumes or the attainment of revenue milestones for a specified period, the customer receives a rebate. Since rebates are contractually agreed upon, they are estimated based on the specific terms in each agreement based on historical trends and expected sales. Externally obtained inventory levels and expected sales usage by contract are evaluated in relation to estimates made for rebates payable to indirect customers and managed care agreements. Medicaid and Other Governmental Rebates Pharmaceutical manufacturers whose products are covered by the Medicaid program are required to provide a rebate to each state as a percentage of their average manufacturer’s price for generic products dispensed and “best price” for specialty products dispensed. Many states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. The Company estimates these rebates based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales. Chargebacks The Company has arrangements with various third parties, such as managed care organizations and drug store chains, establishing prices for certain of Teva’s products. While these arrangements are made between the Company and the customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with Teva’s concurrence, which establish the pricing for certain products which the wholesalers provide. Under either arrangement, Teva will issue a credit (referred to as a “chargeback”) to the wholesaler for the difference between the invoice price to the wholesaler and the customer’s contract prices. Provisions for chargebacks involve estimates of contract prices of over 2,000 products and multiple contracts with multiple wholesalers. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inventory at the wholesalers and, therefore, will not necessarily fluctuate in proportion to an increase or decrease in sales. Provisions for estimating chargebacks are calculated using historical chargeback experience and/or expected chargeback levels for new products and anticipated pricing changes. Teva considers current and expected price competition when evaluating the provision for chargebacks. Chargeback provisions are compared to externally obtained distribution channel reports for reasonableness. The Company regularly monitors the provision for chargebacks and makes adjustments when the Company believes that actual chargebacks may differ from estimated provisions. Other Promotional Arrangements Other promotional or incentive arrangements are periodically offered to customers, specifically related to the launch of products or other targeted promotions. Provisions are made in the period for which the Company can estimate the incentive earned by the customer, in accordance with the contractual terms. The Company regularly monitors the provision for other promotional arrangements and makes adjustments when it believes that the actual provision may differ from the estimated provisions. Shelf Stock Adjustments The custom in the pharmaceutical industry is generally to grant customers a shelf stock adjustment based on the customers’ existing inventory contemporaneously with decreases in the market price of the related product. The most significant of these relate to products for which an exclusive or semi-exclusive period exists. Provisions for price reductions depend on future events, including price competition, new competitive launches and the level of customer inventories at the time of the price decline. Teva regularly monitors the competitive factors that influence the pricing of its products and customer inventory levels and adjust these estimates where appropriate. Returns Returns primarily relate to customer returns of expired products which, the customer has the right to return up to one year following the expiration date. Such returned products are destroyed and credits and/or refunds are issued to the customer for the value of the returns. Accordingly, no returned assets are recoded in connection with those products. The returns provision is estimated by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Revenue subject to returns is estimated based on the lag time from time of sale to date of return. The estimated lag time is developed by analyzing historical experience. Additionally, The Company considers specific factors, such as estimated levels of inventory in the distribution channel, product dating and expiration, size and maturity of launch, entrance of new competitors, changes in formularies or packaging and any changes to customer terms, for determining the overall expected levels of returns. Prompt Pay Discounts Prompt pay discounts are offered to most customers to encourage timely payment. Discounts are estimated at the time of invoice based on historical discounts in relation to sales. Prompt pay discounts are almost always utilized by customers. As a result, the actual discounts do not vary significantly from the estimated amount.
Research and development	u. Research and development: Research and development expenses are charged to statement of income (loss) as incurred. Participations and grants in respect of research and development expenses are recognized as a reduction of research and development expenses as the related costs are incurred, or as the related milestone is met. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the related goods are used or the services are rendered. Research and development in-process acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use, is expensed as incurred.
Shipping and handling costs	v. Shipping and handling costs: Shipping and handling costs, which are included in S&M expenses, were $111 million, $124 million and $138 million for the years ended December 31, 2021, 2020 and 2019, respectively.
Advertising costs	w. Advertising costs: Advertising costs are expensed as incurred. Advertising costs for the years ended December 31, 2021, 2020 and 2019 were $246 million, $225 million and $213 million, respectively.
Restructuring	x. Restructuring: Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. Contractual termination benefits are provided to employees when employment is terminated due to an event specified in the provisions of an existing plan or agreement. A liability is recorded and the expense is recognized when it is probable that employees will be entitled to the benefits and the amount is reasonably estimable. Special termination benefits arise when the Company offers, for a short period of time, to provide certain additional benefits to employees electing voluntary termination. A liability is recorded and the expense is recognized in the period the employees irrevocably accept the offer and the amount of the termination liability is reasonably estimable.
Segment reporting	y. Segment reporting: The Company’s business includes three reporting segments based on three geographical areas: (a) North America segment, which includes the United States and Canada. (b) Europe segment, which includes the European Union, the United Kingdom and certain other European countries. (c) International Markets segment, which includes all countries in which Teva operates other than those in the North America and Europe segments. Each business segment manages the entire product portfolio in its region, including generics, specialty and over-the-counter (“OTC”) products. In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Earnings per share	z. Earnings per share: Basic earnings per share are computed by dividing the net income attributable to ordinary shareholders by the weighted average number of ordinary shares (including fully vested RSUs and PSUs) outstanding during the year, net of treasury shares. In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i) the exercise of options and non-vested RSUs and PSUs granted under employee stock compensation plans and one series of convertible senior debentures, using the treasury stock method; and (ii) the conversion of the remaining convertible senior debentures using the “if-converted” method, by adding to net income interest expense on the debentures and amortization of issuance costs, net of tax benefits, and by adding the weighted average number of shares issuable upon assumed conversion of the debentures.
Securitization	aa. Securitization Teva accounts for transfers of certain of its trade receivable as sales when it has surrendered control over the related assets in accordance with ASC Topic 860 “Transfer and Servicing” of Financial Assets. Whether control has been relinquished requires, among other things, an evaluation of relevant legal considerations and an assessment of the nature and extent of the Company’s continuing involvement with the assets transferred. Assets obtained and liabilities incurred in connection with transfers reported as sales are initially recognized in the balance sheet at fair value. Refer to note 10 f.
Divestitures	bb. Divestitures The Company nets the proceeds on the divestitures of products with the carrying amount of the related assets and records gain or loss on sale within other income. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when it is probable that a significant reversal of income will not occur, or in the case of a business, when such payments are realizable. For divestures of businesses, including divestitures of products that qualify as a business, the Company reflects the relative fair value of goodwill associated with the businesses in the determination of gain or loss on sale.
Debt instruments	cc. Debt instruments Debt instruments are initially recognized at the fair value of the consideration received. Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liability. They are subsequently recognized at amortized cost using the effective interest method. Debt may be considered extinguished when it has been modified and the terms of the new debt instruments and old debt instruments are “substantially different” (as defined in the debt modification guidance in ASC 470-50 “Debt—Modifications and Extinguishments”). The Company classifies the current portion of long term debt as non-current liabilities on the Balance Sheet when it has the intent and ability to refinance the obligation on a long-term basis, in accordance with ASC 470-50 “Debt”.
Leases	dd. Leases Teva adopted the new accounting standard ASC 842 “Leases” and all the related amendments on January 1, 2019 and used the effective date as Teva’s date of initial application. Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva’s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset. Operating leases are included in operating lease ROU assets, other current liabilities and operating lease liabilities in the consolidated balance sheets. Finance leases are included in property, plant and equipment, other current liabilities, and other long-term liabilities in the consolidated balance sheets. ROU assets represent Teva’s right to use an underlying asset for the lease term and lease liabilities represent Teva’s obligation to make lease payments arising from the lease. Operating lease ROU and finance lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Teva uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. For finance leases, Teva recognizes interest on the lease liability separately from amortization of the assets in the consolidated statement of income. For operating leases, lease expenses are recognized on a straight-line basis over the lease term. The new standard also provides practical expedients for an entity’s ongoing accounting. Teva elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, Teva does not recognize ROU assets or lease liabilities, including ROU assets or lease liabilities for existing short-term leases of assets in transition, but recognizes lease expenses over the lease term on a straight line basis. Teva also elected the practical expedient to not separate lease and non-lease components for all of Teva’s leases, other than leases of real estate. Lease terms will include options to extend or terminate the lease when it is reasonably certain that Teva will either exercise or not exercise the option to renew or terminate the lease. Teva’s lease agreements have remaining lease terms ranging from 1 year to 78 years. Some of these agreements include options to extend the leases for up to 10 years and some include options to terminate the leases immediately. Certain leases also include options to purchase the leased property. The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise. Some of Teva’s vehicle lease agreements include rental payments based on the actual usage of the vehicles and other lease agreements include rental payments adjusted periodically for inflation. Teva’s lease agreements do not contain any material residual value guarantees. The new lease standard had no impact on Teva’s debt-covenant compliance under its syndicated revolving credit facility. Teva rents out or subleases certain assets to third parties, which has an immaterial impact on Teva’s consolidated financial statements.

Certain transactions (Tables)

Certain transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Major Classes of Assets and Liabilities Included as Held for Sale	The table below summarizes all Teva assets and liabilities included as held for sale as of December 31, 2021 and December 31, 2020: December 31, December 31, (U.S. $ in millions) Inventories 2 146 Property, plant and equipment, net and others 86 312 Goodwill 7 27 Adjustments of assets held for sale to fair value (76 ) (296 ) Total assets of the disposal group classified as held for sale in the consolidated balance sheets $ 19 $ 189 Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets under accrued expenses ($23 million) and other long-term liabilities ($20 million) $ (43 ) $ —

Revenue from contracts with c_2

Revenue from contracts with customers (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of disaggregates revenues by major revenue streams	The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. Year ended December 31, 2021 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,394 4,807 1,889 739 13,829 Licensing arrangements 92 50 13 4 160 Distribution 1,323 1 65 — 1,390 Other (1 ) 27 65 408 500 $ 7,809 $ 4,886 $ 2,032 $ 1,151 $ 15,878 Year ended December 31, 2020 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,902 4,736 1,946 772 14,354 Licensing arrangements 84 32 9 4 129 Distribution 1,462 3 30 — 1,495 Other § (14 ) 169 527 680 $ 8,447 $ 4,757 $ 2,154 $ 1,302 $ 16,659 Year ended December 31, 2019 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,941 4,770 2,045 754 14,510 Licensing arrangements 109 29 4 5 147 Distribution 1,492 2 20 — 1,514 Other § (6 ) 177 545 716 $ 8,542 $ 4,795 $ 2,246 $ 1,304 $ 16,887 § Represents an amount less than $1 million.
Summary of Sales Reserves and Allowances	The changes in SR&A for third-party sales for the period ended December 31, 2021 and 2020 were as follows: Sales Reserves and Allowances Reserves Rebates Medicaid and Chargebacks Returns Other Total Total (U.S.$ in millions) Balance at January 1, 2020 $ 87 2,895 $ 1,109 $ 1,342 $ 637 $ 176 $ 6,159 $ 6,246 Provisions related to sales made in current year period 391 4,703 744 8,438 459 71 14,415 $ 14,806 Provisions related to sales made in prior periods — (219 ) (184 ) (65 ) (28 ) (1 ) (497 ) $ (497 ) Credits and payments (398 ) (5,360 ) (849 ) (8,614 ) (386 ) (100 ) (15,309 ) $ (15,707 ) Translation differences — 35 8 7 4 2 56 $ 56 Balance at December 31, 2020 $ 80 2,054 $ 828 $ 1,108 $ 686 $ 148 $ 4,824 $ 4,904 Provisions related to sales made in current year period 382 4,030 852 7,967 263 314 13,426 $ 13,808 Provisions related to sales made in prior periods (9 ) (125 ) (51 ) (47 ) (60 ) (26 ) (309 ) $ (318 ) Credits and payments (385 ) (4,275 ) (768 ) (7,937 ) (350 ) (321 ) (13,651 ) $ (14,036 ) Translation differences — (29 ) (7 ) (6 ) (4 ) (3 ) (49 ) $ (49 ) Balance at December 31, 2021 $ 68 1,655 854 1,085 535 112 4,241 $ 4,309

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Inventories	December 31, 2021 2020 (U.S. $ in millions) Finished products $ 1,932 $ 2,378 Raw and packaging materials 1,136 1,231 Products in process 587 605 Materials in transit and payments on account 163 189 $ 3,818 $ 4,403

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Property, Plant and Equipment, Net	Property, plant and equipment, net, consisted of the following: December 31, 2021 2020 (U.S. $ in millions) Machinery and equipment $ 5,098 $ 5,245 Buildings 2,568 2,720 Computer equipment and other assets 2,261 2,197 Assets under construction and payments on account 1,034 933 Land 262 292 11,223 11,388 Less—accumulated depreciation (5,241 ) (5,092 ) $5,982 $6,296

Identifiable Intangible Assets

Identifiable Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Identifiable Intangible Assets	Identifiable intangible assets consisted of the following: Gross carrying amount Accumulated Net carrying amount December 31, 2021 2020 2021 2020 2021 2020 (U.S. $ in millions) Product rights $ 18,815 $ 19,650 $ 12,318 $ 12,094 $ 6,497 $ 7,556 Trade names 590 621 198 165 392 456 In-process research and development (IPR&D) 577 911 — — 577 911 Total $ 19,982 $ 21,182 $ 12,516 $ 12,259 $ 7,466 $ 8,923

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Changes in the Carrying Amount of Goodwill by Segment	The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 were as follows: North Europe International Other Total (U.S. $ in millions) Balance as of December 31, 2019 (1) $ 11,091 $ 8,536 $ 2,532 $ 2,687 $ 24,846 Changes during the period: Goodwill reclassified as assets held for sale — (8 ) (19 ) — (27 ) Goodwill impairment (4,628 ) — — — (4,628 ) Translation differences 10 574 (151 ) — 433 Balance as of December 31, 2020 (1) $ 6,473 $ 9,102 $ 2,362 $ 2,687 $ 20,624 Changes during the period: Goodwill reclassified as assets held for sale — (7 ) — (11 ) (18 ) Translation differences 1 (551 ) (34 ) 18 (566 ) Balance as of December 31, 2021 (1) $ 6,474 $ 8,544 $ 2,328 $ 2,694 $ 20,040 (1) Accumulated goodwill impairment as of December 31, 2021, December 31, 2020 and December 31, 2019 was approximately $25.6 billion, $25.6 billion and $21.0 billion, respectively.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Components Of Lease Expense	The components of operating lease cost for the years ended December 31, 2021, 2020 and 2019 were as follows: Year ended Year ended Year ended 2021 2020 2019 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Operating lease cost: Fixed payments and variable payments that depend on an index or rate $ 135 $ 148 $ 166 Variable lease payments not included in the lease liability 4 4 6 Short-term lease cost 2 3 6 $ 141 $ 155 $ 178
Supplemental cash flow information related to leases	Supplemental cash flow information related to operating leases was as follows: Year ended Year ended Year ended 2021 2020 2019 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 143 $ 151 $ 169 Right-of-use assets obtained in exchange for lease obligations (non-cash): Operating leases $ 81 $ 211 $ 142
Supplemental Balance Sheet Information Related To Leases	Supplemental balance sheet information related to operating leases was as follows: December 31, December 31, 2021 2020 (U.S. $ in millions) (U.S. $ in millions) Operating leases: Operating lease ROU assets $ 495 $ 559 Other current liabilities 109 116 Operating lease liabilit 416 479 Total operating lease liabilities $ 525 $ 595 December 31, December 31, 2021 2020 Weighted average remaining lease term Operating leases 7.3 years 7.5 years Weighted average discount rate Operating leases 5.4 % 5.2 %
Maturities of lease liabilities	Maturities of operating lease liabilities were as follows: December 31, 2021 (U.S. $ in millions) 2022 $ 133 2023 106 2024 81 2025 71 2026 and thereafter 255 Total operating lease payments $ 646 Less: imputed interest 121 Present value of lease liabilities $ 525

Debt obligations (Tables)

Debt obligations (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Short-term Debt	a. Short-term debt: December 31, Weighted average Maturity 2021 2020 (U.S. $ in millions) Convertible debentures 0.25 % 2026 23 514 Current maturities of long-term liabilities 1,403 2,674 Total short term debt $ 1,426 $ 3,188
Schedule of Senior Notes and Loans	Weighted average Maturity December 31, December 31, % (U.S. $ in millions) Senior notes EUR 1,500 million (6) 1.13 % 2024 708 1,839 Sustainability-linked senior notes EUR 1,500 million (2)(*) 4.38 % 2030 1,699 — Senior notes EUR 1,300 million (6) 1.25 % 2023 670 1,595 Sustainability-linked senior notes EUR 1,100 million (3)(*) 3.75 % 2027 1,246 — Senior notes EUR 1,000 million 6.00 % 2025 1,134 1,230 Senior notes EUR 900 million 4.50 % 2025 1,020 1,107 Senior notes EUR 750 million 1.63 % 2028 844 916 Senior notes EUR 700 million (6) 3.25 % 2022 307 861 Senior notes EUR 700 million 1.88 % 2027 792 860 Senior notes USD 3,500 million 3.15 % 2026 3,496 3,495 Senior notes USD 3,000 million (6) 2.80 % 2023 1,453 2,996 Senior notes USD 2,000 million 4.10 % 2046 1,986 1,986 Senior notes USD 1,475 million (1) 2.20 % 2021 — 1,472 Senior notes USD 1,250 million 6.00 % 2024 1,250 1,250 Senior notes USD 1,250 million 6.75 % 2028 1,250 1,250 Senior notes USD 1,000 million 7.13 % 2025 1,000 1,000 Sustainability-linked senior notes USD 1,000 million (4)(*) 4.75 % 2027 1,000 — Sustainability-linked senior notes USD 1,000 million (5)(*) 5.13 % 2029 1,000 — Senior notes USD 844 million (6) 2.95 % 2022 715 853 Senior notes USD 789 million 6.15 % 2036 783 783 Weighted average Maturity December 31, December 31, % (U.S. $ in millions) Senior notes USD 613 million (7) 3.65 % 2021 — 616 Senior notes USD 588 million (7) 3.65 % 2021 — 586 Senior notes CHF 350 million 0.50 % 2022 382 397 Senior notes CHF 350 million 1.00 % 2025 383 398 Total senior notes 23,118 25,490 Other long-term debt 2 1 Less current maturities (1,403 ) (2,674 ) Less debt issuance costs (100 ) (86 ) Total senior notes and loans $ 21,617 $ 22,731 (1) In July 2021, Teva repaid $1,475 million of its 2.2% senior notes at maturity. (2) In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of 1,500 million euro bearing 4.38% annual interest and due May 2030. (3) In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of 1,100 million euro bearing 3.75% annual interest and due May 2027. (4) In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of $1,000 million bearing 4.75% annual interest and due May 2027. (5) In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of $1,000 million bearing 5.13% annual interest and due May 2029 (6) In November 2021, Teva consummated a cash tender offer and extinguished 873 million euro aggregate principal amount of its 1,500 million euro 1.13% senior notes due in October 2024 March 2023 April 2022 July 2023 December 2022 (7) In November 2021, Teva repaid $613 million and $588 million of its 3.65% senior notes at maturity. (8) Debt issuance costs as of December 31, 2021 include $40 million * Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 10c.
Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost	As of December 31, 2021, the required annual principal payments of long-term debt (excluding debt discount and issuance costs and fair value hedge adjustments), including convertible senior debentures, starting from the year 2023, are as follows: December 31, (U.S. $ in millions) 2023 $ 2,124 2024 1,960 2025 3,535 2026 * 3,523 2027 and thereafter 10,626 $ 21,768 * including $23 million convertible notes. See note 9a.

Derivative instruments and he_2

Derivative instruments and hedging activities (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Classification and Fair Values of Derivative Instruments	The following table summarizes the classification and fair values of derivative instruments: Fair value Not designated as hedging instruments December 31, 2021 December 31, 2020 Reported under (U.S. $ in millions) Asset derivatives: Other current assets: Option and forward contracts $ 30 $ 24 Liability derivatives: Other current liabilities: Option and forward contracts (23 ) (79 )
Derivatives Not Designated as Hedging Instruments	The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives designated in fair value or cash flow hedging relationships: Financial expenses, net Other comprehensive Year ended December 31, Year ended December 31, 2021 2020 2019 2021 2020 2019 Reported under (U.S. $ in millions) Line items in which effects of hedges are recorded $ 1,058 $ 834 $ 822 $ (391 ) $ (30 ) $ 160 Cross-currency swaps—cash flow hedge (1) — — (2 ) — — (33 ) Cross-currency swaps—net investment hedge (2) — (2 ) (29 ) — (21 ) (22 ) Interest rate swaps—fair value hedge (3) . — — 2 — — —
Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships	The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives not designated as hedging instruments: Financial expenses, net Net revenues Year ended December 31, Year ended December 31, 2021 2020 2019 2021 2020 2019 Reported under (U.S. $ in millions) Line items in which effects of hedges are recorded $ 1,058 $ 834 $ 822 $ 15,878 $ 16,659 $ 16,887 Option and forward contracts (4) (45 ) 130 (51 ) — — — Option and forward contracts (5) — — — 31 * 14 * Represents an amount less than $0.5 million. (1) With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $588 million in cross-currency swap agreements against its outstanding 3.65% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $95 million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. (2) In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500 million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva’s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the float-for-float interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3 million. (3) In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its 2.8% senior notes due 2023 with respect to $500 million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $10 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. (4) Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. (5) Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2021 and 2022. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In 2021, the positive impact from these derivatives recognized under revenues was $31 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.
Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program	The following table summarizes the sold receivables outstanding balance net of the DPP asset under the outstanding securitization program: As of and for the year ended 2021 2020 (U.S. $ in millions) Sold receivables at the beginning of the year $ 734 $ 690 Proceeds from sale of receivables 5,139 4,606 Cash collections (remitted to the owner of the receivables) (5,152 ) (4,607 ) Effect of currency exchange rate changes (36 ) 45 Sold receivables at the end of the year $ 685 $ 734

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Income Before Income Taxes	Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Parent Company and its Israeli subsidiaries $ 126 $ 947 $ 542 Non-Israeli subsidiaries 532 (5,353 ) (1,807 ) $ 658 $ (4,406 ) $ (1,265 )
Schedule of the Provision for Income Taxes	b. Income taxes: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) In Israel $ 124 $ 60 $ 107 Outside Israel 87 (228 ) (385 ) $ 211 $ (168 ) $ (278 ) Current $ 270 $ 182 $ 885 Deferred (59 ) (350 ) (1,163 ) $ 211 $ (168 ) $ (278 )
Accumulated Other Comprehensive Income/(Loss) (Net of Tax)	2021 2020 2019 (U.S. $ in millions) Income (loss) before income taxes $ 658 $ (4,406 ) $ (1,265 ) Statutory tax rate in Israel 23 % 23 % 23 % Theoretical provision for income taxes $ 151 $ (1,013 ) $ (291 ) Increase (decrease) in the provision for income taxes due to: The Parent Company and its Israeli subsidiaries - Tax benefits arising from reduced tax rates under benefit programs (12 ) (153 ) (77 ) Mainly nondeductible items and prior year tax 20 (30 ) 33 Non-Israeli subsidiaries, including impairments (*) 117 1,369 (115 ) Increase (decrease) in other uncertain tax positions—net (65 ) (341 ) 172 Effective consolidated income taxes $ 211 $ (168 ) $ (278 ) (*) In 2020, income before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect.
Schedule of Deferred Income Taxes	c. Deferred income taxes: December 31, 2021 2020 (U.S. $ in millions) Deferred tax assets (liabilities), net: Inventory related $ 104 $ 212 Sales reserves and allowances 136 173 Provision for legal settlements 360 235 Intangible assets (*) (814 ) (1,064 ) Carryforward losses and deductions and credits (**) 2,093 2,176 Property, plant and equipment (215 ) (142 ) Deferred interest 617 527 Provisions for employee related obligations 95 107 Other 159 54 2,535 2,278 Valuation allowance—in respect of carryforward losses and deductions that may not be (2,723 ) (2,547 ) $ (188 ) $ (269 ) (*) The decrease in deferred tax liability is mainly due to impairment and amortization. (**) The amounts are shown following a reduction for unrecognized tax benefits of $10 million and $63 million as of December 31, 2021 and 2020, respectively.
Schedule of Deferred Tax Assets and Liabilities By Report Caption	The deferred income taxes are reflected in the balance sheets among: December 31, 2021 2020 (U.S. $ in millions) Long-term assets—deferred income taxes 596 695 Long-term liabilities—deferred income taxes (784 ) (964 ) $ (188 ) $ (269 )
Schedule of Unrecognized Tax Benefits	The following table summarizes the activity of Teva’s gross unrecognized tax benefits: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Balance at the beginning of the year $ 888 $ 1,223 $ 1,072 Increase (decrease) related to prior year tax positions, net (106 ) (238 ) 23 Increase related to current year tax positions 7 10 246 Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations (115 ) (105 ) (118 ) Other (2 ) (2 ) — Balance at the end of the year $ 672 $ 888 $ 1,223

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Stock Option Activity	A summary of the status of the options granted by Teva as of December 31, 2021, 2020 and 2019, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). Year ended December 31, 2021 2020 2019 Number (in thousands) Weighted average Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 35,234 $ 37.27 40,064 $ 37.90 48,393 $ 38.62 Changes during the year: Exercised — — — — (11 ) 16.99 Forfeited (3,644 ) 36.09 (3,610 ) 40.24 (8,318 ) 42.12 Expired (2,575 ) 42.40 (1,220 ) 49.35 — — Balance outstanding at end of year 29,015 36.96 35,234 37.27 40,064 37.90 Balance exercisable at end of year 26,989 38.30 28,556 40.56 26,601 43.41 No options were granted during 2019, 2020 and 2021.
Schedule of Ordinary Shares Issued Upon Outstanding Options	The following tables summarize information as of December 31, 2021 regarding the number of ordinary shares issuable upon (1) outstanding options and (2) vested options: (1) Number of ordinary shares issuable upon exercise of outstanding options Range of exercise prices Balance at end of Weighted average Weighted average Number of shares $ Years Lower than $15.01 592 11.40 5.84 $15.01 - $25.00 8,762 18.95 6.12 $25.01 - $35.00 6,364 34.61 5.16 $35.01 - $45.00 2,679 39.83 0.96 $45.01 - $55.00 6,801 51.01 3.18 $55.01 - $65.00 3,817 59.15 3.33 Total 29,015 36.96 4.37
Schedule of Ordinary Shares Issued Upon Vested Options	(2) Number of ordinary shares issuable upon exercise of vested options Range of exercise prices Balance at end of Weighted average Weighted average Number of shares $ Years Lower than $15.01 592 11.40 5.84 $15.01 - $25.00 6,736 18.90 6.11 $25.01 - $35.00 6,364 34.61 5.16 $35.01 - $45.00 2,679 39.83 0.96 $45.01 - $55.00 6,801 51.01 3.18 $55.01 - $65.00 3,817 59.15 3.33 Total 26,989 38.30 4.24
Schedule of the Number of RSUs Issued and Outstanding	The following table summarizes information about the number of RSUs and PSUs granted and outstanding: Year ended December 31, 2021 2020 2019 Number (in thousands) Weighted Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 20,720 $ 13.81 15,977 $ 16.49 10,403 $ 20.93 Granted 12,748 10.42 10,848 11.42 9,303 15.36 Vested (6,818 ) 15.60 (4,324 ) 19.49 (2,435 ) 30.24 Forfeited (2,238 ) 12.18 (1,781 ) 18.18 (1,294 ) 18.74 Balance outstanding at end of year 24,412 11.58 20,720 13.81 15,977 16.49
Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value	The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2021, 2020 and 2019, the Company recorded stock-based compensation costs as follows: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Employee stock options $ 16 $ 30 $ 46 RSUs and PSUs 103 99 73 Total stock-based compensation expense 119 129 119 Tax effect on stock-based compensation expense 12 14 14 Net effect $ 107 $ 115 $ 105
Accumulated Other Comprehensive Income/(Loss) (Net of Tax)	The components of accumulated other comprehensive loss attributable to Teva are presented in the table below: Net Unrealized Gains/(Losses) Benefit Plans Foreign Available- Derivative Actuarial Total (U.S. $ in millions) Balance as of January 1, 2019 $ (1,878 ) $ 1 $ (504 ) $ (78 ) $ (2,459 ) Other comprehensive income/(loss) before reclassifications 100 (1 ) 54 (11 ) 142 Amounts reclassified to the statements of income — — 30 (10 ) 20 Net other comprehensive income/(loss) before tax 100 (1 ) 84 (21 ) 162 Corresponding income tax (16 ) — — 1 (15 ) Net other comprehensive income/(loss) after tax* 84 (1 ) 84 (20 ) 147 Balance as of December 31, 2019 (1,794 ) — (420 ) (98 ) (2,312 ) Other comprehensive income/(loss) before reclassifications (190 ) — 22 (7 ) (175 ) Amounts reclassified to the statements of income — — 35 (12 ) 23 Net other comprehensive income/(loss) before tax (190 ) — 57 (19 ) (152 ) Corresponding income tax 65 — — 1 66 Net other comprehensive income/(loss) after tax* (125 ) — 57 (18 ) (86 ) Balance as of December 31, 2020 (1,919 ) — (363 ) (117 ) (2,399 ) Other comprehensive income/(loss) before reclassifications (386 ) — — 18 (368 ) Amounts reclassified to the statements of income — — 39 18 57 Net other comprehensive income/(loss) before tax (386 ) — 39 36 (311 ) Corresponding income tax 31 — — (4 ) 27 Net other comprehensive income/(loss) after tax* (355 ) — 39 32 (283 ) Balance as of December 31, 202 1 $ (2,274 ) — $ (324 ) $ (85 ) $ (2,683 ) * Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $107 million loss in 2021, $56 million gain in 2020 and $14 million gain in 2019.

Other assets impairments, res_2

Other assets impairments, restructuring and other items (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Other Assets Impairments, Restructuring and Other Items	Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Impairment of long-lived tangible assets (1) $ 160 $ 416 $ 139 Contingent consideration (see note 20) 7 (81 ) 59 Restructuring 133 120 199 Other 41 24 26 Total $ 341 $ 479 $ 423
Summary of Restructuring Plan Including Costs Related to Exit and Disposal	The following tables provide the components of restructuring costs: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Restructuring Employee termination $ 117 $ 71 $ 159 Other 16 49 40 Total $ 133 $ 120 $ 199
Summary of Restructuring Accruals	The following table provides the components of and changes in the Company’s restructuring accruals: Employee Other Total (U.S. $ in millions ) Balance as of January 1, 2019 $ (204 ) $ (29 ) $ (233 ) Provision (159 ) (40 ) (199 ) Utilization and other* 155 62 217 Balance as of January 1, 2020 $ (208 ) $ (7 ) $ (215 ) Provision (71 ) (49 ) (120 ) Utilization and other* 164 49 213 Balance as of December 31, 2020 $ (115 ) $ (7 ) $ (122 ) Provision (117 ) (16 ) (133 ) Utilization and other* 101 16 117 Balance as of December 31, 2021 $ (131 ) $ (7 ) $ (138 ) * Includes adjustments for foreign currency translation.

Other income (Tables)

Other income (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Other Income	Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Gain on divestitures, net of divestitures related costs (1) 51 8 50 Section 8 and similar payments (2) 19 — 5 Gain (loss) on sale of assets 7 11 (1 ) Other, net 22 20 22 Total other income $ 98 $ 40 $ 76 (1) In 2021, mainly In 2020 and 2019, mainly related to the divestment of several activities in the International Markets segment. (2) Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada.

Financial expenses-net (Tables)

Financial expenses-net (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Financial Expenses	Year ended December, 31 2021 2020 2019 (U.S. $ in millions) Interest expenses and other bank charges 891 901 822 (Income) loss from investments (1) 90 (104 ) (41 ) Foreign exchange (gains) losses, net 7 (26 ) (15 ) Other, net (2) 71 62 55 Total finance expense, net $ 1,058 $ 834 $ 822 (1) (Income) loss from investments in 2021 and 2020 comprised mainly of revaluation gains and loss of Teva’s investment in American Well Corporation (“American Well”). See note 20. (2) Amortization of issuance costs and terminated derivative instruments.

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Earnings per Share	Net income (loss) attributable to Teva and weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2021, 2020 and 2019 are as follows: Year ended December, 31 2021 2020 2019 (U.S. $ in millions, except share data) Net income (loss) used for the computation of basic and diluted earnings (loss) per share 417 $ (3,990 ) $ (999 ) Weighted average number of shares used in the computation of basic earnings (loss) per share 1,102 1,095 1,091 Weighted average number of shares used in the computation of diluted earnings (loss) per share 1,107 1,095 1,091

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Segment Profit	Year ended December 31, 2021 North America Europe International Markets (U.S. $ in millions) Revenues $ 7,809 $ 4,886 $ 2,032 Gross profit 4,226 2,823 1,118 R&D expenses 618 244 68 S&M expenses 988 846 417 G&A expenses 427 244 109 Other income (31 ) (5 ) (5 ) Segment profit $ 2,224 $ 1,494 $ 529 Year ended December 31, 2020 North America Europe International Markets (U.S. $ in millions) Revenues $ 8,447 $ 4,757 $ 2,154 Gross profit 4,489 2,666 1,096 R&D expenses 622 247 70 S&M expenses 1,013 830 427 G&A expenses 443 261 136 Other income (10 ) (3 ) (11 ) Segment profit $ 2,421 $ 1,331 $ 474 Year ended December 31, 2019 North America Europe International Markets (U.S. $ in millions) Revenues $ 8,542 $ 4,795 $ 2,246 Gross profit 4,350 2,704 1,167 R&D expenses 652 262 88 S&M expenses 1,021 890 481 G&A expenses 439 239 138 Other income (14 ) (5 ) (3 ) Segment profit $ 2,252 $ 1,318 $ 464
Schedule Of Consolidated Income Before Income Tax	Year ended December 31, 2021 2020 2019 (U.S. $ in millions) North America profit $ 2,224 $ 2,421 $ 2,252 Europe profit 1,494 1,331 1,318 International Markets profit 529 474 464 Total reportable segments profit 4,246 4,225 4,034 Profit of other activities 154 163 108 Total segments profit 4,401 4,388 4,142 Amounts not allocated to segments: Amortization 802 1,020 1,113 Other assets impairments, restructuring and other items 341 479 423 Goodwill impairment — 4,628 — Intangible asset impairments 424 1,502 1,639 Legal settlements and loss contingencies 717 60 1,178 Other unallocated amounts 402 271 232 Consolidated operating income (loss) 1,716 (3,572 ) (443 ) Financial expenses, net 1,058 834 822 Consolidated income (loss) before income taxes $ 658 $ (4,406 ) $ (1,265 )
Schedule of Net Sales by Product Line	North America segment: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Generic products $ 3,769 $ 4,010 $ 3,963 AJOVY 176 134 93 AUSTEDO 802 637 412 BENDEKA/TREANDA 385 415 496 COPAXONE 577 884 1,017 ProAir* 180 241 274 Anda 1,323 1,462 1,492 Other 597 664 796 Total $ 7,809 $ 8,447 $ 8,542 * Does not include revenues from the ProAir authorized generic, which are included under generic products. Europe segment: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Generic products $ 3,569 $ 3,513 $ 3,470 AJOVY 87 31 3 COPAXONE 391 400 432 Respiratory products 356 353 354 Other 483 459 536 Total $ 4,886 $ 4,757 $ 4,795 International Markets segment: Year ended December 31, 2021 2020 2019 (U.S. $ in millions) Generic products $ 1,649 $ 1,792 $ 1,893 AJOVY 50 18 § COPAXONE 37 53 63 Other 295 291 291 Total $ 2,032 $ 2,154 $ 2,246 § Represents an amount less than $1 million
Schedule of Sales Percentage by Therapeutic Category	The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2021, 2020 and 2019. Percentage of Third Party Net Sales 2021 2020 2019 McKesson Corporation 11 % 12 % 13 % AmerisourceBergen Corporation 11 % 12 % 12 %
Schedule of Property, Plant and Equipment by Geographic Location	December 31, 2021 2020 (U.S. $ in millions) Israel $ 1,543 $ 1,611 United States 692 790 Croatia 481 539 Germany 1,045 933 Czech republic 324 330 Hungary 321 325 Ireland 269 267 Other 1,307 1,501 Total property, plant and equipment $ 5,982 $ 6,296

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Financial Items Carried at Fair Value	Financial items carried at fair value as of December 31, 2021 and 2020 are classified in the tables below in one of the three categories described in note 1f: December 31, 2021 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 220 $ — $ — $ 220 Cash, deposits and other 1,945 — — 1,945 Investment in securities: Equity securities* 18 — — 18 Other 6 — 1 7 Restricted cash 33 — — 33 Derivatives: Asset derivatives—options and forward contracts — 30 — 30 Liabilities derivatives: — Options and forward contracts — (23 ) — (23 ) Bifurcated embedded derivatives — — § — Contingent consideration** — — (176 ) (176 ) Total $ 2,222 $ 7 $ (175 ) $ 2,054 § Represents an amount less than 0.5 million. December 31, 2020 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 367 $ — $ — $ 367 Cash, deposits and other 1,810 — — 1,810 Investment in securities: Equity securities 25 259 — 284 Other, mainly debt securities 5 — 10 15 Derivatives: Asset derivatives—options and forward contracts — 24 — 24 Liability derivatives—options and forward contracts — (79 ) — (79 ) Contingent consideration** — — (268 ) (268 ) Total $ 2,207 $ 204 $ (258 ) $ 2,153 * During the first quarter of 2021, Teva’s shares in American Well Corporation (“American Well”) moved from a Level 2 measurement to a Level 1 measurement within the fair value hierarchy, since they were no longer subject to a sale restriction. By the end of September, 2021, Teva sold all of its holdings in American Well. ** Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.
Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs	The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs. December 31, December 31, (U.S. $ in millions) Fair value at the beginning of the period $ (258 ) $ (448 ) Transfer into Level 3- equity securities — 179 Revaluation of equity securities — 80 Redemption of debt securities (9 ) — Revaluation of debt securities — (2 ) Reclassification to Level 2- equity securities — (259 ) Bifurcated embedded derivatives § — Adjustments to provisions for contingent consideration: Actavis Generics transaction 15 156 Eagle transaction (23 ) (75 ) Settlement of contingent consideration: Eagle transaction 100 111 Fair value at the end of the period $ (175 ) $ (258 ) § Represents an amount less than $0.5 million.
Summary of Financial Instrument Measured on a Basis Other Than Fair Value	Financial instruments measured on a basis other than fair value consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value: Estimated fair value* December 31, 2021 2020 (U.S. $ in millions) Senior notes and sustainability-linked senior notes included under senior notes and loans $ 21,477 $ 22,684 Senior notes and convertible senior debentures included under short-term debt 1,426 3,207 Total $ 22,903 $ 25,891 * The fair value was estimated based on quoted market prices.

Long-term Employee-related Ob_2

Long-term Employee-related Obligations (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Long Term Employee Related Obligation	a. Long-term employee-related obligations consisted of the following: December 31, 2021 2020 (U.S. $ in millions) Accrued severance obligations $ 83 $ 82 Defined benefit plans 142 192 Total $ 225 $ 275

Significant Accounting Polici_3

Significant Accounting Policies - Additional information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Significant Accounting Policies [Line Items]
Cash deposited with financially sound European us and Israeli banks and financial institutions	$ 2,191
Percentage of consolidated sales in North America	46.00%
Shipping and handling costs, which are included in selling and marketing expenses	$ 111	$ 124	$ 138
Advertising expense	$ 246	225	213
Operating Lease description	Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva’s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.
Royalty income	$ 160	$ 129	$ 147
Building [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	40 years
Other Machinery and Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	20 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Credit terms to customers	30 days
Operating Lease Remaining Lease Term	1 year
Minimum [Member] | Other Capitalized Property Plant and Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	5 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Credit terms to customers	90 days
Operating Lease Remaining Lease Term	78 years
Maximum [Member] | Other Capitalized Property Plant and Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	10 years

Certain Transactions - Other Tr

Certain Transactions - Other Transactions - Additional Information (Detail) - USD ($) $ in Millions

Jan. 08, 2018

May 12, 2017

Oct. 31, 2021

Aug. 31, 2021

Sep. 30, 2016

Dec. 31, 2021

Sep. 30, 2021

Sep. 30, 2020

Mar. 31, 2020

Sep. 30, 2016

Dec. 31, 2021

Dec. 31, 2018

Dec. 31, 2017

Mar. 31, 2021

Alder [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Upfront payment

$ 25

Milestone payment

$ 25

Collaborative agreement milestone payments

$ 150

Otsuka [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Upfront payment

$ 50

Milestone payment

$ 35

$ 15

Celltrion [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Refundable payment

$ 60

Total associated cost

$ 160

Regeneron [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Upfront payment

$ 250

Collaborative agreement milestone payments

$ 2,230

$ 120

$ 120

Research and development costs

$ 1,000

Alvotech [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Collaborative agreement milestone payments

$ 455

MedinCell [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Collaborative agreement milestone payments

$ 112

MODAG [Member]

Noncash or Part Noncash Acquisitions [Line Items]

License agreement potential aggregate milestone payments amount

$ 70

MODAG [Member] | Research and Development Expense [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Milestone payment

$ 10

Certain Transactions - Assets a

Certain Transactions - Assets and Liabilities Held For Sale - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Nov. 30, 2015
Impairment charge	$ 247	$ 247
Teva [Member]
Equity Method Investment Ownership Percentage			51.00%
Minority Interest Ownership Percentage			49.00%

Certain Transactions - Business

Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Business Combinations [Abstract]
Inventories	$ 2	$ 146
Property, plant and equipment, net and others	86	312
Goodwill	7	27
Adjustments of assets held for sale to fair value	(76)	(296)
Total assets of the disposal group classified as held for sale in the consolidated balance sheets	19	189
Disposal Group, Including Discontinued Operation, Liabilities, Current	$ (43)	$ 0

Certain Transactions - Busine_2

Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Parenthetical) ( (Detail) $ in Millions	Dec. 31, 2021USD ($)
Business Combinations [Abstract]
Accrued expenses	$ 23
Other long-term liabilities	$ 20

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021
United States [Member]
Revenue Recognition [Line Items]
Percentage sales reserves and allowances to U.S. customers	76.00%

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 15,878	$ 16,659	$ 16,887
Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	13,829	14,354	14,510
Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	160	129	147
Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,390	1,495	1,514
Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	500	680	716
International Markets [Member]
Disaggregation of Revenue [Line Items]
Total revenue	2,032	2,154	2,246
International Markets [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,889	1,946	2,045
International Markets [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	13	9	4
International Markets [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	65	30	20
International Markets [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	65	169	177
Other activities [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,151	1,302	1,304
Other activities [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	739	772	754
Other activities [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	4	4	5
Other activities [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	0	0	0
Other activities [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	408	527	545
North America [Member]
Disaggregation of Revenue [Line Items]
Total revenue	7,809	8,447	8,542
North America [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	6,394	6,902	6,941
North America [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	92	84	109
North America [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,323	1,462	1,492
North America [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	(1)
Europe [Member]
Disaggregation of Revenue [Line Items]
Total revenue	4,886	4,757	4,795
Europe [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	4,807	4,736	4,770
Europe [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	50	32	29
Europe [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1	3	2
Europe [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 27	$ (14)	$ (6)

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue Recognition [Line Items]
Balance at beginning of period	$ 4,904	$ 6,246
Provisions related to sales made in current year period	13,808	14,806
Provisions related to sales made in prior periods	(318)	(497)
Credits and payments	(14,036)	(15,707)
Translation differences	(49)	56
Balance at end of period	4,309	4,904
Reserves Included in Accounts Receivable, Net [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	80	87
Provisions related to sales made in current year period	382	391
Provisions related to sales made in prior periods	(9)	0
Credits and payments	(385)	(398)
Translation differences	0	0
Balance at end of period	68	80
Rebates [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	2,054	2,895
Provisions related to sales made in current year period	4,030	4,703
Provisions related to sales made in prior periods	(125)	(219)
Credits and payments	(4,275)	(5,360)
Translation differences	(29)	35
Balance at end of period	1,655	2,054
Medicaid and Other Governmental Allowances [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	828	1,109
Provisions related to sales made in current year period	852	744
Provisions related to sales made in prior periods	(51)	(184)
Credits and payments	(768)	(849)
Translation differences	(7)	8
Balance at end of period	854	828
Chargebacks [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	1,108	1,342
Provisions related to sales made in current year period	7,967	8,438
Provisions related to sales made in prior periods	(47)	(65)
Credits and payments	(7,937)	(8,614)
Translation differences	(6)	7
Balance at end of period	1,085	1,108
Returns [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	686	637
Provisions related to sales made in current year period	263	459
Provisions related to sales made in prior periods	(60)	(28)
Credits and payments	(350)	(386)
Translation differences	(4)	4
Balance at end of period	535	686
Other [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	148	176
Provisions related to sales made in current year period	314	71
Provisions related to sales made in prior periods	(26)	(1)
Credits and payments	(321)	(100)
Translation differences	(3)	2
Balance at end of period	112	148
Total Reserves Included in Sales Reserves and Allowances [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	4,824	6,159
Provisions related to sales made in current year period	13,426	14,415
Provisions related to sales made in prior periods	(309)	(497)
Credits and payments	(13,651)	(15,309)
Translation differences	(49)	56
Balance at end of period	$ 4,241	$ 4,824

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Inventories [Line Items]
Finished products	$ 1,932	$ 2,378
Raw and packaging materials	1,136	1,231
Products in process	587	605
Materials in transit and payments on account	163	189
Total	$ 3,818	$ 4,403

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Machinery and equipment	$ 5,098	$ 5,245
Buildings	2,568	2,720
Computer equipment and other assets	2,261	2,197
Assets under construction and payments on account	1,034	933
Land	262	292
Subtotal	11,223	11,388
Less—accumulated depreciation	(5,241)	(5,092)
Property, Plant and Equipment, Net, Total	$ 5,982	$ 6,296

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Depreciation expense for the year	$ 528	$ 537	$ 609
Impairment charge during the year on property, plant and equipment	$ 160	$ 416	$ 139

Identifiable Intangible Asset_2

Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	$ 19,982	$ 21,182
Accumulated amortization	12,516	12,259
Net carrying amount	7,466	8,923
Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	18,815	19,650
Accumulated amortization	12,318	12,094
Net carrying amount	6,497	7,556
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	590	621
Accumulated amortization	198	165
Net carrying amount	392	456
In Process Research and Development (IPR&D) [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	577	911
Net carrying amount	$ 577	$ 911

Identifiable Intangible Asset_3

Identifiable Intangible Assets - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets useful life	10 years
Amortization of intangible assets	$ 802	$ 1,020	$ 1,113
2022	689
2023	711
2024	651
2025	630
2026	652
Impairment of intangible assets excluding goodwill	424	1,502	1,639
In Process Research And Development To Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Prior periods adjustments	192
lenalidomide [Member]
Finite-Lived Intangible Assets [Line Items]
Prior periods adjustments	$ 153
Minimum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	7.5
Maximum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	8
Lenalidomide Product [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		262	125
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		797	681
In Process Research and Development [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	0.0725
In Process Research and Development [Member] | Minimum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	0.20
In Process Research and Development [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	0.10
In Process Research and Development [Member] | Maximum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	0.90
In Process Research and Development [Member] | Generic Pipeline Products [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	$ 127
Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		705	958
Identifiable product rights [Member] | Lenalidomide Product [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	267
Actavis [Member] | In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		110	59
Actavis [Member] | In Process Research and Development [Member] | Lenalidomide Product [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		300	497
Actavis [Member] | Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	297	398	647
AUSTEDO [Member] | In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		211
International Markets [Member] | Discontinued business [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			123
Japan [Member] | Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		$ 165	$ 128
United States [Member] | Actavis [Member] | Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	$ 30

Goodwill - Summary of Changes i

Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020		Dec. 31, 2019
Goodwill [Line Items]
Beginning balance	$ 20,624	$ 24,846	[1]
Goodwill reclassified as assets to held for sale	(18)	(27)
Goodwill impairment	0	(4,628)		$ 0
Translation differences	(566)	433
Ending balance	20,040	20,624		24,846	[1]
North America [Member]
Goodwill [Line Items]
Beginning balance	6,473	11,091	[1]
Goodwill impairment		(4,628)
Translation differences	1	10
Ending balance	6,474	6,473		11,091	[1]
Europe [Member]
Goodwill [Line Items]
Beginning balance	9,102	8,536	[1]
Goodwill reclassified as assets to held for sale	(7)	(8)
Translation differences	(551)	574
Ending balance	8,544	9,102		8,536	[1]
International Markets [Member]
Goodwill [Line Items]
Beginning balance	2,362	2,532	[1]
Goodwill reclassified as assets to held for sale		(19)
Translation differences	(34)	(151)
Ending balance	2,328	2,362		2,532	[1]
Other [Member]
Goodwill [Line Items]
Beginning balance	2,687	2,687	[1]
Goodwill reclassified as assets to held for sale	(11)
Translation differences	18
Ending balance	$ 2,694	$ 2,687		$ 2,687	[1]
[1]	Accumulated goodwill impairment as of December 31, 2021, December 31, 2020 and December 31, 2019 was approximately $25.6 billion, $25.6 billion and $21.0 billion, respectively.

Goodwill - Summary of Changes_2

Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail) - USD ($) $ in Billions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill [Line Items]
Accumulated goodwill impairment	$ 25.6	$ 25.6	$ 21

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating lease cost:
Fixed payments and variable payments that depend on an index or rate	$ 135	$ 148	$ 166
Variable lease payments not included in the lease liability	4	4	6
Short-term lease cost	2	3	6
Total operating lease cost	$ 141	$ 155	$ 178

Leases - Supplemental cash flow

Leases - Supplemental cash flow information related to leases (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 143	$ 151	$ 169
Right-of-use assets obtained in exchange for lease obligations (non-cash):
Operating leases	$ 81	$ 211	$ 142

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related To Leases (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Operating leases:
Operating lease ROU assets	$ 495	$ 559
Other current liabilities	109	116
Operating lease liabilities	416	479
Total operating lease liabilities	$ 525	$ 595
Weighted average remaining lease term Operating leases	7 years 3 months 18 days	7 years 6 months
Weighted average discount rate Operating leases	5.40%	5.20%
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Operating lease liabilities	Operating lease liabilities

Leases - Maturities of lease l

Leases - Maturities of lease liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
2022	$ 133
2023	106
2024	81
2025	71
2026 and thereafter	255
Total operating lease payments	646
Less: imputed interest	121
Present value of lease liabilities	$ 525	$ 595

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2020
Finance Lease, Right-of-Use Asset	$ 32	$ 29
Finance Lease, Liability	$ 25	21
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Finance Lease, Right-of-Use Asset
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Finance Lease, Liability
Operating lease right-of-use assets	$ 495	559
Operating lease liability	$ 525	$ 595
Maximum [Member]
Operating lease liability			$ 66
Minimum [Member]
Operating lease right-of-use assets			$ 74

Debt Obligations - Schedule of

Debt Obligations - Schedule of Short-term Debt (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Current maturities of long-term liabilities	$ 1,403	$ 2,674
Total short term debt	$ 1,426	3,188
Convertible senior debentures [Member]
Debt Instrument [Line Items]
Weighted average interest rate	0.25%
Maturity	2026
Short-term borrowings	$ 23	$ 514

Debt Obligations - Schedule o_2

Debt Obligations - Schedule of Senior Notes and Loans (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total senior notes		$ 23,118	$ 25,490
Less current maturities		(1,403)	(2,674)
Less debt issuance costs		(100)	(86)
Total senior notes and loans		21,617	22,731
Other Debentures [Member]
Debt Instrument [Line Items]
Total senior notes and loans		$ 2	1
Senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[1]	1.13%
Maturity	[1]	2024
Total senior notes	[1]	$ 708	1,839
Sustainability-linked senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[2]	4.38%
Maturity	[2]	2030
Total senior notes	[2]	$ 1,699
Senior notes EUR 1,300 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[1]	1.25%
Maturity	[1]	2023
Total senior notes	[1]	$ 670	1,595
Sustainability-linked senior notes EUR 1,100 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[3]	3.75%
Maturity	[3]	2027
Total senior notes	[3]	$ 1,246
Senior notes EUR 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		6.00%
Maturity		2025
Total senior notes		$ 1,134	1,230
Senior notes EUR 900 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		4.50%
Maturity		2025
Total senior notes		$ 1,020	1,107
Senior notes EUR 750 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1.63%
Maturity		2028
Total senior notes		$ 844	916
Senior notes EUR 700 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[1]	3.25%
Maturity	[1]	2022
Total senior notes	[1]	$ 307	861
Senior notes EUR 700 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1.88%
Maturity		2027
Total senior notes		$ 792	860
Senior notes USD 3,500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		3.15%
Maturity		2026
Total senior notes		$ 3,496	3,495
Senior notes USD 3,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[1]	2.80%
Maturity	[1]	2023
Total senior notes	[1]	$ 1,453	2,996
Senior notes USD 2,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		4.10%
Maturity		2046
Total senior notes		$ 1,986	1,986
Senior notes USD 1,475 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[4]	2.20%
Maturity	[3]	2021
Total senior notes	[3]		1,472
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		6.00%
Maturity		2024
Total senior notes		$ 1,250	1,250
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		6.75%
Maturity		2028
Total senior notes		$ 1,250	1,250
Senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		7.13%
Maturity		2025
Total senior notes		$ 1,000	1,000
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[5]	4.75%
Maturity	[5]	2027
Total senior notes	[5]	$ 1,000
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[6]	5.13%
Maturity	[6]	2029
Total senior notes	[6]	$ 1,000
Senior notes USD 844 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[1]	2.95%
Maturity	[1]	2022
Total senior notes	[1]	$ 715	853
Senior notes USD 789 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		6.15%
Maturity		2036
Total senior notes		$ 783	783
Senior notes USD 613 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[7]	3.65%
Maturity		2021
Total senior notes	[7]		616
Senior notes USD 588 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[7]	3.65%
Maturity		2021
Total senior notes	[7]		586
Senior notes CHF 350 Million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		0.50%
Maturity		2022
Total senior notes		$ 382	397
Senior notes CHF 350 Million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1.00%
Maturity		2025
Total senior notes		$ 383	$ 398
[1]	In November 2021, Teva consummated a cash tender offer and extinguished 873 million euro aggregate principal amount of its 1,500 million euro 1.13% senior notes due in October 2024; 708 million euro aggregate principal amount of its 1,300 million euro 1.25% senior notes due in March 2023; 428 million euro aggregate principal amount of its 700 million euro 3.25% senior notes due in April 2022; $1,546 million aggregate principal amount of its $3,000 million 2.8% senior notes due in July 2023; and $132 million aggregate principal amount of its $1,300 million 2.95% senior notes due in December 2022.
[2]	In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of 1,500 million euro bearing 4.38% annual interest and due May 2030. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.
[3]	In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of 1,100 million euro bearing 3.75% annual interest and due May 2027. If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.
[4]	In July 2021, Teva repaid $1,475 million of its 2.2% senior notes at maturity.
[5]	In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of $1,000 million bearing 4.75% annual interest and due May 2027. If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.
[6]	In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of $1,000 million bearing 5.13% annual interest and due May 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.
[7]	In November 2021, Teva repaid $613 million and $588 million of its 3.65% senior notes at maturity.

Debt Obligations - Schedule o_3

Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail) € in Millions, SFr in Millions, $ in Millions		Dec. 31, 2021EUR (€)	Dec. 31, 2021USD ($)	Dec. 31, 2021CHF (SFr)	Nov. 30, 2021USD ($)
Debt Instrument [Line Items]
Debt instrument face amount					$ 1,000
Senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	[1]	€ 1,500
Senior notes EUR 1,300 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	[1]	1,300
Senior notes EUR 900 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €		900
Senior notes EUR 750 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €		750
Senior notes EUR 700 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	[1]	700
Senior notes EUR 700 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €		700
Senior notes EUR 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €		1,000
Senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount			$ 1,000
Senior notes USD 3,500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount			3,500
Senior notes USD 1,475 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount	[2]		1,475
Senior notes USD 3,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount	[1]		3,000
Senior notes USD 2,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount			2,000
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount			1,250
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount			1,250
Senior notes USD 844 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount	[1]		844
Senior notes USD 789 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount			789
Senior notes USD 613 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount	[3]		613
Senior notes USD 588 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount	[3]		588
Senior notes CHF 350 Million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | SFr				SFr 350
Senior notes CHF 350 Million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | SFr				SFr 350
Sustainability-linked senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	[4]	1,500
Sustainability-linked senior notes EUR 1,100 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €	[5]	€ 1,100
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount	[6]		1,000
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount	[7]		$ 1,000
[1]	In November 2021, Teva consummated a cash tender offer and extinguished 873 million euro aggregate principal amount of its 1,500 million euro 1.13% senior notes due in October 2024; 708 million euro aggregate principal amount of its 1,300 million euro 1.25% senior notes due in March 2023; 428 million euro aggregate principal amount of its 700 million euro 3.25% senior notes due in April 2022; $1,546 million aggregate principal amount of its $3,000 million 2.8% senior notes due in July 2023; and $132 million aggregate principal amount of its $1,300 million 2.95% senior notes due in December 2022.
[2]	In July 2021, Teva repaid $1,475 million of its 2.2% senior notes at maturity.
[3]	In November 2021, Teva repaid $613 million and $588 million of its 3.65% senior notes at maturity.
[4]	In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of 1,500 million euro bearing 4.38% annual interest and due May 2030. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.
[5]	In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of 1,100 million euro bearing 3.75% annual interest and due May 2027. If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.
[6]	In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of $1,000 million bearing 4.75% annual interest and due May 2027. If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.
[7]	In November 2021, Teva issued sustainability-linked senior notes in an aggregate principal amount of $1,000 million bearing 5.13% annual interest and due May 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.

Debt Obligation - Schedule Requ

Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Detail) $ in Millions	Dec. 31, 2021USD ($)
Long Term Debt Maturity [Line Items]
2023	$ 2,124
2024	1,960
2025	3,535
2026	3,523	[1]
2027 and thereafter	10,626
Total	$ 21,768
[1]	including $23 million convertible notes. See note 9a.

Debt Obligation - Schedule Re_2

Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Parenthetical) (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Feb. 01, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Principal amount currently outstanding on the debt instruments	$ 40
Convertible Debt [Member]
Short-term Debt [Line Items]
Principal amount currently outstanding on the debt instruments	$ 23	$ 491	$ 514

Debt Obligations - Additional I

Debt Obligations - Additional Information (Detail) € in Millions, $ in Millions		1 Months Ended	12 Months Ended
		Nov. 30, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Nov. 30, 2021EUR (€)	Jul. 31, 2021USD ($)	Feb. 01, 2021USD ($)
Debt Instrument [Line Items]
Principal amount currently outstanding on the debt instruments			$ 40
Senior notes			$ 23,118	$ 25,490
Long term debt currency portion USD				61.00%
Long term debt currency portion EUR				37.00%
Long term debt currency portion CHF				2.00%
Line of Credit Facility, Maximum Borrowing Capacity				$ 2,200
Debt Instrument, Face Amount		$ 1,000
Debt Instrument, Interest Rate, Stated Percentage		5.13%			5.13%
Trache A [Member] | RCF agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 1,150
Debt Instrument, Maturity Date				Apr. 8, 2022
Trache A [Member] | Maximum [Member] | RCF agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date				Apr. 8, 2024
Trache B [Member] | RCF agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 1,150
Debt Instrument, Maturity Date				Apr. 8, 2024
Trache B [Member] | Maximum [Member] | RCF agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 1,065
Senior Notes [Member]
Debt Instrument [Line Items]
Weighted average interest rate						2.20%
Senior notes						$ 1,475
Four Point Three Eight Percentage Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount | €					€ 1,500
Debt Instrument, Interest Rate, Stated Percentage		4.38%			4.38%
Four Point Three Eight Percentage Senior Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		May 1, 2030
Debt Instrument, Interest Rate, Increase (Decrease)		0.375%
Four Point Three Eight Percentage Senior Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		May 9, 2026
Debt Instrument, Interest Rate, Increase (Decrease)		0.125%
Three Point Seven Five Percentage Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount | €					€ 1,100
Debt Instrument, Interest Rate, Stated Percentage		3.75%			3.75%
Three Point Seven Five Percentage Senior Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		May 1, 2027
Debt Instrument, Interest Rate, Increase (Decrease)		0.45%
Three Point Seven Five Percentage Senior Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		May 9, 2026
Debt Instrument, Interest Rate, Increase (Decrease)		0.15%
Five Point One Three Percentage Senior Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		May 1, 2029
Debt Instrument, Interest Rate, Increase (Decrease)		0.375%
Five Point One Three Percentage Senior Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		May 9, 2026
Debt Instrument, Interest Rate, Increase (Decrease)		0.125%
Five Point Seven Five Percentage Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 1,000
Debt Instrument, Interest Rate, Stated Percentage		4.75%			4.75%
Five Point Seven Five Percentage Senior Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		May 1, 2027
Debt Instrument, Interest Rate, Increase (Decrease)		0.45%
Five Point Seven Five Percentage Senior Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date		May 9, 2026
Debt Instrument, Interest Rate, Increase (Decrease)		0.15%
One Point One Three Percentage Senior Notes Due October 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Principal Amount Redeemed | €					€ 873
Debt Instrument, Face Amount | €					€ 1,500
Debt Instrument, Interest Rate, Stated Percentage		1.13%			1.13%
Debt Instrument, Maturity Date		Oct. 1, 2024
One Point Two Five Percentage Senior Notes Due March 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Principal Amount Redeemed | €					€ 708
Debt Instrument, Face Amount | €					€ 1,300
Debt Instrument, Interest Rate, Stated Percentage		1.25%			1.25%
Debt Instrument, Maturity Date		Mar. 1, 2023
Three Point Seven Five Percentage Senior Notes Due April 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Principal Amount Redeemed | €					€ 428
Debt Instrument, Face Amount | €					€ 700
Debt Instrument, Interest Rate, Stated Percentage		3.25%			3.25%
Debt Instrument, Maturity Date		Apr. 1, 2022
Two Point Eight Percentage Senior Notes Due July 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Principal Amount Redeemed		$ 1,546
Debt Instrument, Face Amount		$ 3,000
Debt Instrument, Interest Rate, Stated Percentage		2.80%			2.80%
Debt Instrument, Maturity Date		Jul. 1, 2023
Two Point Nine Five Percentage Senior Notes Due July 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Principal Amount Redeemed		$ 132
Debt Instrument, Face Amount		$ 1,300
Debt Instrument, Interest Rate, Stated Percentage		2.95%			2.95%
Debt Instrument, Maturity Date		Dec. 1, 2022
Three Point Six Five Percentage Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		3.65%			3.65%
Senior notes USD 613 million [Member]
Debt Instrument [Line Items]
Senior notes	[1]			616
Weighted average interest rate	[1]		3.65%
Repayments of debt		$ 613
Debt Instrument, Face Amount	[1]		$ 613
Senior notes USD 588 million [Member]
Debt Instrument [Line Items]
Senior notes	[1]			586
Weighted average interest rate	[1]		3.65%
Repayments of debt		$ 588
Debt Instrument, Face Amount	[1]		$ 588
Convertible Debt [Member]
Debt Instrument [Line Items]
Principal amount currently outstanding on the debt instruments			$ 23	$ 514			$ 491
Weighted average interest rate			0.25%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Description			The net debt to EBITDA ratio limit was 5.00x through the fourth quarter of 2021, gradually declines to 4.50x in the first and second quarters of 2022, 4.00x in the third and fourth quarters of 2022, and will decline to 3.50x in the first quarter of 2023.
Long Term Debt Payable Under Revolving Credit Facility			$ 0
Line of Credit Facility, Maximum Borrowing Capacity			$ 2,300
[1]	In November 2021, Teva repaid $613 million and $588 million of its 3.65% senior notes at maturity.

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) - Not Designated as Hedging Instrument [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Accounts Payable [Member]
Derivative [Line Items]
Liability derivatives	$ (23)	$ (79)
Other Current Assets [Member]
Derivative [Line Items]
Asset derivatives	$ 30	$ 24

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships (Details) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Comprehensive Income
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		$ (391)	$ (30)	$ 160
Other Comprehensive Income | Cash Flow Hedging [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]	0	0	(33)
Other Comprehensive Income | Net Investment Hedging [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[2]	0	(21)	(22)
Other Comprehensive Income | Fair Value Hedging [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[3]	0	0	0
Financial expenses [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		1,058	834	822
Financial expenses [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]	0	0	(2)
Financial expenses [Member] | Net Investment Hedging [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[2]	0	(2)	(29)
Financial expenses [Member] | Fair Value Hedging [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[3]	$ 0	$ 0	$ 2
[1]	With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $588 million in cross-currency swap agreements against its outstanding 3.65% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $95 million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense.
[2]	In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500 million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva’s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the float-for-float interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3 million.
[3]	In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its 2.8% senior notes due 2023 with respect to $500 million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $10 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense.

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021		Dec. 31, 2020	Dec. 31, 2019
Net Revenues [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		$ 15,878		$ 16,659	$ 16,887
Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		31	[1]	0.5	14	[1]
Financial expenses [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		1,058		834	822
Financial expenses [Member] | Not Designated as Hedging Instrument, Trading [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[2]	$ (45)		130	$ (51)
Financial expenses [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]			$ 0
[1]	Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2021 and 2022. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In 2021, the positive impact from these derivatives recognized under revenues was $31 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.
[2]	Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities - Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Derivative [Line Items]
Sold receivables at the beginning of the year	$ 734	$ 690
Proceeds from sale of receivables	5,139	4,606
Cash collections (remitted to the owner of the receivables)	(5,152)	(4,607)
Effect of currency exchange rate changes	(36)	45
Sold receivables at the end of the year	$ 685	$ 734

Derivative Instruments and He_7

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2021		Dec. 31, 2020	Dec. 31, 2019		Sep. 30, 2019	Dec. 31, 2016
Derivative [Line Items]
Revenues other than USD		48.00%
Teva other comprehensive loss		$ 493
Forward starting interest rate swaps and treasury lock agreements losses		37		$ 31	$ 29
Interest Rate Swap Gain		5		3	6
Deferred purchase asset		235		266
Sold receivables		685		734	690
Cash received on settlement of position				3
Cost of sales [Member]
Derivative [Line Items]
Derivative, Gain on Derivative				31
Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		31	[1]	0.5	14	[1]
Senior Notes Due 2023 Two [Member]
Derivative [Line Items]
Notional amount hedge debt	$ 3,000						$ 500	$ 500
Previously hedge debt rate							2.80%	2.80%
Settlement gain position		$ 10
Cash received on settlement of position							$ 10
Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)	41
Senior Notes Due 2022 [Member]
Derivative [Line Items]
Notional amount hedge debt	$ 844
Previously hedge debt rate	2.95%
Senior Notes Due 2021 [Member]
Derivative [Line Items]
Notional amount hedge debt	$ 450				$ 588
Previously hedge debt rate	3.65%				3.65%
Cash received on settlement of position					$ 95
Senior Notes Due 2020 [Member]
Derivative [Line Items]
Cash received on settlement of position				$ 500
Senior Notes Due 2021 Two [Member]
Derivative [Line Items]
Previously hedge debt rate					3.65%
Cash received on settlement of position					$ 95
[1]	Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2021 and 2022. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In 2021, the positive impact from these derivatives recognized under revenues was $31 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.

Legal Settlements and Loss Co_2

Legal Settlements and Loss Contingencies - Additional Information (Detail) € in Millions, $ in Millions	Jan. 27, 2022USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2021EUR (€)
Loss Contingencies [Line Items]
Legal settlements and loss contingencies, expense	$ 420	$ 717	$ 60
Legal settlements, income				$ 1,178
Accrued amount for legal settlements and loss contingencies		$ 2,710	$ 1,625		€ 60.5
Settlement On Account Of Product Liability [Member] | United States [Member]
Loss Contingencies [Line Items]
Restructuring expense and income		The expenses in 2021 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, the provision for the carvedilol patent litigation as well as a liability which was substantially offset by insurance receivable related to the Ontario Teachers Securities Litigation discussed in note 12.

Commitments and Contingencies -

Commitments and Contingencies - Commitments - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Commitment And Contingencies [Line Items]
Royalty expense	$ 522	$ 505	$ 403
Maximum [Member]
Commitment And Contingencies [Line Items]
Milestone contingent expense	$ 121

Commitments and Contingencies_2

Commitments and Contingencies - Contingencies - Additional Information (Detail) € in Millions

Feb. 04, 2022USD ($)

Jan. 27, 2022USD ($)

Aug. 05, 2021USD ($)

Jul. 21, 2021USD ($)

Feb. 11, 2021USD ($)

Oct. 21, 2019USD ($)

May 31, 2019USD ($)

Sep. 30, 2013USD ($)

Apr. 30, 2013USD ($)

Aug. 31, 2012USD ($)

Dec. 31, 2010USD ($)

Sep. 30, 2021USD ($)

Dec. 31, 2021USD ($)

Dec. 31, 2020USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2014USD ($)

Aug. 21, 2021USD ($)

Dec. 31, 2021EUR (€)

Jul. 08, 2021USD ($)

Jan. 31, 2019USD ($)

Jul. 31, 2008USD ($)

Feb. 28, 2005USD ($)

Commitment And Contingencies [Line Items]

Damages assessment

$ 235,500,000

Annual sales at the time of settlement

700,000,000

$ 350,000,000

Annual sales of Effexor

$ 2,600,000,000

Annual sales of Lamictal

$ 2,300,000,000

$ 950,000,000

Annual sales of Niaspan

$ 1,100,000,000

$ 416,000,000

Annual sales of Actos

$ 2,800,000,000

$ 3,700,000,000

Annual sales of Acto plus

$ 430,000,000

$ 500,000,000

Annual Sales Of Sensipar

$ 1,400,000,000

Annual sales of Copaxone

$ 373,000,000

Generic modafinil, and imposed fines amount

2,710,000,000

$ 1,625,000,000

€ 60.5

Loss Contingency Accrual, Provision

$ 235,500,000

Annual sales of Narcan

420,000,000

Annual sales of the time of settlement of viread

582,000,000

Annual sales of the time of settlement of Truvada

2,400,000,000

Annual sales of the time of settlement of Atripla

2,900,000,000

Annual sales of the time of New launch of viread

728,000,000

Annual sales of the time of New launch of Truvada

2,100,000,000

Annual sales of the time of New launch of Atripla

444,000,000

Annual sales of Colcrys

187,000,000

Loss Contingency Claims Dismissed Value

$ 925,000

Litigation Settlement, Expense

$ 420,000,000

717,000,000

$ 60,000,000

Accrual for Environmental Loss Contingencies

$ 300,000

Loss Contingencies On Environmental Laws Penalty

$ 1,400,000

Attorney General Of Louisana [Member]

Commitment And Contingencies [Line Items]

Litigation Settlement Amount DistributableIn Kind

$ 3,000,000

Four Other Defendants Other Than Teva Member

Commitment And Contingencies [Line Items]

Loss contingency payment

$ 26,000,000,000

Litigation settlement amount awarded distribution period

18 years

Subsequent Event [Member]

Commitment And Contingencies [Line Items]

Percentage of population of subdivisions will formally release as a part of settlement

96

Subsequent Event [Member] | Attorney General Of Louisana [Member]

Commitment And Contingencies [Line Items]

Litigation Settlement Amount DistributableIn Kind

$ 75,000,000

Opioid Litigation [Member]

Commitment And Contingencies [Line Items]

Litigation settlement amount

$ 15,000,000

$ 25,000,000

$ 85,000,000

Litigation settlement amount awarded cash amount

$ 20,000,000

Litigation settlement amount awarded cash amount distribution period

18 years

Opioid Litigation [Member] | Subsequent Event [Member]

Commitment And Contingencies [Line Items]

Litigation settlement amount

$ 150,000,000

Litigation settlement amount awarded cash amount distribution period

15 years

Europe [Member]

Commitment And Contingencies [Line Items]

Damage claimed

50,000,000

Eosinophilic Esophagitis [Member]

Commitment And Contingencies [Line Items]

Damage claimed

200,000,000

Eosinophilic Esophagitis [Member] | United States [Member]

Commitment And Contingencies [Line Items]

Damage claimed

$ 150,000,000

AndroGel Rate at 1% [Member]

Commitment And Contingencies [Line Items]

Annual sales at the time of settlement

$ 140,000,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Before Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
Parent Company and its Israeli subsidiaries	$ 126	$ 947	$ 542
Non-Israeli subsidiaries	532	(5,353)	(1,807)
Income (loss) before income taxes	$ 658	$ (4,406)	$ (1,265)

Income Taxes - Schedule of the

Income Taxes - Schedule of the Provision for Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
In Israel	$ 124	$ 60	$ 107
Outside Israel	87	(228)	(385)
Effective consolidated income taxes	211	(168)	(278)
Current	270	182	885
Deferred	(59)	(350)	(1,163)
Income tax expense (benefit)	$ 211	$ (168)	$ (278)

Income Taxes - Accumulated Othe

Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
Income (Loss) before income taxes		$ 658	$ (4,406)	$ (1,265)
Statutory tax rate in Israel		23.00%	23.00%	23.00%
Theoretical provision for income taxes		$ 151	$ (1,013)	$ (291)
Increase (decrease) in the provision for income taxes due to:
The Parent Company and its Israeli subsidiaries - Tax benefits arising from reduced tax rates under benefit programs		(12)	(153)	(77)
Mainly nondeductible items and prior year tax		20	(30)	33
Non-Israeli subsidiaries, including impairments	[1]	117	1,369	(115)
Increase (decrease) in other uncertain tax positions—net		(65)	(341)	172
Effective consolidated income taxes		$ 211	$ (168)	$ (278)
[1]	In 2020, income before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect.

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Defered Income Taxes (Detail) - USD ($) $ in Millions		Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets Liabilities Net [Line Items]
Inventory related		$ 104	$ 212
Sales reserves and allowances		136	173
Provision for legal settlements		360	235
Intangible assets	[1]	(814)	(1,064)
Carryforward losses and deductions and credits	[2]	2,093	2,176
Property, plant and equipment		(215)	(142)
Deferred interest		617	527
Provisions for employee related obligations		95	107
Other		159	54
Long-term deferred tax assets (liabilities)-gross		2,535	2,278
Valuation allowance—in respect of carryforward losses and deductions that may not be utilized		(2,723)	(2,547)
Deferred tax assets liabilities net		$ (188)	$ (269)
[1]	The decrease in deferred tax liability is mainly due to impairment and amortization.
[2]	The amounts are shown following a reduction for unrecognized tax benefits of $10 million and $63 million as of December 31, 2021 and 2020, respectively.

Income Taxes - Schedule of De_2

Income Taxes - Schedule of Defered Income Taxes (Parenthetical) (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets Liabilities Net [Line Items]
Unrecognized tax benefits	$ 10	$ 63

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) ₪ in Millions, $ in Millions	Jan. 01, 2017	Oct. 31, 2021USD ($)	Jul. 31, 2020USD ($)	Dec. 31, 2021USD ($)Employee	Dec. 31, 2021ILS (₪)Employee	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2016
Income Tax [Line Items]
Balance of accrued potential penalties and interest in unrecognized tax benefits				$ 210		$ 173	$ 164
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense				$ 37		$ 9	$ 33
Statutory tax rate in Israel				23.00%	23.00%	23.00%	23.00%
Annual revenue				$ 15,878		$ 16,659	$ 16,887
Expected impairment of income tax benefit			$ 141
Israel Tax Authority [Member]
Income Tax [Line Items]
Income tax audit period				2008 2009 2010 2011	2008 2009 2010 2011
Withholding tax percentage on dividends								8.00%
Israel Tax Authority [Member] | Tax Year 2005 To 2007 [Member]
Income Tax [Line Items]
Income tax settlement amount						$ 213
Israel Tax Authority [Member] | Tax Year 2008 To 2011 [Member]
Income Tax [Line Items]
Income Tax Examination, Estimate of Possible Loss		$ 350
Tax Carryforwards And Deductions Expiration Period One [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				$ 20
Tax Carryforwards And Deductions Expiration Period Two [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				828
Tax Carryforwards And Deductions No Expiration [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				123
Tax Carryforwards And Deductions Indefinite [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				1,133
Amendment 69 to Investment Law [Member]
Income Tax [Line Items]
Payment of corporate tax				577
Exempt Income				9,400
Amendment 68 to Investment Law [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Statutory tax rate in Israel								16.00%
Amendment 68 to Investment Law [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Statutory tax rate in Israel								9.00%
Amendment 73 to Investment Law [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Statutory tax rate in Israel	7.50%
Preferred Enterprise [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Withholding tax percentage on dividends								20.00%
Preferred Enterprise [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Withholding tax percentage on dividends								5.00%
Preferred Technological Enterprises [Member]
Income Tax [Line Items]
Venture capital investment				$ 2
Average growth rate in sales or workforce				25.00%	25.00%
Average growth preceding period in sales or workforce				3 years	3 years
Preferred Technological Enterprises [Member] | Research and Development Arrangement [Member]
Income Tax [Line Items]
Minimum percentage of investment income				7.00%	7.00%
Minimum investment income				$ 22	₪ 75
Minimum percentage of workforce				200.00%	200.00%
Minimum number of employees employed | Employee				20	20
Preferred Technological Enterprises [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Statutory tax rate in Israel				12.00%	12.00%
Preferred Technological Enterprises [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Statutory tax rate in Israel				7.50%	7.50%
Special Preferred Technological Enterprise [Member]
Income Tax [Line Items]
Annual revenue				$ 2,900	₪ 10,000
Special Preferred Technological Enterprise [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Statutory tax rate in Israel				6.00%	6.00%
Withholding tax percentage on dividends				4.00%	4.00%
Minimum [Member] | Tax Carryforwards And Deductions Expiration Period One [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2022	Dec. 31, 2022
Minimum [Member] | Tax Carryforwards And Deductions Expiration Period Two [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2024	Dec. 31, 2024
Minimum [Member] | Tax Carryforwards And Deductions No Expiration [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2032	Dec. 31, 2032
Maximum [Member] | Tax Carryforwards And Deductions Expiration Period One [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2023	Dec. 31, 2023
Maximum [Member] | Tax Carryforwards And Deductions Expiration Period Two [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2031	Dec. 31, 2031

Income Taxes - Schedule of De_3

Income Taxes - Schedule of Deferred Tax Assets and Liabilities By Report Caption (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets Liabilities Net [Line Items]
Long-term assets—deferred income taxes	$ 596	$ 695
Long-term liabilities—deferred income taxes	(784)	(964)
Deferred tax assets liabilities net	$ (188)	$ (269)

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Unrecognized Tax Benefits [Line Items]
Balance at the beginning of the year	$ 888	$ 1,223	$ 1,072
Increase (decrease) related to prior year tax positions, net	(106)	(238)	23
Increase related to current year tax positions	7	10	246
Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations	(115)	(105)	(118)
Other	(2)	(2)
Balance at the end of the year	$ 672	$ 888	$ 1,223

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	Jul. 13, 2017	Apr. 18, 2016	Dec. 31, 2021	Dec. 31, 2020	Jun. 11, 2020	Dec. 31, 2019	Sep. 03, 2015	Jun. 29, 2010
Class of Stock [Line Items]
Ordinary shares issuance ADSs			1,200,000
Share price				$ 8.01
Number of shares exercisable			26,989
Number of shares available for future awards			78,800
Vesting period, description			The vesting period of the outstanding options and RSUs is generally between 1 to 4 years from the date of grant. The vesting period of PSUs is generally 3 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for ten years.
Company average share price						$ 11.50
Total unrecognized compensation cost before tax on employee stock options			$ 2
Total unrecognized compensation cost before tax on employee stock RSUs			$ 164
Share based compensation arrangements expected over weighted average period for options			2 months 12 days
Share based compensation arrangements expected over weighted average period for RSU/PSUs			2 years 6 months
2010 Long-Term Equity-Based Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares exercisable								70,000
2015 Long-Term Equity-Based Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares exercisable	142,000	77,000					43,700
Number of additional shares authorized	65,000	33,300
2020 Long-Term Equity-Based Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares exercisable					68,000

Equity - Summary of Stock Optio

Equity - Summary of Stock Option Activity (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance outstanding at begining of year	35,234	40,064	48,393
Exercised			(11)
Forfeited	(3,644)	(3,610)	(8,318)
Expired	(2,575)	(1,220)
Balance outstanding at end of year	29,015	35,234	40,064
Balance exercisable at end of year	26,989	28,556	26,601
Balance outstanding at begining of year	$ 37.27	$ 37.90	$ 38.62
Exercised			16.99
Forfeited	36.09	40.24	42.12
Expired	42.40	49.35
Balance outstanding at end of year	36.96	37.27	37.90
Balance exercisable at end of year	$ 38.30	$ 40.56	$ 43.41

Equity - Schedule of Ordinary S

Equity - Schedule of Ordinary Shares Issued Upon Outstanding Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2021yr$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	29,015
Weighted average exercise price	$ 36.96
Weighted average remaining life Years | yr	4.37
Lower than $15.01 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	592
Weighted average exercise price	$ 11.40
Weighted average remaining life Years | yr	5.84
Range of exercise prices, upper limit	$ 15.01
$15.01 - $25.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	8,762
Weighted average exercise price	$ 18.95
Weighted average remaining life Years | yr	6.12
Range of exercise prices, lower limit	$ 15.01
Range of exercise prices, upper limit	$ 25
$25.01 - $35.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	6,364
Weighted average exercise price	$ 34.61
Weighted average remaining life Years | yr	5.16
Range of exercise prices, lower limit	$ 25.01
Range of exercise prices, upper limit	$ 35
$35.01 - $45.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	2,679
Weighted average exercise price	$ 39.83
Weighted average remaining life Years | yr	0.96
Range of exercise prices, lower limit	$ 35.01
Range of exercise prices, upper limit	$ 45
$45.01 - $55.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	6,801
Weighted average exercise price	$ 51.01
Weighted average remaining life Years | yr	3.18
Range of exercise prices, lower limit	$ 45.01
Range of exercise prices, upper limit	$ 55
$55.01 - $65.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	3,817
Weighted average exercise price	$ 59.15
Weighted average remaining life Years | yr	3.33
Range of exercise prices, lower limit	$ 55.01
Range of exercise prices, upper limit	$ 65

Equity - Schedule of Ordinary_2

Equity - Schedule of Ordinary Shares Issued Upon Vested Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2021yr$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	26,989
Weighted average exercise price	$ 38.30
Weighted average remaining life Years | yr	4.24
Lower than $15.01 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	592
Weighted average exercise price	$ 11.40
Weighted average remaining life Years | yr	5.84
Range of exercise prices, upper limit	$ 15.01
$15.01 - $25.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	6,736
Weighted average exercise price	$ 18.90
Weighted average remaining life Years | yr	6.11
Range of exercise prices, lower limit	$ 15.01
Range of exercise prices, upper limit	$ 25
$25.01 - $35.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	6,364
Weighted average exercise price	$ 34.61
Weighted average remaining life Years | yr	5.16
Range of exercise prices, lower limit	$ 25.01
Range of exercise prices, upper limit	$ 35
$35.01 - $45.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	2,679
Weighted average exercise price	$ 39.83
Weighted average remaining life Years | yr	0.96
Range of exercise prices, lower limit	$ 35.01
Range of exercise prices, upper limit	$ 45
$45.01 - $55.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	6,801
Weighted average exercise price	$ 51.01
Weighted average remaining life Years | yr	3.18
Range of exercise prices, lower limit	$ 45.01
Range of exercise prices, upper limit	$ 55
$55.01 - $65.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	3,817
Weighted average exercise price	$ 59.15
Weighted average remaining life Years | yr	3.33
Range of exercise prices, lower limit	$ 55.01
Range of exercise prices, upper limit	$ 65

Equity - Schedule of Number of

Equity - Schedule of Number of RSUs Issued and Outstanding (Detail) - Restricted Stock Units [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance outstanding at beginning of year	20,720	15,977	10,403
Granted	12,748	10,848	9,303
Vested	(6,818)	(4,324)	(2,435)
Forfeited	(2,238)	(1,781)	(1,294)
Balance outstanding at end of year	24,412	20,720	15,977
Weighted-average grant date fair value per share - RSUs at beginning year	$ 13.81	$ 16.49	$ 20.93
Granted	10.42	11.42	15.36
Vested	15.60	19.49	30.24
Forfeited	12.18	18.18	18.74
Weighted-average grant date fair value per share - RSUs at end of year	$ 11.58	$ 13.81	$ 16.49

Equity - Summary of Company Exp

Equity - Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018
Stock Options Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 16	$ 30	$ 46
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	103	99	73
Omnibus Long Term Share Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	119	129	119
Tax effect on stock-based compensation expense	12	14	14
Net effect	$ 107	$ 115	$ 105

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		$ (2,399)
Amounts reclassified to the statements of income				$ 20
Ending Balance		(2,683)	$ (2,399)
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(1,919)	(1,794)	(1,878)
Other comprehensive income/(loss) before reclassifications		(386)	(190)	100
Amounts reclassified to the statements of income				0
Net other comprehensive income/(loss) before tax		(386)	(190)	100
Corresponding income tax		31	65	(16)
Net other comprehensive income/(loss) after tax	[1]	(355)	(125)	84
Ending Balance		(2,274)	(1,919)	(1,794)
Available-for-sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance				1
Other comprehensive income/(loss) before reclassifications				(1)
Amounts reclassified to the statements of income				0
Net other comprehensive income/(loss) before tax				(1)
Net other comprehensive income/(loss) after tax	[1]			(1)
Derivative Financial Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(363)	(420)	(504)
Other comprehensive income/(loss) before reclassifications		0	22	54
Amounts reclassified to the statements of income		39	35	30
Net other comprehensive income/(loss) before tax		39	57	84
Net other comprehensive income/(loss) after tax	[1]	39	57	84
Ending Balance		(324)	(363)	(420)
Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(117)	(98)	(78)
Other comprehensive income/(loss) before reclassifications		18	(7)	(11)
Amounts reclassified to the statements of income		18	(12)	(10)
Net other comprehensive income/(loss) before tax		36	(19)	(21)
Corresponding income tax		(4)	1	1
Net other comprehensive income/(loss) after tax	[1]	32	(18)	(20)
Ending Balance		(85)	(117)	(98)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(2,399)	(2,312)	(2,459)
Other comprehensive income/(loss) before reclassifications		(368)	(175)	142
Amounts reclassified to the statements of income		57	23
Net other comprehensive income/(loss) before tax		(311)	(152)	162
Corresponding income tax		27	66	(15)
Net other comprehensive income/(loss) after tax	[1]	(283)	(86)	147
Ending Balance		$ (2,683)	$ (2,399)	$ (2,312)
[1]	Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $107 million loss in 2021, $56 million gain in 2020 and $14 million gain in 2019.

Equity - Accumulated Other Co_2

Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Foreign Currency Translation Adjustments Attributable to Non-controlling Interests [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation attributable to non-controlling interests	$ 107	$ 56	$ 14

Other assets impairments, res_3

Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring and Impairment Costs [Line Items]
Impairments of long-lived tangible assets	[1]	$ 160	$ 416	$ 139
Contingent consideration (see note 20)		7	(81)	59
Restructuring		133	120	199
Other		41	24	26
Total		$ 341	$ 479	$ 423
[1]	Including impairments related to exit and disposal activities.

Other assets impairments, res_4

Other assets impairments, restructuring and other items - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring and Impairment Costs [Line Items]
Impairments of property, plant and equipment	$ 160	$ 416	$ 139
Business combination contingent consideration arrangements change in amount of contingent consideration liability	7	(81)	59
Restructuring costs	$ 133	$ 120	$ 199

Other assets impairments, res_5

Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 133	$ 120	$ 199
Employee termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	117	71	159
Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 16	$ 49	$ 40

Other assets impairments, res_6

Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Beginning balance		$ (122)	$ (215)	$ (233)
Provision		(133)	(120)	(199)
Utilization and other	[1]	117	213	217
Ending balance		(138)	(122)	(215)
Employee termination costs [Member]
Restructuring Cost and Reserve [Line Items]
Beginning balance		(115)	(208)	(204)
Provision		(117)	(71)	(159)
Utilization and other	[1]	101	164	155
Ending balance		(131)	(115)	(208)
Other Exit and Disposal [Member]
Restructuring Cost and Reserve [Line Items]
Beginning balance		(7)	(7)	(29)
Provision		(16)	(49)	(40)
Utilization and other	[1]	16	49	62
Ending balance		$ (7)	$ (7)	$ (7)
[1]	Includes adjustments for foreign currency translation.

Other Income - Schedule of Othe

Other Income - Schedule of Other Income (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Income [Line Items]
Gain on divestitures, net of divestitures related costs	[1]	$ 51	$ 8	$ 50
Section 8 and similar payments	[2]	19		5
Gain (loss) on sale of assets		7	11	(1)
Other, net		22	20	22
Total other income		$ 98	$ 40	$ 76
[1]	In 2021, mainly due to capital gains related to the sale of certain OTC assets. In 2020 and 2019, mainly related to the divestment of several activities in the International Markets segment.
[2]	Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada.

Financial expenses, net - Sched

Financial expenses, net - Schedule of Financial Expenses (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Expenses [Line Items]
Interest expenses and other bank charges		$ 891	$ 901	$ 822
(Income) loss from investments	[1]	90	(104)	(41)
Foreign exchange (gains) losses, net		7	(26)	(15)
Other, net	[2]	71	62	55
Total finance expense, net		$ 1,058	$ 834	$ 822
[1]	(Income) loss from investments in 2021 and 2020 comprised mainly of revaluation gains and loss of Teva’s investment in American Well Corporation (“American Well”). See note 20.
[2]	Amortization of issuance costs and terminated derivative instruments.

Earnings (Loss) per Share - Sch

Earnings (Loss) per Share - Schedule of Earnings per Share (Detail) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net income (loss) used for the computation of basic and diluted earnings (loss) per share	$ 417	$ (3,990)	$ (999)
Weighted average number of shares used in the computation of basic earnings (loss) per share	1,102	1,095	1,091
Weighted average number of shares used in the computation of diluted earnings (loss) per share	1,107	1,095	1,091

Earnings (Loss) per Share - Add

Earnings (Loss) per Share - Additional Information (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Basic and diluted loss per share	$ 0.38	$ 3.64	$ 0.91
Weighted average shares with dilutive effect on earnings per share	5,000,000
Stock Option Restricted Stock Units And Performance Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average shares with anti-dilutive effect on earnings per share		104,000,000	113,000,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average shares with anti-dilutive effect on earnings per share	0

Segments - Summary of Segment P

Segments - Summary of Segment Profit (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	$ 15,878	$ 16,659	$ 16,887
Gross profit	7,594	7,726	7,537
R&D expenses	967	997	1,010
S&M expenses	2,429	2,498	2,614
G&A expenses	1,099	1,173	1,192
Segment profit	1,716	(3,572)	(443)
North America [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	7,809	8,447	8,542
Gross profit	4,226	4,489	4,350
R&D expenses	618	622	652
S&M expenses	988	1,013	1,021
G&A expenses	427	443	439
Other (income) expense	(31)	(10)	(14)
Segment profit	2,224	2,421	2,252
Europe [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	4,886	4,757	4,795
Gross profit	2,823	2,666	2,704
R&D expenses	244	247	262
S&M expenses	846	830	890
G&A expenses	244	261	239
Other (income) expense	(5)	(3)	(5)
Segment profit	1,494	1,331	1,318
International Markets [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues	2,032	2,154	2,246
Gross profit	1,118	1,096	1,167
R&D expenses	68	70	88
S&M expenses	417	427	481
G&A expenses	109	136	138
Other (income) expense	(5)	(11)	(3)
Segment profit	$ 529	$ 474	$ 464

Segments - Summary of Profit by

Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Amounts allocated to segments:
Segments profit	$ 1,716	$ (3,572)	$ (443)
Amounts not allocated to segments:
Amortization	802	1,020	1,113
Other asset impairments, restructuring and other items	341	479	423
Intangible asset impairments	424	1,502	1,639
Goodwill impairment	0	4,628	0
Legal settlements and loss contingencies	717	60	1,178
Other unallocated amounts	402	271	232
Consolidated operating income (loss)	1,716	(3,572)	(443)
Financial expenses, net	1,058	834	822
Income (loss) before income taxes	658	(4,406)	(1,265)
North America [Member]
Amounts allocated to segments:
Segments profit	2,224	2,421	2,252
Amounts not allocated to segments:
Consolidated operating income (loss)	2,224	2,421	2,252
Europe [Member]
Amounts allocated to segments:
Segments profit	1,494	1,331	1,318
Amounts not allocated to segments:
Consolidated operating income (loss)	1,494	1,331	1,318
International Markets [Member]
Amounts allocated to segments:
Segments profit	529	474	464
Amounts not allocated to segments:
Consolidated operating income (loss)	529	474	464
Corporate Segment [Member]
Amounts allocated to segments:
Segments profit	4,246	4,225	4,034
Amounts not allocated to segments:
Consolidated operating income (loss)	4,246	4,225	4,034
Other Segments [Member]
Amounts allocated to segments:
Segments profit	154	163	108
Amounts not allocated to segments:
Consolidated operating income (loss)	154	163	108
Segments and Other Activities [Member]
Amounts allocated to segments:
Segments profit	4,401	4,388	4,142
Amounts not allocated to segments:
Consolidated operating income (loss)	$ 4,401	$ 4,388	$ 4,142

Segments - Schedule of Revenues

Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Product Information [Line Items]
Revenues	$ 15,878	$ 16,659	$ 16,887
North America [Member]
Product Information [Line Items]
Revenues	7,809	8,447	8,542
Europe [Member]
Product Information [Line Items]
Revenues	4,886	4,757	4,795
International Markets [Member]
Product Information [Line Items]
Revenues	2,032	2,154	2,246
Generic products [Member] | North America [Member]
Product Information [Line Items]
Revenues	3,769	4,010	3,963
Generic products [Member] | Europe [Member]
Product Information [Line Items]
Revenues	3,569	3,513	3,470
Generic products [Member] | International Markets [Member]
Product Information [Line Items]
Revenues	1,649	1,792	1,893
COPAXONE [Member] | North America [Member]
Product Information [Line Items]
Revenues	577	884	1,017
COPAXONE [Member] | Europe [Member]
Product Information [Line Items]
Revenues	391	400	432
COPAXONE [Member] | International Markets [Member]
Product Information [Line Items]
Revenues	37	53	63
BENDEKA and TREANDA [Member] | North America [Member]
Product Information [Line Items]
Revenues	385	415	496
ProAir [Member] | North America [Member]
Product Information [Line Items]
Revenues	180	241	274
AJOVY [Member] | North America [Member]
Product Information [Line Items]
Revenues	176	134	93
AJOVY [Member] | Europe [Member]
Product Information [Line Items]
Revenues	87	31	3
AJOVY [Member] | International Markets [Member]
Product Information [Line Items]
Revenues	50	18
AUSTEDO [Member] | North America [Member]
Product Information [Line Items]
Revenues	802	637	412
Respiratory Product [Member] | Europe [Member]
Product Information [Line Items]
Revenues	356	353	354
Anda [Member] | North America [Member]
Product Information [Line Items]
Revenues	1,323	1,462	1,492
Other [Member] | North America [Member]
Product Information [Line Items]
Revenues	597	664	796
Other [Member] | Europe [Member]
Product Information [Line Items]
Revenues	483	459	536
Other [Member] | International Markets [Member]
Product Information [Line Items]
Revenues	$ 295	$ 291	$ 291

Segments - Schedule of Sales Pe

Segments - Schedule of Sales Percentage by Therapeutic Category (Detail)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
McKesson Corporation [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Third party net sales present	11.00%	12.00%	13.00%
AmerisourceBergen Corporation [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Third party net sales present	11.00%	12.00%	12.00%

Segments - Schedule of Net Sale

Segments - Schedule of Net Sales by Product Line - Schedule of Property, Plant and Equipment by Geographic Location (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 5,982	$ 6,296
Israel [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	1,543	1,611
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	692	790
Croatia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	481	539
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	1,045	933
Czech republic [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	324	330
Hungary [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	321	325
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	269	267
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 1,307	$ 1,501

Segments - Additional Informati

Segments - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)Segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | Segment	3
Consolidated operating income (loss)	$ 1,716	$ (3,572)	$ (443)
Europe [Member]
Segment Reporting Information [Line Items]
Consolidated operating income (loss)	1,494	$ 1,331	$ 1,318
Sales Revenue, Net [Member] | Europe [Member]
Segment Reporting Information [Line Items]
Consolidated operating income (loss)	$ 1
Israel [Member] | Sales Revenue, Net [Member] | Revenue from Rights Concentration Risk [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	2.00%	2.00%	2.00%
UNITED STATES | Sales Revenue, Net [Member] | Revenue from Rights Concentration Risk [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	46.00%	48.00%	47.00%

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail) - USD ($) $ in Millions		Dec. 31, 2021		Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash		$ 33
Derivatives		0
Contingent consideration	[1]	(176)		$ (268)
Total		2,054		2,153
Asset Derivatives - Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives		30		24
Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives		0
Liability Derivatives Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives		(23)		(79)
Money Markets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		220		367
Cash, Deposits and Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		1,945		1,810
Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities		18	[2]	284
Other, Mainly Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities				15
Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities		7
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash		33
Contingent consideration	[1]			0
Total		2,222		2,207
Level 1 [Member] | Money Markets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		220		367
Level 1 [Member] | Cash, Deposits and Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		1,945		1,810
Level 1 [Member] | Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities		18	[2]	25
Level 1 [Member] | Other, Mainly Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities				5
Level 1 [Member] | Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities		6
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	[1]			0
Total		7		204
Level 2 [Member] | Asset Derivatives - Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives		30		24
Level 2 [Member] | Liability Derivatives Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives		(23)		(79)
Level 2 [Member] | Money Markets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents				0
Level 2 [Member] | Cash, Deposits and Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents				0
Level 2 [Member] | Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities				259
Level 2 [Member] | Other, Mainly Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities				0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	[1]	(176)		(268)
Total		(175)		(258)
Level 3 [Member] | Money Markets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents				0
Level 3 [Member] | Cash, Deposits and Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents				0
Level 3 [Member] | Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities				0
Level 3 [Member] | Other, Mainly Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities				$ 10
Level 3 [Member] | Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities		$ 1
[1]	Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.
[2]	During the first quarter of 2021, Teva’s shares in American Well Corporation (“American Well”) moved from a Level 2 measurement to a Level 1 measurement within the fair value hierarchy, since they were no longer subject to a sale restriction. By the end of September, 2021, Teva sold all of its holdings in American Well.

Fair value measurement - Additi

Fair value measurement - Additional Information (Detail)	Dec. 31, 2021
Maximum [Member] | Measurement input probability of success [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	100
Maximum [Member] | Measurement input, discount rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	8
Minimum [Member] | Measurement input probability of success [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	90
Minimum [Member] | Measurement input, discount rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	7.5
Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	7.7

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value at the beginning of the period	$ (258)	$ (448)
Transfer into Level 3- equity securities	0	179
Revaluation of equity securities	0	80
Redemption of debt securities	(9)	0
Revaluation of debt securities	0	(2)
Reclassification to Level 2- equity securities	0	(259)
Bifurcated embedded derivatives		0
Fair value at the end of the period	(175)	(258)
Actavis Generics [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Actavis Generics transaction	15	156
Eagle Transaction [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Adjustments to provisions for contingent consideration	(23)	(75)
Settlement of contingent consideration	$ 100	$ 111

Fair Value Measurement - Summ_3

Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 22,903	$ 25,891
Senior Notes And Sustainability Linked Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	21,477	22,684
Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 1,426	$ 3,207

Long-term Employee-related Ob_3

Long-term Employee-related Obligations - Schedule of Long Term Employee Related Obligation (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Accrued severance obligations	$ 83	$ 82
Defined benefit plans	142	192
Total	$ 225	$ 275

Long-term Employee-related Ob_4

Long-term Employee-related Obligations - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Long-term investments earmarked for severance pay liabilities in Israel	$ 97	$ 86
Expected contributions to pension funds	114
2022	13
2023	12
2024	11
2025	11
2026	11
2027 to 2031	$ 63

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	$ 4,904	$ 6,246
Deductions	(14,036)	(15,707)
Balance at end of period	4,309	4,904	$ 6,246
Allowance For Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	200	209	232
Charged to costs and expenses	(8)	(11)	(16)
Charged to other accounts	0	2	0
Deductions	(28)	0	(7)
Balance at end of period	164	200	209
Valuation Allowance in Tax Carryforward Losses And Deductions [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	2,547	1,974	1,633
Charged to costs and expenses	336	670	555
Deductions	(160)	(97)	(214)
Balance at end of period	$ 2,723	$ 2,547	$ 1,974